<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="review-article" dtd-version="1.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id>
<journal-title-group>
<journal-title>Frontiers in Pharmacology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Pharmacol.</abbrev-journal-title>
</journal-title-group>
<issn pub-type="epub">1663-9812</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">1748368</article-id>
<article-id pub-id-type="doi">10.3389/fphar.2025.1748368</article-id>
<article-version article-version-type="Version of Record" vocab="NISO-RP-8-2008"/>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Exploring cannabinoid modulation on autophagy mechanisms in Alzheimer&#x2019;s disease: a review</article-title>
<alt-title alt-title-type="left-running-head">Ntsapi et al.</alt-title>
<alt-title alt-title-type="right-running-head">
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fphar.2025.1748368">10.3389/fphar.2025.1748368</ext-link>
</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Ntsapi</surname>
<given-names>C.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/3087549"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal Analysis</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x26; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/">Writing - review and editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing - original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Weyers</surname>
<given-names>M.</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing - original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x26; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/">Writing - review and editing</role>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Chinheya</surname>
<given-names>R.</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/3336155"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x26; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/">Writing - review and editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing - original draft</role>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Jim</surname>
<given-names>T.</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>&#x2020;</sup>
</xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x26; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/">Writing - review and editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing - original draft</role>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Matsabisa</surname>
<given-names>M.</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1003280"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing - original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x26; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/">Writing - review and editing</role>
</contrib>
</contrib-group>
<aff id="aff1">
<label>1</label>
<institution>Department of Basic Medical Sciences, School of Biomedical Sciences, Faculty of Health Sciences, University of the Free State</institution>, <city>Bloemfontein</city>, <country country="ZA">South Africa</country>
</aff>
<aff id="aff2">
<label>2</label>
<institution>Department of Pharmacology, School of Clinical Medicine, Faculty of Health Sciences, University of the Free State</institution>, <city>Bloemfontein</city>, <country country="ZA">South Africa</country>
</aff>
<aff id="aff3">
<label>3</label>
<institution>University of the Free State &#x2013; Technology Innovation Agency Pharmacology Platform (AMITD)</institution>, <city>Bloemfontein</city>, <country country="ZA">South Africa</country>
</aff>
<author-notes>
<corresp id="c001">
<label>&#x2a;</label>Correspondence: C. Ntsapi, <email xlink:href="mailto:ntsapiMC@ufs.ac.za">ntsapiMC@ufs.ac.za</email>
</corresp>
<fn fn-type="equal" id="fn001">
<label>&#x2020;</label>
<p>These authors have contributed equally to this work</p>
</fn>
</author-notes>
<pub-date publication-format="electronic" date-type="pub" iso-8601-date="2026-01-12">
<day>12</day>
<month>01</month>
<year>2026</year>
</pub-date>
<pub-date publication-format="electronic" date-type="collection">
<year>2025</year>
</pub-date>
<volume>16</volume>
<elocation-id>1748368</elocation-id>
<history>
<date date-type="received">
<day>17</day>
<month>11</month>
<year>2025</year>
</date>
<date date-type="rev-recd">
<day>11</day>
<month>12</month>
<year>2025</year>
</date>
<date date-type="accepted">
<day>16</day>
<month>12</month>
<year>2025</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2026 Ntsapi, Weyers, Chinheya, Jim and Matsabisa.</copyright-statement>
<copyright-year>2026</copyright-year>
<copyright-holder>Ntsapi, Weyers, Chinheya, Jim and Matsabisa</copyright-holder>
<license>
<ali:license_ref start_date="2026-01-12">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License (CC BY)</ext-link>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<p>Alzheimer&#x2019;s disease (AD) is a neurodegenerative disorder characterized by the accumulation of toxic protein aggregates in the brain, leading to brain cell death and cognitive impairment. Central to AD pathogenesis is the autophagy pathway, a crucial cellular self-digestion process. Cannabinoids, the fundamental phytochemical compounds derived from the <italic>Cannabis sativa</italic> plant, have been demonstrated to exhibit neuroprotective qualities when used as a treatment at microdoses. However, the impact of multi-cannabinoid treatments on autophagy induction and subsequent cell survival in AD <italic>in vitro</italic> models remains uncertain. This review seeks to explore the potential of a multi-cannabinoid treatment strategy in enhancing neuronal cell survival through autophagy activation within an AD <italic>in vitro</italic> model. The proposed approach involves a combination of cannabinoids in their potential to upregulate autophagy mechanisms, potentially supporting neuronal cell resilience. By unravelling the mechanistic link between autophagy, cannabinoid treatment, and neuronal viability, this review aims to elucidate how cannabinoids influence neuronal function and survival at a cellular and molecular level. By offering insights into the exploitation of the endocannabinoid system, this review contributes to the development of novel cannabinoid-based treatment avenues for AD. This pursuit aligns with the broader objective of addressing the debilitating effects of AD on the quality of life for those affected.</p>
</abstract>
<kwd-group>
<kwd>Alzheimer&#x2019;s disease</kwd>
<kwd>amyloid precursor protein</kwd>
<kwd>amyloid-&#x3b2; (A&#x3b2;)</kwd>
<kwd>autophagy</kwd>
<kwd>cannabinoid-based therapeutics</kwd>
<kwd>Cannabis sativa</kwd>
</kwd-group>
<funding-group>
<award-group id="gs1">
<funding-source id="sp1">
<institution-wrap>
<institution>Universiteit van die Vrystaat</institution>
<institution-id institution-id-type="doi" vocab="open-funder-registry" vocab-identifier="10.13039/open_funder_registry">10.13039/501100004765</institution-id>
</institution-wrap>
</funding-source>
</award-group>
<funding-statement>The author(s) declared that financial support was received for this work and/or its publication. This work received support from the National Research Foundation (Grant number CSUR23042496513), the South African Medical Research Council (SAMRC) Self-Initiated Research (SIR) Grant, and the University of the Free State (UFS) Faculty of Health Sciences (3SoM) Postgraduate Funding Committee.</funding-statement>
</funding-group>
<counts>
<fig-count count="4"/>
<table-count count="0"/>
<equation-count count="0"/>
<ref-count count="222"/>
<page-count count="19"/>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Ethnopharmacology</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec sec-type="intro" id="s1">
<label>1</label>
<title>Introduction</title>
<p>Neurodegeneration involves the progressive decline of neurons and is a hallmark of disorders such as Alzheimer&#x2019;s disease (AD), Parkinson&#x2019;s disease (PD), and Amyotrophic Lateral Sclerosis (<xref ref-type="bibr" rid="B117">Mistretta et al., 2023</xref>; <xref ref-type="bibr" rid="B1">Agnello and Ciaccio, 2022</xref>). AD, the most prevalent neurodegenerative disorder (<xref ref-type="bibr" rid="B180">&#x15a;wietlik et al., 2022</xref>), is characterized by the accumulation of amyloid-&#x3b2; (A&#x3b2;) plaques and hyperphosphorylated tau, leading to neuronal dysfunction, inflammation, and oxidative stress in the central nervous system (<xref ref-type="bibr" rid="B69">Halawani et al., 2010</xref>; <xref ref-type="bibr" rid="B163">Rohn and Head, 2009</xref>). AD is broadly classified based on its pathophysiology as either sporadic (late-onset) or familial (early-onset). Sporadic AD, accounting for approximately 95% of cases, is a complex disorder influenced by multiple factors that remain incompletely understood. These include genetic factors, such as the Apolipoprotein E allele, as well as environmental and lifestyle influences, and the interplay of epigenetic and genetic processes (<xref ref-type="bibr" rid="B181">Tailor et al., 2019</xref>; <xref ref-type="bibr" rid="B76">Ibanez et al., 2021</xref>). Familial AD, which affects fewer than 5% of patients, results from mutations in specific genes that alter the amyloid precursor protein (APP) or presenilin-1 and -2 (PS1/PS2) (<xref ref-type="bibr" rid="B204">Xiao et al., 2021</xref>; <xref ref-type="bibr" rid="B95">Lanoisel&#xe9;e et al., 2017</xref>). Both sporadic and familial forms of AD share these pathological features, though the underlying causes differ (<xref ref-type="bibr" rid="B181">Tailor et al., 2019</xref>; <xref ref-type="bibr" rid="B76">Ibanez et al., 2021</xref>; <xref ref-type="bibr" rid="B95">Lanoisel&#xe9;e et al., 2017</xref>; <xref ref-type="bibr" rid="B44">d&#x2018;Errico and Meyer-Luehmann, 2020</xref>). The amyloid cascade hypothesis suggests that impaired clearance of A&#x3b2; triggers downstream tau pathology and neuronal toxicity, as demonstrated in cellular and animal models (<xref ref-type="bibr" rid="B71">Hardy and Higgins, 1992</xref>; <xref ref-type="bibr" rid="B4">Alawode et al., 2022</xref>). Despite strong preclinical evidence, translating these findings into effective clinical therapies has been challenging, often due to safety concerns and limitations of conventional drug approaches.</p>
<p>Despite the strong preclinical evidence linking A&#x3b2; accumulation and tau pathology to AD progression, translating this robust preclinical and biomarker science into clinical benefit has proven challenging. Logistical difficulties, safety concerns, and limited tolerable dosages have hindered the success of secretase-inhibiting therapies, and several clinical trials have been prematurely halted due to adverse effects or other pharmaceutical limitations (<xref ref-type="bibr" rid="B68">Haass and Selkoe, 2022</xref>; <xref ref-type="bibr" rid="B160">Ricciarelli and Fedele, 2017</xref>). These challenges underscore the need for alternative therapeutic strategies, such as cannabinoids, which have shown potential in modulating neuroinflammation, oxidative stress, and A&#x3b2;- and tau-mediated neuronal toxicity, positioning them as promising multi-target agents in AD management (<xref ref-type="bibr" rid="B44">d&#x2018;Errico and Meyer-Luehmann, 2020</xref>; <xref ref-type="bibr" rid="B41">DeTure and Dickson, 2019</xref>; <xref ref-type="bibr" rid="B69">Halawani et al., 2010</xref>; <xref ref-type="bibr" rid="B163">Rohn and Head, 2009</xref>; <xref ref-type="bibr" rid="B208">Yankner et al., 1989</xref>).</p>
</sec>
<sec id="s2">
<label>2</label>
<title>APP processing and A&#x3b2; peptide formation</title>
<p>APP is a widely spread transmembrane protein (<xref ref-type="bibr" rid="B120">Morley et al., 2019</xref>) involved in multiple physiological processes, including wound healing, calcium regulation in neurons, transport of molecules across cell membranes, and the formation and maintenance of synapses, which are critical for neuronal communication (<xref ref-type="bibr" rid="B120">Morley et al., 2019</xref>; <xref ref-type="bibr" rid="B137">O&#x2019;Brien and Wong, 2011</xref>; <xref ref-type="bibr" rid="B18">Bergstr&#xf6;m et al., 2016</xref>). Importantly, abnormal accumulation of APP&#x2019;s proteolytic product, the A&#x3b2; peptide, is a defining feature of AD (<xref ref-type="bibr" rid="B137">O&#x2019;Brien and Wong, 2011</xref>; <xref ref-type="bibr" rid="B18">Bergstr&#xf6;m et al., 2016</xref>). A&#x3b2; peptides are produced through the sequential cleavage of APP by &#x3b2;-secretase (BACE) and &#x3b3;-secretase enzymes. This processing produces N-terminal fragments, such as soluble amyloid precursor protein-alpha (sAPP&#x3b1;) and soluble amyloid precursor protein-beta (sAPP&#x3b2;), A&#x3b2; peptides, and C-terminal fragments (<xref ref-type="bibr" rid="B137">O&#x2019;Brien and Wong, 2011</xref>).</p>
<p>A&#x3b2; peptides are hydrophobic and prone to aggregate, forming oligomers and protofibrils that eventually deposit as A&#x3b2; plaque in the brain (<xref ref-type="bibr" rid="B120">Morley et al., 2019</xref>). APP can undergo either non-amyloidogenic or amyloidogenic processing, with the latter favored in AD (<xref ref-type="bibr" rid="B53">Fong et al., 2018</xref>; <xref ref-type="bibr" rid="B217">Zhao et al., 2020</xref>). In the amyloidogenic pathway (<xref ref-type="fig" rid="F1">Figure 1</xref>), &#x3b2;-secretase mediates the initial cleavage of APP, producing sAPP&#x3b2; and a carboxy-terminal fragment &#x3b2; (CTF&#x3b2; or C99) (<xref ref-type="bibr" rid="B162">Roberds et al., 2001</xref>; <xref ref-type="bibr" rid="B70">Hampel et al., 2021</xref>). C99 fragments are subsequently cleaved by &#x3b3;-secretase, generating A&#x3b2; and carboxy-terminal fragment &#x3b3; (CTF&#x3b3;) or APP intracellular domain (AICD). Excessive APP cleavage drives the accumulation of A&#x3b2; fragments, which aggregate into oligomers and fibrils, culminating in plaque formation, and contributing to the synaptic dysfunction, inflammation, and neurotoxicity characteristic of AD (<xref ref-type="bibr" rid="B162">Roberds et al., 2001</xref>; <xref ref-type="bibr" rid="B70">Hampel et al., 2021</xref>; <xref ref-type="bibr" rid="B182">Takahashi et al., 2017</xref>).</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>Schematic representation of the amyloid precursor protein (APP) processing cascade. The diagram illustrates the normal (left) and abnormal (right) pathways of APP cleavage. In the normal, non-amyloidogenic pathway, &#x3b1;-secretase cleaves APP to generate soluble fragments and prevents the formation of amyloid-&#x3b2; (A&#x3b2;) peptides. In Alzheimer&#x2019;s disease (AD), or in the presence of pathogenic mutations in APP or the presenilin genes PSEN1 and PSEN2, APP is preferentially processed by &#x3b2;-secretase and &#x3b3;-secretase, leading to the production of A&#x3b2; peptides that accumulate extracellularly. These peptides oligomerize and aggregate to form amyloid plaques, a neuropathological hallmark of AD.</p>
</caption>
<graphic xlink:href="fphar-16-1748368-g001.tif">
<alt-text content-type="machine-generated">Diagram comparing normal and abnormal cleavage of amyloid precursor protein (APP). On the left, normal cleavage involves &#x3B1;-secretase, producing soluble fragments. On the right, abnormal cleavage due to APP mutations involves &#x3B2;-secretase and &#x3B3;-secretase, leading to amyloid-beta (A&#x3B2;) peptide accumulation and plaque formation. This process is linked to genetic mutations increasing enzyme activity.</alt-text>
</graphic>
</fig>
</sec>
<sec id="s3">
<label>3</label>
<title>Approved drugs for AD treatment and their mechanism of action</title>
<p>The growing global prevalence of AD underscores the urgent need for effective therapeutic strategies. Although scientific and medical advances have improved understanding of AD, no treatment currently exists that can halt or reverse disease progression. The disorder remains non-preventable, incurable, and challenging to diagnose with high accuracy (<xref ref-type="bibr" rid="B44">d&#x2018;Errico and Meyer-Luehmann, 2020</xref>; <xref ref-type="bibr" rid="B71">Hardy and Higgins, 1992</xref>). To date, two major classes of medications are approved for AD: acetylcholinesterase inhibitors and N-methyl-D-aspartate (NMDA) receptor antagonists (<xref ref-type="bibr" rid="B4">Alawode et al., 2022</xref>; <xref ref-type="bibr" rid="B68">Haass and Selkoe, 2022</xref>). In the United States, the Food and Drug Administration (FDA) has approved drugs that either modestly slow clinical decline or offer temporary symptomatic relief. These include the acetylcholinesterase inhibitors - Rivastigmine, Donepezil, Galantamine, and Tacrine - alongside Memantine (MEM), the primary NMDA receptor antagonist (glutamate inhibitor) (<xref ref-type="bibr" rid="B158">Reisberg et al., 2003</xref>). These conventional drug classes are summarized in <xref ref-type="fig" rid="F2">Figure 2</xref>.</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>Conventional symptomatic drug classes used in Alzheimer&#x2019;s disease (AD) treatment. Acetylcholinesterase inhibitors (AChEIs) - donepezil, galantamine, rivastigmine, and tacrine - enhance cholinergic signalling by increasing acetylcholine availability, providing temporary cognitive and functional benefits in mild to moderate AD. Glutamatergic modulation is achieved with the N-methyl-D-aspartate (NMDA) receptor antagonist memantine, which reduces excitotoxicity and is indicated for moderate to severe AD. These drugs offer symptomatic relief but do not modify underlying disease progression.</p>
</caption>
<graphic xlink:href="fphar-16-1748368-g002.tif">
<alt-text content-type="machine-generated">Diagram showing conventional Alzheimer&#x27;s disease drugs categorized into two types: Acetylcholinesterase inhibitors, including Donepezil, Galantamine, Rivastigmine, and Tacrine; and Glutamate inhibitors, specifically Memantine.</alt-text>
</graphic>
</fig>
<sec id="s3-1">
<label>3.1</label>
<title>Acetylcholinesterase in AD treatment</title>
<p>Neurodegeneration in AD is driven in part by the accumulation of A&#x3b2; aggregates and hyperphosphorylated tau, leading to progressive neuronal loss and deterioration of cognitive, language, and memory functions (<xref ref-type="bibr" rid="B174">Sharma, 2019</xref>). Acetylcholine (ACh), a key neurotransmitter within cholinergic neurons of the central and autonomic nervous systems, plays an essential role in learning, memory, and synaptic plasticity (<xref ref-type="bibr" rid="B152">Radu et al., 2017</xref>; <xref ref-type="bibr" rid="B146">Picciotto et al., 2012</xref>). These systems include the well-known neuromuscular junctions, each exhibiting distinct nicotinic and muscarinic receptors (<xref ref-type="bibr" rid="B146">Picciotto et al., 2012</xref>). In the brain, all five subtypes of muscarinic receptors (M1&#x2013;M5) are present, with the M1 receptor subtype being particularly important for higher-order cognitive processing (<xref ref-type="bibr" rid="B186">Tizabi et al., 2023</xref>; <xref ref-type="bibr" rid="B202">Wright et al., 2009</xref>).</p>
<p>Under normal conditions, ACh is rapidly degraded in the synaptic cleft by acetylcholinesterase (AChE), which terminates cholinergic signaling. Reductions in ACh levels can arise from decreased synthesis or release, increased AChE activity or expression, or altered cholinergic receptor function (<xref ref-type="bibr" rid="B94">Kuo et al., 2007</xref>). In AD, dysfunction of the cholinergic system is well-documented: both the concentration and functional activity of ACh are significantly reduced, impairing cognitive processes (<xref ref-type="bibr" rid="B59">GBD, 2019, 2022</xref>). AChE, predominantly located at neuromuscular and neuronal synapses, hydrolyses into acetic acid and choline (<xref ref-type="bibr" rid="B190">Trang and Khandhar, 2023</xref>). Its upregulation accelerates ACh breakdown, contributing to synaptic failure and cognitive impairment (<xref ref-type="bibr" rid="B77">Iliyasu et al., 2023</xref>).</p>
<p>Notably, AChE also enhances A&#x3b2; aggregation by binding to A&#x3b2; and inducing fibril formation, generating a neurotoxic A&#x3b2;-AChE complex that disrupts normal synaptic function, particularly in the hippocampus (<xref ref-type="bibr" rid="B146">Picciotto et al., 2012</xref>; <xref ref-type="bibr" rid="B42">Dinama et al., 2010</xref>). Elevated AChE around amyloid plaques and neurofibrillary tangles is a characteristic feature of AD, although the mechanistic significance remains unclear (<xref ref-type="bibr" rid="B58">Garc&#xed;a-Ayll&#xf3;n et al., 2011</xref>).</p>
<p>AChE inhibitors remain the primary pharmacological strategy for symptom management (<xref ref-type="bibr" rid="B114">McGleenon et al., 1999</xref>). These inhibitors provide two main therapeutic benefits: (i) enhancement of synaptic ACh levels, improving cognitive function through strengthened cholinergic signaling; and (ii) potential long-term neuroprotective effects, including slower cortical atrophy and delayed clinical progression of dementia (<xref ref-type="bibr" rid="B121">Moss, 2020</xref>).</p>
<p>Given the role of ACh across sensory, cognitive, and sleep-wake systems (<xref ref-type="bibr" rid="B67">H Ferreira-Vieira et al., 2016</xref>), disruptions in cholinergic neurotransmission amplify AD-related deficits. More specifically, A&#x3b2; and tau pathology impairs synaptic integrity within the cholinergic pathways, reducing ACh availability and further compromising neuronal communication (<xref ref-type="bibr" rid="B67">H Ferreira-Vieira et al., 2016</xref>; <xref ref-type="bibr" rid="B109">Machado et al., 2020</xref>). Early cholinergic lesions occur presynaptically and later extend to post-synaptic nicotinic and muscarinic receptors, particularly M1, reinforcing the rationale for targeting the cholinergic system (<xref ref-type="bibr" rid="B90">Klaassens et al., 2019</xref>). Moreover, impaired cholinergic function may intensify downstream AD pathology, including tau phosphorylation, neuroinflammation, and neuronal injury (<xref ref-type="bibr" rid="B31">Chen et al., 2022</xref>), further accelerating cognitive decline in AD.</p>
</sec>
<sec id="s3-2">
<label>3.2</label>
<title>Memantine in AD treatment</title>
<p>The glutamatergic hypothesis of AD proposes that dysregulated glutamate signaling contributes to synaptic dysfunction and neurodegeneration. Glutamate, the major excitatory neurotransmitter in the brain, activates NMDA receptors essential for learning, memory; however, chronic overstimulation leads to excitotoxicity and neuronal injury (<xref ref-type="bibr" rid="B180">&#x15a;wietlik et al., 2022</xref>). MEM, an antagonist of extra-synaptic NMDA receptors, is an established therapeutic option and frequently administered alongside AChE inhibitors. Compared with other non-competitive NMDA receptor antagonists, MEM demonstrates superior tolerability and a more favorable pharmacological profile (<xref ref-type="bibr" rid="B106">Lipton and Chen, 2005</xref>).</p>
<p>MEM preferentially binds to open NMDA receptor-operated calcium channels, attenuating pathological calcium influx while preserving physiological synaptic transmission (<xref ref-type="bibr" rid="B209">Yiannopou et al., 2020</xref>). Through this mechanism, MEM reduces the harmful effects of sustained glutamate elevation and reduces excitotoxic neuronal loss (<xref ref-type="bibr" rid="B52">Folch et al., 2018</xref>). Despite these mechanisms, MEM only provides modest symptomatic benefit, may cause side effects, and does not alter disease progression (<xref ref-type="bibr" rid="B158">Reisberg et al., 2003</xref>; <xref ref-type="bibr" rid="B6">Alhazmi and Albratty, 2022</xref>). This therapeutic limitation highlights the need for innovative interventions capable of targeting underlying pathophysiological processes rather than solely managing symptoms.</p>
</sec>
<sec id="s3-3">
<label>3.3</label>
<title>Failure of A&#x3b2;-based therapeutics</title>
<p>A&#x3b2; peptides accumulate in the brain long before clinical symptoms emerge (<xref ref-type="bibr" rid="B74">Hector and Brouillette, 2021</xref>; <xref ref-type="bibr" rid="B149">Porsteinsson et al., 2021</xref>). Their aggregation disrupts synaptic function, alters membrane dynamics, and induces structural neuronal damage, including dystrophy, synaptic loss, and impaired neurotransmission (<xref ref-type="bibr" rid="B182">Takahashi et al., 2017</xref>; <xref ref-type="bibr" rid="B73">Hashimoto et al., 2003</xref>; <xref ref-type="bibr" rid="B214">Zempel et al., 2010</xref>). A&#x3b2; accumulation also contributes to glutamatergic dysfunction and excitotoxicity (<xref ref-type="bibr" rid="B29">Catania et al., 2019</xref>; <xref ref-type="bibr" rid="B62">Gong et al., 2018</xref>; <xref ref-type="bibr" rid="B40">de Rojas et al., 2021</xref>), which further compromises cholinergic signaling and reduces ACh levels (<xref ref-type="bibr" rid="B143">Pars et al., 2013</xref>; <xref ref-type="bibr" rid="B197">Wang and Reddy, 2017</xref>). Current FDA-approved therapies, including acetylcholinesterase inhibitors and NMDA receptor antagonists, address these downstream neurotransmitter disturbances but only offer limited symptomatic relief and do not meaningfully modify disease trajectory (<xref ref-type="bibr" rid="B143">Pars et al., 2013</xref>; <xref ref-type="bibr" rid="B197">Wang and Reddy, 2017</xref>; <xref ref-type="bibr" rid="B164">Ruangritchankul et al., 2021</xref>).</p>
<p>Although A&#x3b2; has long been a key therapeutic target, many A&#x3b2;-directed strategies have failed in clinical trials (<xref ref-type="bibr" rid="B37">Cummings J. L. et al., 2022</xref>; <xref ref-type="bibr" rid="B38">Cummings J. et al., 2022</xref>; <xref ref-type="bibr" rid="B171">Schott et al., 2019</xref>; <xref ref-type="bibr" rid="B9">Anderson et al., 2017</xref>). These failures may reflect the complexity and multifactorial nature of AD. Interventions are often initiated after extensive A&#x3b2; pathology has already developed, reducing the likelihood of therapeutic success (<xref ref-type="bibr" rid="B9">Anderson et al., 2017</xref>). Additionally, targeting A&#x3b2; alone is insufficient, as AD progression is shaped by interconnected processes such as neuroinflammation, oxidative stress, autophagy dysfunction, synaptic loss, and dysregulated APP processing (<xref ref-type="bibr" rid="B29">Catania et al., 2019</xref>; <xref ref-type="bibr" rid="B62">Gong et al., 2018</xref>; <xref ref-type="bibr" rid="B40">de Rojas et al., 2021</xref>). Collectively, these factors emphasize the need for multi-targeted or combination therapeutic strategies capable of addressing AD&#x2019;s broad pathological landscape.</p>
<p>Given the substantial time and financial investment required for new drug development, drug repurposing has emerged as a practical approach to accelerating therapeutic discovery. Repurposed drugs bypass early safety and pharmacokinetic stages and offer a more efficient and lower-risk path toward identifying agents with disease-modifying potential. Ultimately, the clinical imperative remains the development of therapies that can meaningfully slow or reverse AD progression, while improving patient quality of life.</p>
</sec>
</sec>
<sec id="s4">
<label>4</label>
<title>Autophagy dysregulation in AD pathogenesis</title>
<p>Autophagy is a key cellular pathway responsible for removing damaged proteins and organelles through lysosomal processing (<xref ref-type="bibr" rid="B54">Galluzzi et al., 2017</xref>). This process is essential for neuronal function and survival, as neurons are post-mitotic and cannot dilute toxic aggregates through cell division. Moreover, the adult brain has limited regenerative capacity, in part, due to inhibitory glial signaling and a restrictive extracellular environment, making efficient autophagy flux critical for maintaining neuronal homeostasis (<xref ref-type="bibr" rid="B50">Evans and Holzbaur, 2020</xref>; <xref ref-type="bibr" rid="B179">Suzuki et al., 2017</xref>; <xref ref-type="bibr" rid="B51">Fawcett, 2020</xref>).</p>
<p>Autophagic is a dynamic, lysosome-driven process that supports not only intracellular quality control but also key neuronal activities, including axonal maintenance, synaptic function, neuronal connectivity, and stem cell development (<xref ref-type="bibr" rid="B177">Stavoe and Holzbaur, 2019</xref>; <xref ref-type="bibr" rid="B193">Valencia et al., 2021</xref>; <xref ref-type="bibr" rid="B11">B et al., 2014</xref>). Impaired autophagy flux is strongly implicated in neurodegenerative diseases, particularly AD, where defective clearance of protein aggregates contributes to synaptic dysfunction, neuronal injury, and cell death (<xref ref-type="bibr" rid="B216">Zhang et al., 2022</xref>; <xref ref-type="bibr" rid="B141">Park et al., 2020</xref>). Understanding how autophagy becomes dysregulated in AD is therefore central to identifying new therapeutic targets.</p>
<p>Three primary autophagy pathways operate in mammalian cells: microautophagy, chaperone-mediated autophagy (CMA), and macroautophagy (<xref ref-type="bibr" rid="B54">Galluzzi et al., 2017</xref>). Microautophagy involves direct lysosomal membrane invagination, while CMA selectively delivers misfolded proteins to lysosomes via chaperone recognition (<xref ref-type="bibr" rid="B184">Tekirdag and Cuervo, 2018</xref>). Macroautophagy, the best-characterized pathway, sequesters cytoplasmic components within double-membrane autophagosomes that subsequently fuse with lysosomes for degradation (<xref ref-type="bibr" rid="B61">Gomes et al., 2017</xref>). This pathway is particularly important for clearing large structures, such as protein aggregates and dysfunctional mitochondria (<xref ref-type="bibr" rid="B50">Evans and Holzbaur, 2020</xref>; <xref ref-type="bibr" rid="B19">Bloemberg and Quadrilatero, 2019</xref>).</p>
<p>Although all three pathways contribute to proteostasis, dysfunction of macroautophagy has been most strongly associated with AD pathology (<xref ref-type="bibr" rid="B134">Ntsapi et al., 2018</xref>; <xref ref-type="bibr" rid="B91">Klionsky et al., 2021</xref>). As a result, therapeutic strategies aimed at restoring autophagic flux have gained substantial interest as potential interventions to mitigate neurodegeneration and promote neuronal resilience in AD.</p>
<sec id="s4-1">
<label>4.1</label>
<title>Mammalian target of rapamycin complex 1 (mTORC1) - dependent autophagy pathway</title>
<p>Autophagy is tightly coordinated by a conserved network of autophagy-related genes (ATGs) (<xref ref-type="bibr" rid="B101">Levine and Kroemer, 2019</xref>). A central upstream regulator of this process is the mammalian target of rapamycin (mTOR), a serine-threonine protein kinase that forms two major complexes: mTOR complex 1 (mTORC1) and mTOR complex 2 (<xref ref-type="bibr" rid="B170">Saxton and Sabatini, 2017</xref>). Among these, mTORC1 is the primary metabolic sensor, integrating inputs related to nutrient availability, growth factors, energy status, chronic stress, oxidative stress, and glucocorticoids (<xref ref-type="bibr" rid="B103">Li and hua, 2019</xref>; <xref ref-type="bibr" rid="B151">Rabanal-Ruiz et al., 2017</xref>).</p>
<p>mTORC1 negatively regulates autophagy; when activated, it inhibits the initiation of autophagosome formation. Hyperactivation of mTORC1, a hallmark of aging, suppresses autophagy flux, resulting in the progressive accumulation of damaged proteins and organelles (<xref ref-type="bibr" rid="B130">Nixon and Yang, 2012</xref>). Age-related increases in mTORC1 signalling, combined with general cellular decline, diminish autophagy efficiency (<xref ref-type="bibr" rid="B219">Zinecker and Simon, 2022</xref>; <xref ref-type="bibr" rid="B215">Zhang and Cuervo, 2008</xref>; <xref ref-type="bibr" rid="B132">Ntsapi and Loos, 2016</xref>). As clearance capacity falters, toxic aggregates and dysfunctional organelles accumulate, driving cellular stress and increasing susceptibility to age-associated pathologies, including neurodegenerative diseases.</p>
</sec>
<sec id="s4-2">
<label>4.2</label>
<title>An overview of the autophagy process</title>
<p>Upstream regulators such as phosphoinositide 3-kinase (PI3K) and protein kinase B (Akt/PKB) primarily through the PI3K/Akt/mTOR pathway (<xref ref-type="bibr" rid="B151">Rabanal-Ruiz et al., 2017</xref>). Inhibition of PI3K, Akt, or mTOR promotes autophagy and enhances A&#x3b2; clearance in AD models (<xref ref-type="bibr" rid="B124">Nilsson and Saido, 2014</xref>; <xref ref-type="bibr" rid="B125">Nilsson et al., 2013</xref>; <xref ref-type="bibr" rid="B126">Nilsson et al., 2014</xref>; <xref ref-type="bibr" rid="B128">Nixon, 2017</xref>; <xref ref-type="bibr" rid="B127">Nixon, 2007</xref>). Reactive oxygen species (ROS) also stimulate autophagy by suppressing Akt/mTORC1 signalling (<xref ref-type="bibr" rid="B87">Kaushal et al., 2019</xref>; <xref ref-type="bibr" rid="B92">Kma and Baruah, 2022</xref>).</p>
<p>Under nutrient-rich conditions, active mTORC1 inhibits autophagy initiation by phosphorylating the Unc-51-like autophagy activating kinase 1 (ULK1) complex (<xref ref-type="bibr" rid="B151">Rabanal-Ruiz et al., 2017</xref>). Upon mTORC1 inactivation, the ULK1 complex triggers formation of the phagophore, the precursor membrane that expands to form the autophagosome. The phagophore elongates through two ubiquitin-like conjugating systems: the ATG12-ATG5-ATG16L complex and microtubule-associated protein light chain 3 (LC3I, MAP1LC3B) (<xref ref-type="bibr" rid="B54">Galluzzi et al., 2017</xref>; <xref ref-type="bibr" rid="B207">Yang and Klionsky, 2010</xref>). LC3 is converted from its cytosolic (LC3-I) to its lipidated, membrane-bound form (LC3-II), which stabilizes the autophagosomal membrane and facilitates fusion with lysosomes (<xref ref-type="bibr" rid="B198">Wang et al., 2013</xref>) (<xref ref-type="fig" rid="F3">Figure 3</xref>). Autophagosomes sequester cytoplasmic cargo, including APP, A&#x3b2;, and tau-containing aggregates, relevant to AD pathology (<xref ref-type="bibr" rid="B108">Luc&#xe0; et al., 2021</xref>; <xref ref-type="bibr" rid="B212">Yu and Goncharova, 2022</xref>; <xref ref-type="bibr" rid="B72">Harrison et al., 2009</xref>).</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>Autophagy regulation by the mTORC1-dependent signalling pathway. Under nutrient-rich conditions, phosphoinositide 3-kinase (PI3K)/AKT signalling activates mTORC1, which inhibits the UNC-51-like kinase 1 (ULK1) complex and suppresses autophagy initiation. Mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) signalling also interacts with mTORC1, enhancing its activity and further contributing to autophagy suppression. In contrast, low adenosine triphosphate (ATP) levels activate AMP-activated protein kinase (AMPK), which inhibits mTORC1 and promotes ULK1 activation. Activated ULK1 stimulates class III phosphatidylinositol 3-kinase complex (PI3KC3; Vps34-ATG14L-Beclin 1), driving omegasome formation and phagophore nucleation. Beclin 1 is essential for omegasome nucleation and facilitates microtubule-associated protein 1 light chain 3 (LC3) lipidation. LC3 is conjugated to phosphatidylethanolamine (PE) to form LC3-II, a modification coordinated by Beclin 1 that enables phagophore elongation and autophagosome maturation. MAPK/c-Jun N-terminal kinase (MAPK/JNK) signalling inhibits B-cell lymphoma 2 (Bcl-2), relieving its suppression of the PI3KC3-Beclin 1 complex and thereby promoting autophagy initiation. The selective autophagy receptor sequestosome-1 (p62/SQSTM1) binds ubiquitinated cargo and is sequestered into the expanding phagophore. Mature autophagosomes fuse with lysosomes to form autolysosomes (autophagolysosomes), where autophagic cargo is degraded by lysosomal hydrolases and recycled into amino acids.</p>
</caption>
<graphic xlink:href="fphar-16-1748368-g003.tif">
<alt-text content-type="machine-generated">Diagram illustrating autophagy regulation and mTORC1-dependent signaling. It shows the interaction between various complexes and the formation of autophagic structures. Key components include PI3K/AKT, mTORC1, ULK1 Complex, and PI3KC3 Complex, leading to the formation of omegasome, phagophore, autophagosome, lysosome, and auto-lysosome. Processes like elongation, nucleation, fusion, and amino acid recycling are depicted, with visual elements like arrows indicating directional flow and interactions.</alt-text>
</graphic>
</fig>
<p>Mature autophagosomes fuse with lysosomes to form an autophagolysosome (autolysosome), where cargo is degraded by lysosomal hydrolases and the resulting metabolites are recycled (<xref ref-type="bibr" rid="B179">Suzuki et al., 2017</xref>; <xref ref-type="bibr" rid="B207">Yang and Klionsky, 2010</xref>). LC3-II serves as a marker of autophagosome formation, whereas decreased levels of sequestosome 1 (p62/SQSTM1) indicate efficient autophagic flux (<xref ref-type="bibr" rid="B11">B et al., 2014</xref>).</p>
<p>Beyond mTORC1, AMP-activated protein kinase (AMPK) is a key metabolic regulator that promotes autophagy under low-energy conditions (<xref ref-type="bibr" rid="B102">Li and Chen, 2019</xref>; <xref ref-type="bibr" rid="B199">Wang S. et al., 2022</xref>; <xref ref-type="bibr" rid="B183">Tamargo-G&#xf3;mez and Mari&#xf1;o, 2018</xref>). AMPK both inhibits mTORC1 and directly activates ULK1 (<xref ref-type="bibr" rid="B199">Wang S. et al., 2022</xref>; <xref ref-type="bibr" rid="B56">Garcia and Shaw, 2017</xref>). It also regulates the class III phosphatidylinositol 3-phosphate (class III PI3P) complex - comprising vacuolar protein sorting 34 (Vps34), Beclin-1 (BECN1), and Atg14L - which drives autophagosome nucleation (<xref ref-type="bibr" rid="B179">Suzuki et al., 2017</xref>; <xref ref-type="bibr" rid="B116">Menon and Dhamija, 2018</xref>; <xref ref-type="bibr" rid="B115">McKnight and Zhenyu, 2013</xref>).</p>
<p>mTORC2 also contributes to autophagy regulation by phosphorylating Akt (protein kinase B, PKB), which in turn enhances mTORC1 signaling (<xref ref-type="bibr" rid="B55">Gao et al., 2014</xref>). Full activation of mTORC1additionally requires the small GTPase Rheb, which is controlled by the tuberous sclerosis complex subunit 2 (TSC1/2) (<xref ref-type="bibr" rid="B100">Lemmon and Schlessinger, 2010</xref>; <xref ref-type="bibr" rid="B88">Khan et al., 2013</xref>). Akt suppresses TSC1/2, thereby releasing Rheb and promoting mTORC1 activation (<xref ref-type="bibr" rid="B134">Ntsapi et al., 2018</xref>; <xref ref-type="bibr" rid="B221">Zou et al., 2020</xref>; <xref ref-type="bibr" rid="B108">Luc&#xe0; et al., 2021</xref>). Dysregulation of both mTORC1 and mTORC2 has been implicated in AD (<xref ref-type="bibr" rid="B212">Yu and Goncharova, 2022</xref>; <xref ref-type="bibr" rid="B22">Boutouja et al., 2019</xref>), with reduced levels of each complex observed in human AD brain tissue (<xref ref-type="bibr" rid="B97">Lee et al., 2017</xref>). Pharmacological modulation of mTORC1 restores autophagic balance and demonstrates therapeutic potential in transgenic AD models (<xref ref-type="bibr" rid="B97">Lee et al., 2017</xref>; <xref ref-type="bibr" rid="B72">Harrison et al., 2009</xref>; <xref ref-type="bibr" rid="B28">Carro et al., 2006</xref>).</p>
</sec>
<sec id="s4-3">
<label>4.3</label>
<title>Impaired autophagy and protein aggregation in AD</title>
<p>In AD, the accumulation of A&#x3b2; compromises autophagy at later stages of the pathway, contributing to neuronal dysfunction and accelerated neuronal death <italic>in vitro</italic> and <italic>in vivo</italic>, as reported by Ntsapi and Loos (<xref ref-type="bibr" rid="B133">Ntsapi and Loos, 2021</xref>) and Lee et al. (<xref ref-type="bibr" rid="B98">Lee et al., 2022</xref>). A&#x3b2; accumulation is the central hallmark of AD and exerts neurotoxic effects. Dysregulated or suboptimal autophagy activity is therefore considered a key contributor to the onset and progression of AD (<xref ref-type="bibr" rid="B24">Cai et al., 2015</xref>). Whether autophagy is protective or harmful depends on the context, including the type of stress, the duration and intensity of autophagy induction, the efficiency of lysosomal clearance, and the overall &#x201c;autophagic flux&#x201d; (<xref ref-type="bibr" rid="B78">Jaeger and Wyss-Coray, 2009</xref>). Deleterious overactivation or prolonged induction may lead to autophagic cell death, occurring when autophagy persists excessively, causing the degradation of cytoplasm, organelles, or essential components, leading to energy failure and neuronal death. In contrast, neuroprotective autophagy typically occurs under normal or moderately stressed conditions, acting as a quality control mechanism that removes toxic proteins, maintains metabolic and organelle homeostasis, reduces neurotoxicity, and supports neuronal health (<xref ref-type="bibr" rid="B36">Cui and Zhao, 2025</xref>; <xref ref-type="bibr" rid="B176">Son et al., 2012</xref>).</p>
<p>Increased mTORC1 activity, associated with aging, further suppresses autophagy and promotes the buildup of damaged proteins and organelles (<xref ref-type="bibr" rid="B130">Nixon and Yang, 2012</xref>; <xref ref-type="bibr" rid="B129">Nixon and Yang, 2011</xref>). Age-related decline in autophagic efficiency is thus thought to facilitate the pathological processes underlying AD (<xref ref-type="bibr" rid="B7">Aman et al., 2021</xref>).</p>
<p>Autophagy is the primary intracellular mechanism involved in modulating APP processing and A&#x3b2; production, with substantial amounts of APP and its cleavage products found within autophagic vacuoles (AVs) (<xref ref-type="bibr" rid="B131">Nixon et al., 2005</xref>). AVs refer broadly to vesicular structures engaged in the autophagy pathway, including the pre-autophagosomal structures, autophagosomes, lysosomes, or autophagolysosomes (<xref ref-type="bibr" rid="B128">Nixon, 2017</xref>; <xref ref-type="bibr" rid="B20">Boland et al., 2008</xref>). These vesicles contain immunoreactive A&#x3b2; and APP-related cleavage products <italic>in vivo</italic> AD models (<xref ref-type="bibr" rid="B127">Nixon, 2007</xref>), highlighting their central role in A&#x3b2; generation and clearance.</p>
<p>Inhibition of mTOR has been shown to induce autophagy and reduce BACE expression in the APP/PS1 transgenic mouse model of AD (<xref ref-type="bibr" rid="B126">Nilsson et al., 2014</xref>; <xref ref-type="bibr" rid="B126">Nilsson et al., 2014</xref>; <xref ref-type="bibr" rid="B153">Rahman et al., 2020</xref>). Conversely, the autophagy inhibitor, 3-methyladenine (3-MA), enhances &#x3b3;-secretase activity and increases A&#x3b2; production (<xref ref-type="bibr" rid="B141">Park et al., 2020</xref>), highlighting the importance of maintaining normal autophagy activity for APP clearance. Loss of key ATGs leads to neurodegeneration driven by the accumulation of ubiquitinated aggregates (<xref ref-type="bibr" rid="B85">Karsli-Uzunbas et al., 2014</xref>; <xref ref-type="bibr" rid="B89">Kim et al., 2015</xref>; <xref ref-type="bibr" rid="B80">Jogalekar et al., 2021</xref>; <xref ref-type="bibr" rid="B189">Towers and Thorburn, 2016</xref>), whereas enhanced autophagy flux reverses protein buildup and supports neuronal and organismal health (<xref ref-type="bibr" rid="B178">Suresh et al., 2020</xref>).</p>
<p>Excessive activation of BACE and &#x3b3;-secretase accelerates AD progression by increasing APP processing and A&#x3b2; formation (<xref ref-type="bibr" rid="B175">Sinha et al., 1999</xref>; <xref ref-type="bibr" rid="B195">Vassar et al., 1999</xref>), further underscoring the regulatory role of autophagy in APP metabolism (<xref ref-type="bibr" rid="B153">Rahman et al., 2020</xref>; <xref ref-type="bibr" rid="B93">Kuang et al., 2020</xref>). Pharmacological induction of autophagy in animal models of AD promotes early degradation of APP and reduces (<xref ref-type="bibr" rid="B185">Tian et al., 2011</xref>). Ntsapi and Loos (<xref ref-type="bibr" rid="B133">Ntsapi and Loos, 2021</xref>) reported that the persistent A&#x3b2; accumulation compromises autophagy at later stages, leading to neuronal dysfunction and accelerated cell death <italic>in vitro</italic>. Indeed, dysregulated or insufficient autophagy is considered a major contributor to AD development and progression (<xref ref-type="bibr" rid="B134">Ntsapi et al., 2018</xref>; <xref ref-type="bibr" rid="B131">Nixon et al., 2005</xref>; <xref ref-type="bibr" rid="B178">Suresh et al., 2020</xref>).</p>
<p>Autophagy is also central to the intracellular processing of APP and A&#x3b2;, as AVs contain high levels of APP and its cleavage products (<xref ref-type="bibr" rid="B126">Nilsson et al., 2014</xref>; <xref ref-type="bibr" rid="B127">Nixon, 2007</xref>; <xref ref-type="bibr" rid="B21">Bordi et al., 2016</xref>). AVs in AD models contain immunoreactive A&#x3b2; and APP precursors (<xref ref-type="bibr" rid="B132">Ntsapi and Loos, 2016</xref>; <xref ref-type="bibr" rid="B100">Lemmon and Schlessinger, 2010</xref>), and the relatively stable levels of APP within AVs indicate that the cleavage of APP can also occur inside these vesicles (<xref ref-type="bibr" rid="B127">Nixon, 2007</xref>). This suggests that AVs may serve as sites for abnormal APP processing (<xref ref-type="bibr" rid="B213">Yu et al., 2004</xref>). Consistent with these findings, inhibition of mTOR induces autophagy and reduces BACE expression in the APP/PS1 transgenic mouse model of AD (<xref ref-type="bibr" rid="B125">Nilsson et al., 2013</xref>; <xref ref-type="bibr" rid="B126">Nilsson et al., 2014</xref>; <xref ref-type="bibr" rid="B131">Nixon et al., 2005</xref>). In contrast, the autophagy inhibitor 3-MA enhances &#x3b3;-secretase activity and increases A&#x3b2; production (<xref ref-type="bibr" rid="B24">Cai et al., 2015</xref>; <xref ref-type="bibr" rid="B213">Yu et al., 2004</xref>). Taken together, maintaining functional autophagy is essential for efficient and sustained clearance of APP and A&#x3b2;-related substrates in neuronal cells.</p>
</sec>
<sec id="s4-4">
<label>4.4</label>
<title>Modulation of autophagy in AD</title>
<p>There is substantial evidence supporting the therapeutic potential of targeting autophagy in the treatment of AD (<xref ref-type="bibr" rid="B217">Zhao et al., 2020</xref>; <xref ref-type="bibr" rid="B7">Aman et al., 2021</xref>; <xref ref-type="bibr" rid="B104">Li et al., 2022</xref>). In AD, impaired autophagy and protein aggregation reinforce one another in a vicious cycle that accelerates neurodegeneration, highlighting the need to identify safe and effective autophagy modulators. Recent research has explored cannabinoid-based therapeutics, which have shown promise in inducing autophagy and promoting cell death <italic>in vivo</italic> and <italic>in vitro</italic> in the context of cancer (<xref ref-type="bibr" rid="B96">Lastres-Becker et al., 2005</xref>; <xref ref-type="bibr" rid="B57">Garc&#xed;a et al., 2011</xref>). For example, Salazar and colleagues demonstrated that activation of the autophagy pathway is required for the antitumor effects of cannabinoids (<xref ref-type="bibr" rid="B167">Salazar et al., 2009</xref>). Additional work in MDA-MB-231 breast cancer cells indicated that cannabinoid-induced cell death and autophagy can occur independently of cannabinoid receptor activation. More recently, cannabidiol was shown to induce autophagy in an <italic>in vitro</italic> model of PD (<xref ref-type="bibr" rid="B82">Kang et al., 2021</xref>).</p>
<p>Collectively, these studies suggest that cannabinoid-based treatment approaches may hold therapeutic potential for a range of human diseases, including AD. However, further research is needed to identify cannabinoid-derived modulators that are both safe and effective, and to clarify the mechanisms through which cannabinoid-based autophagy may contribute to AD treatment. Continued advances in understanding pharmacokinetics and neuronal effects of cannabinoid-based therapeutics have made this an increasingly prominent area of biomedical research.</p>
</sec>
</sec>
<sec id="s5">
<label>5</label>
<title>The endocannabinoid system</title>
<p>The endocannabinoid system (ECS) is a complex cell-signalling system in humans and other animals (<xref ref-type="bibr" rid="B210">Yoder and Watson, 2017</xref>). It regulates a wide range of physiological and cognitive processes, including motor function (<xref ref-type="bibr" rid="B211">Young and Denovan-Wright, 2022</xref>; <xref ref-type="bibr" rid="B14">Basavarajappa et al., 2017</xref>), synaptic plasticity (<xref ref-type="bibr" rid="B147">Piette et al., 2020</xref>; <xref ref-type="bibr" rid="B75">Heifets and Castillo, 2009</xref>), neuroinflammation (<xref ref-type="bibr" rid="B23">Burstein and Zurier, 2009</xref>; <xref ref-type="bibr" rid="B110">Marchalant et al., 2009</xref>), and neural cell fate (<xref ref-type="bibr" rid="B66">Guzm&#xe1;n et al., 2002</xref>; <xref ref-type="bibr" rid="B65">Guzm&#xe1;n, 2003</xref>). The medical benefits of the <italic>Cannabis sativa</italic> plant date back to ancient times, with the earliest documented references appearing in the &#x201c;Pen-ts&#x2019;ao ching&#x201d;, regarded as the world&#x2019;s oldest <italic>pharmacopeia</italic> (China, 2737 BC) (<xref ref-type="bibr" rid="B140">Pantoja-Ruiz et al., 2022</xref>; <xref ref-type="bibr" rid="B222">Zuardi, 1999</xref>). In recent years, research interest has increasingly shifted toward targeting the ECS and investigating the use of phytocannabinoids, naturally occurring compounds that are found in the <italic>Cannabis sativa</italic> plant, as a potential therapeutic agent. This interest is largely driven by growing evidence of ECS dysfunction during the progression of AD (<xref ref-type="bibr" rid="B135">N&#xfa;&#xf1;ez et al., 2004</xref>; <xref ref-type="bibr" rid="B201">Westlake et al., 1994</xref>; <xref ref-type="bibr" rid="B17">Benito et al., 2008</xref>; <xref ref-type="bibr" rid="B165">Russo, 2018</xref>). The ECS plays a central role in maintaining homeostasis across several physiological functions, including cognition, anxiety regulation, pain perception, neurogenesis, immune signalling, inflammation, and synaptic responsiveness and plasticity (<xref ref-type="bibr" rid="B30">Chen et al., 2012</xref>). The ECS consists of two primary G-protein-coupled receptors, cannabinoid receptors 1 and 2 (CB1R and CB2R), as well as endocannabinoids such as anandamide (AEA) and 2-arachidonoylglycerol. It also includes metabolic enzymes such as fatty acid amide hydrolase (FAAH) and monoglyceride lipase (MAGL), which are responsible for the synthesis and degradation of endocannabinoids (<xref ref-type="bibr" rid="B5">Alexander, 2016</xref>; <xref ref-type="bibr" rid="B3">Aizpurua-Olaizola et al., 2017</xref>) (<xref ref-type="fig" rid="F4">Figure 4</xref>).</p>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption>
<p>Simplified scheme representing endocannabinoid system-modulated synaptic transmission. The endocannabinoids anandamide (AEA) and 2-arachidonoylglycerol (2-AG) are not stored in vesicles but are synthesized <italic>de novo</italic> from phospholipid precursors through calcium-dependent mechanisms. N-acylphosphatidylethanolamine (NAPE) is hydrolyzed by N-acylphosphatidylethanolamine-specific phospholipase D (NPLD) to yield AEA, while diacylglycerol (DAG) is converted to 2-AG by diacylglycerol lipase (DAGL). These lipid messengers diffuse retrogradely across the synaptic cleft to activate presynaptic cannabinoid receptor type 1 (CB1). CB1 receptor activation modulates ion channels, inhibits voltage-gated calcium influx, and suppresses neurotransmitter release, thereby providing negative feedback to regulate synaptic strength. Endocannabinoid signalling is terminated by enzymatic degradation: AEA is primarily metabolized to arachidonic acid (AA) and ethanolamine by fatty acid amide hydrolase (FAAH) in the postsynaptic neuron, whereas 2-AG is hydrolyzed presynaptically into AA and glycerol by monoacylglycerol lipase (MAGL). Through these mechanisms, the endocannabinoid system modulates synaptic strength, neuronal excitability, and overall network homeostasis.</p>
</caption>
<graphic xlink:href="fphar-16-1748368-g004.tif">
<alt-text content-type="machine-generated">Diagram of a presynaptic terminal showing neurotransmitter release. Key features include neurotransmitter synthesis in vesicles, calcium ion flows through voltage-gated channels, and activation of CB1 receptors by cannabinoids. The image illustrates processes like neurotransmitter binding to receptors, ion flow regulation, glial cell uptake, and potential generation. It also depicts components such as anandamide, 2-AG, DAG, and the role of metabotropic glutamate receptors. Pathways for synthesis and catabolism are labeled, and the overall flow of neurotransmitters and ions is indicated by arrows.</alt-text>
</graphic>
</fig>
<sec id="s5-1">
<label>5.1</label>
<title>The effects of cannabinoids on autophagy activity</title>
<p>Within the nervous system, the ECS is composed of naturally occurring lipid signalling pathways involved in numerous neurophysiological processes (<xref ref-type="bibr" rid="B173">Schuster et al., 2015</xref>). This system consists of endocannabinoid receptors, primarily CB1, predominantly expressed in the CNS, and CB2, mainly expressed peripherally in the microcirculation, along with metabolic enzymes that regulate the synthesis and degradation of endocannabinoids (<xref ref-type="bibr" rid="B196">Vrechi et al., 2021</xref>; <xref ref-type="bibr" rid="B200">Wang Z. et al., 2022</xref>). Through these components, the ECS plays a central role in maintaining neuronal function and homeostasis (<xref ref-type="bibr" rid="B60">Ghosh et al., 2021</xref>).</p>
<p>Autophagy is an evolutionarily conserved cellular degradation process that maintains cellular homeostasis and responds to proapoptotic stimuli and programmed cell death. It relies on the formation of specialized structures, including phagosomes, autophagosomes, and autophagolysosomes (<xref ref-type="bibr" rid="B139">Padman et al., 2019</xref>). Dysregulated autophagy has been implicated in a range of human diseases, including neurodegenerative disorders, and is closely linked to inflammatory processes (<xref ref-type="bibr" rid="B60">Ghosh et al., 2021</xref>; <xref ref-type="bibr" rid="B34">Chung et al., 2017</xref>). Autophagy can interact with apoptosis pathways, either promoting cell survival by downregulating apoptosis or contributing to cell death when co-activated with apoptotic mechanisms (<xref ref-type="bibr" rid="B167">Salazar et al., 2009</xref>; <xref ref-type="bibr" rid="B107">Lu et al., 2019</xref>).</p>
<p>Cannabinoids, particularly cannabidiol (CBD and tetrahydrocannabinol (THC), exhibit neuroprotective and anti-inflammatory effects, partly through autophagy modulation. One possible mechanism by which cannabinoids exert anti-inflammatory and neuroprotective effects is through the regulation of mitochondrial function through autophagy (<xref ref-type="bibr" rid="B107">Lu et al., 2019</xref>; <xref ref-type="bibr" rid="B218">Zhou et al., 2011</xref>; <xref ref-type="bibr" rid="B79">Ji et al., 2021</xref>). They can regulate mitochondrial function and activate peroxisome proliferator-activated receptor (PPAR)&#x3b3;, restoring autophagy, modulating apoptosis, and enhancing mitochondrial &#x3b2;-oxidation and biosynthesis (<xref ref-type="bibr" rid="B138">O&#x2019;Sullivan, 2016</xref>; <xref ref-type="bibr" rid="B123">Ni et al., 2022</xref>; <xref ref-type="bibr" rid="B159">Ribeiro et al., 2012</xref>). Activation of PPAR by cannabinoids has been associated with reduced inflammation in models of acute and chronic neuronal injury (<xref ref-type="bibr" rid="B83">Kapadia et al., 2008</xref>).</p>
<p>In animal studies, chronic administration of THC has been shown to influence apoptosis and immune responses in animal models, promoting cell survival and reducing inflammatory damage (<xref ref-type="bibr" rid="B118">Molina et al., 2014</xref>).</p>
<p>Notably, cannabinoids modulate key autophagy-regulatory pathways. CBD inhibits phosphorylation of PI3K, Akt, and mTORC1 in human cholangiocarcinoma cells, increasing LC3B-II and decreasing p62 expression&#x2013;classical markers of enhanced autophagic flux (<xref ref-type="bibr" rid="B148">Pongking et al., 2024</xref>). Although this study used a cancer model, it demonstrates that cannabinoids can shift PI3K/Akt/mTOR signalling toward autophagy, rather than proliferation. In neuronal models, CBD induces autophagy via Akt and extracellular signal-regulated kinase (ERK) modulation, independently of mTOR (<xref ref-type="bibr" rid="B196">Vrechi et al., 2021</xref>). Using human SH-SY5Y neuroblastoma cells, <xref ref-type="bibr" rid="B196">Vrechi et al. (2021)</xref> reported that 10&#xa0;&#xb5;M CBD increased autophagic flux (LC3-II, autophagosome/lysosome formation), reduced Akt phosphorylation, and activated ERK1/2, without altering classical mTORC1 downstream targets, indicating an mTOR-independent, ULK1-dependent mechanism. CBD also enhances neuronal health and longevity via autophagy. In hippocampal neurons, SH-SY5Y cells, and <italic>in vivo</italic> (<italic>Caenorhabditis elegans</italic>), CBD promoted autophagic flux, improved neuronal integrity, these effects were dependent on core ATGs and the sirtuin pathway, suggesting a multi-pathway mechanism converging on proteostasis and neuroprotection (<xref ref-type="bibr" rid="B200">Wang Z. et al., 2022</xref>).</p>
<p>Collectively, these findings indicate that cannabinoids can modulate autophagy through both PI3K/Akt/mTOR-dependent and independent mechanisms, enhancing neuronal resilience, maintaining proteostasis, and potentially counteracting neurodegenerative processes.</p>
</sec>
<sec id="s5-2">
<label>5.2</label>
<title>Cannabinoid-induced autophagy: receptor-dependent and independent pathways</title>
<p>Cannabinoid-induced autophagy operates through both receptor-dependent and receptor-independent mechanisms, varying with cell type and signalling context. In human SH-SY5Y neuroblastoma cells and murine astrocytes, CBD-induced autophagic flux was markedly reduced by antagonists of CB1, CB2, and transient receptor potential vanilloid 1 (TRPV1) - a Ca<sup>2&#x2b;</sup>-permeable ion channel that drives autophagy via Ca<sup>2&#x2b;</sup>/AMPK and ERK pathways (<xref ref-type="bibr" rid="B84">Karki et al., 2015</xref>). This indicates that activation of these receptors contributes to CBD&#x2019;s autophagy-modulating effects. CBD also modulated signalling pathways by suppressing Akt phosphorylation and activating ERK1/2, with autophagy induction dependent on ULK1, but independent of classical mTORC1 downstream targets (<xref ref-type="bibr" rid="B196">Vrechi et al., 2021</xref>). These observations suggest a receptor-dependent initiation step that feeds into a non-classical, mTOR-independent autophagy mechanism in neuronal cells.</p>
<p>Conversely, there is also evidence that supports receptor-independent activation of autophagy by cannabinoids. In cancer cell models, THC and related cannabinoids induce autophagy and cell death through endoplasmic reticulum (ER) stress, ceramide accumulation, and phosphorylation of eukaryotic initiation factor 2&#x3b1;, leading to inhibition of Akt/mTORC1 signalling and autophagy induction independent of cannabinoid receptor activation (<xref ref-type="bibr" rid="B167">Salazar et al., 2009</xref>). Cannabinoids can also trigger autophagy through non-receptor mechanisms such as ROS generation, ER stress, and activation of transient receptor potential channels, a family of calcium-permeable ion channels involved in Ca<sup>2&#x2b;</sup>-dependent autophagy signalling (<xref ref-type="bibr" rid="B136">Oakes et al., 2019</xref>). These findings support a broader ligand&#x2013;receptor-independent network through which cannabinoids can modulate autophagy. Taken together, current evidence supports a unified model in which cannabinoids induce autophagy through both receptor-dependent and receptor-independent pathways. In receptor-expressing cells, cannabinoids activate canonical targets (CB1/CB2/TRPV1), triggering downstream signalling (e.g., ERK1/2 activation, Akt inhibition) that engages ULK1 and initiates autophagy, often independent of mTORC1 regulation. In other cellular contexts - particularly stressed, non-neuronal, or transformed cells - cannabinoids can bypass surface receptors, promoting ER stress, ceramide accumulation, or ROS generation that converge on autophagic induction via suppression of survival pathways or activation of stress-response signalling. These two complementary mechanisms help reconcile divergent findings across models and demonstrate that cannabinoid-induced autophagy is context-dependent and driven by partially overlapping pathways. In neurodegenerative settings, such flexibility may be beneficial, as non-canonical pathways could maintain pro-autophagic activity even when receptor expression is altered (e.g., CB1 downregulation), thereby supporting proteostasis and cellular clearance.</p>
</sec>
<sec id="s5-3">
<label>5.3</label>
<title>ECS alterations in AD: implications for therapeutic strategies</title>
<p>The ECS has demonstrated neuroprotective properties against excitotoxicity, inflammation, and oxidative stress - pathological processes central to AD and targets of many current AD therapies (<xref ref-type="bibr" rid="B205">Xiong and Lim, 2021</xref>; <xref ref-type="bibr" rid="B194">van der Stelt et al., 2006</xref>; <xref ref-type="bibr" rid="B191">Trezza and Campolongo, 2013</xref>). Early evidence for a role of the ECS&#x2019;s in AD was based on the high density of CB1 receptors in the hippocampus and cerebral cortex (<xref ref-type="bibr" rid="B161">Riedel and Davies, 2005</xref>), as well as an increased expression of the endocannabinoid-metabolizing enzyme, FAAH, on plaque-associated astrocytes (<xref ref-type="bibr" rid="B16">Benito et al., 2003</xref>).</p>
<p>AD is associated with ECS alterations, though it remains debated whether ECS upregulation serves to counteract neuronal hyperactivity and neuroinflammation or whether it contributes to symptoms such as memory loss (<xref ref-type="bibr" rid="B138">O&#x2019;Sullivan, 2016</xref>; <xref ref-type="bibr" rid="B123">Ni et al., 2022</xref>). Consistently, studies have observed increased CB2R receptor expression in the brain tissue of individuals with AD and in AD-relevant animal models. This upregulation reflects immunomodulatory responses to pathogenic events. For example, clinical studies report elevated CB2R expression in microglia near hippocampal plaques (<xref ref-type="bibr" rid="B79">Ji et al., 2021</xref>), with a positive correlation between CB2R expression and A&#x3b2;42 levels and plaque burden (<xref ref-type="bibr" rid="B159">Ribeiro et al., 2012</xref>). Similarly, rats treated with A&#x3b2; exhibit increased CB2R levels (<xref ref-type="bibr" rid="B119">Monteiro et al., 2020</xref>; <xref ref-type="bibr" rid="B46">Esposito et al., 2006</xref>). Activation of microglial CB2R promotes A&#x3b2; clearance in human AD tissue sections (<xref ref-type="bibr" rid="B188">Tol&#xf3;n et al., 2009</xref>), and prevents A&#x3b2;-induced microglia activation <italic>in vitro</italic> and <italic>in vivo</italic> (<xref ref-type="bibr" rid="B156">Ram&#xed;rez et al., 2005</xref>).</p>
<p>In contrast, reductions in CB1R receptor expression have been observed in areas of microglial activation in both humans and AD-relevant rodent models (<xref ref-type="bibr" rid="B156">Ram&#xed;rez et al., 2005</xref>), and decreases in CB1R and the endocannabinoid AEA were reported in A&#x3b2;-treated rats (<xref ref-type="bibr" rid="B47">Esposito et al., 2007a</xref>). Moreover, cortical downregulation of AEA in AD post-mortem tissue correlates inversely with A&#x3b2;42 levels and cognitive deficits (<xref ref-type="bibr" rid="B81">Jung et al., 2012</xref>).</p>
<p>The ECS holds therapeutic potential due to its broad neuromodulatory effects, which in some cases mimic the results of FDA-approved drugs or provide superior symptom relief. For example, the synthetic endocannabinoid HU-211 (Dexanabinol), acts as a stereoselective NMDA receptor inhibitor, similar to MEM, reducing calcium influx and limiting excitotoxicity (<xref ref-type="bibr" rid="B63">Gowran et al., 2011</xref>; <xref ref-type="bibr" rid="B122">Nadler et al., 1993</xref>). Endocannabinoid-mediated neuroprotection against excitotoxicity is a well-established and can occur through multiple mechanisms (<xref ref-type="bibr" rid="B86">Kasatkina et al., 2021</xref>; <xref ref-type="bibr" rid="B206">Xu et al., 2017</xref>; <xref ref-type="bibr" rid="B2">Aguado et al., 2007</xref>; <xref ref-type="bibr" rid="B203">Wu et al., 2019</xref>). While the AD-ECS relationship is complex and requires further investigation, these findings suggest that key ECS components are critically involved in AD pathology and represent promising therapeutic targets.</p>
</sec>
</sec>
<sec id="s6">
<label>6</label>
<title>The effects of phytocannabinoids on A&#x3b2;-related pathology in AD</title>
<p>Cannabis sativa (commonly known as hemp or marijuana) is a multipurpose plant belonging to the family Cannabaceae, widely used for medicinal, recreational, and industrial purposes (<xref ref-type="bibr" rid="B43">Dowling et al., 2021</xref>). The plant contains more than 500 bioactive compounds, including over 100 phytocannabinoids, with diverse pharmacological properties (<xref ref-type="bibr" rid="B64">G&#xfc;lck and M&#xf8;ller, 2020</xref>; <xref ref-type="bibr" rid="B27">Caprioglio et al., 2022</xref>). These compounds have attracted significant interest for their potential therapeutic effects in neurodegenerative diseases such as AD.</p>
<p>Among them, THC and CBD are the most extensively studied for their neuroprotective and disease-modifying potential (<xref ref-type="bibr" rid="B45">Elsohly and Slade, 2005</xref>; <xref ref-type="bibr" rid="B157">Reekie et al., 2017</xref>). Although they share the same molecular formula (C<sub>21</sub>H<sub>30</sub>O<sub>2</sub>) and a terpenophenolic backbone, their distinct functional groups result in different receptor interactions and pharmacokinetic profiles. THC contains a cyclic ether (closed-ring) structure and acts primarily as a partial agonist at CB<sub>1</sub> receptors within the CNS. In contrast, CBD contains free hydroxyl groups (open-chain), shows low direct affinity for CB<sub>1</sub> receptors, and instead modulates the ECS indirectly through allosteric and non-canonical pathways (<xref ref-type="bibr" rid="B145">Pertwee, 2008</xref>).</p>
<p>Both CBD (non-intoxicating) and THC modulate the ECS and exhibit neuroprotective, anti-inflammatory, and antioxidant properties. Emerging evidence suggests that these phytocannabinoids exert therapeutic-like effects on AD-related pathology, including A&#x3b2; accumulation and tau hyperphosphorylation (<xref ref-type="bibr" rid="B35">Coles et al., 2022</xref>; <xref ref-type="bibr" rid="B13">Barber et al., 2023</xref>; <xref ref-type="bibr" rid="B105">Libro et al., 2016</xref>). Collectively, these findings highlight the therapeutic promise of cannabinoids as modulators of key neurodegenerative pathways and support further investigation into their molecular mechanisms and translational potential for AD management.</p>
<sec id="s6-1">
<label>6.1</label>
<title>CBD&#x2019;s neuroprotective potential in AD</title>
<p>Preclinical evidence increasingly supports the therapeutic potential of CBD in AD through multiple molecular and cellular mechanisms.</p>
<p>
<italic>In vitro,</italic> CBD demonstrates several neuroprotective properties directly relevant to AD pathology. It inhibits tau hyperphosphorylation and reduces APP expression in APP-transfected human neuroblastoma cells. CBD also downregulates BACE1, PS1, and PS2 - key genes involved in the enzymatic generation of A&#x3b2; (<xref ref-type="bibr" rid="B105">Libro et al., 2016</xref>). Additionally, CBD protects against A&#x3b2;-induced cytotoxicity in inducible human neuron-like cell models (<xref ref-type="bibr" rid="B172">Schubert et al., 2019</xref>), while hemp CBD-rich hemp seed oil (&#x223c;80% CBD) significantly reduces A&#x3b2;<sub>42</sub> &#x2b; Cu(II)-induced oxidative stress (<xref ref-type="bibr" rid="B155">Raja et al., 2020</xref>). Beyond its antioxidant effects, CBD has been shown to restore mitochondrial function (<xref ref-type="bibr" rid="B155">Raja et al., 2020</xref>; <xref ref-type="bibr" rid="B48">Esposito et al., 2007b</xref>), a central feature of AD pathogenesis. Recent preclinical findings further reinforce these mechanisms, showing that CBD decreases phosphorylated tau and A&#x3b2; aggregation, reduces their axonal spread between cortical and hippocampal neurons, and promotes microglial polarization toward a neuroprotective M2 phenotype (<xref ref-type="bibr" rid="B154">Ra&#xef;ch et al., 2025</xref>). This study additionally showed that CBD reduces ROS formation, enhances neuronal viability, and partially restores neurite formation disrupted by A&#x3b2; and Tau, highlighting CBD&#x2019;s role in supporting neuronal structural integrity.</p>
<p>
<italic>In vivo</italic> studies further support these neuroprotective effects. Short-term CBD treatment (7 days) attenuates A&#x3b2;-evoked neuroinflammation (<xref ref-type="bibr" rid="B113">Mart&#xed;n-Moreno et al., 2011</xref>), whereas chronic administration of 20&#xa0;mg/kg CBD prevents learning and memory impairments in A&#x3b2; pharmacological mouse models (<xref ref-type="bibr" rid="B35">Coles et al., 2022</xref>; <xref ref-type="bibr" rid="B32">Cheng et al., 2014a</xref>). Dose-dependent effects have also been observed in APP/PS1 transgenic mice, where chronic CBD treatment (5&#x2013;50&#xa0;mg/kg) not only reverses established cognitive deficits and, at 20&#xa0;mg/kg, also prevents their onset (<xref ref-type="bibr" rid="B35">Coles et al., 2022</xref>; <xref ref-type="bibr" rid="B33">Cheng et al., 2014b</xref>; <xref ref-type="bibr" rid="B26">Cao et al., 2014</xref>). These results align with emerging evidence showing that chronic daily CBD administration (10&#xa0;mg/kg for 28 days) significantly improves both short- and long-term spatial memory in 5xFAD mice, underscoring CBD&#x2019;s capacity to ameliorate behavioral and cognitive impairments in AD models (<xref ref-type="bibr" rid="B154">Ra&#xef;ch et al., 2025</xref>). Additional evidence from a sporadic AD model demonstrates that CBD restores object recognition, spatial memory, and social behavior, reduces hippocampal pro-inflammatory gene expression, mitigates increases in A&#x3b2; and p-Tau, and exerts its cognitive and anti-inflammatory effects predominantly through CB1 receptor activation (<xref ref-type="bibr" rid="B187">Toledano and Akirav, 2025</xref>).</p>
<p>Although clinical data remain limited, expanding translational interest has triggered several ongoing clinical trials investigating CBD-based therapies for AD (e.g., NCT04436081, 2019-002106-52, ACTRN12621001364864). Notably, emerging evidence from a 26-week randomized controlled trial of low-dose THC-CBD extract reported significantly improved MMSE scores and a favorable safety profile compared with placebo (<xref ref-type="bibr" rid="B154">Ra&#xef;ch et al., 2025</xref>).</p>
<p>Collectively, the preclinical evidence highlights CBD&#x2019;s multimodal actions, including anti-inflammatory, antioxidant, mitochondrial-restorative, and anti-amyloidogenic, underscoring its promise as a disease-modifying candidate for AD intervention.</p>
</sec>
<sec id="s6-2">
<label>6.2</label>
<title>THC&#x2019;s neuroprotective potential in AD</title>
<p>THC is the principal psychoactive phytocannabinoid in <italic>Cannabis sativa</italic>. Structurally, it is a diterpenoid featuring a 6a,7,8,10a-tetrahydro-6H-benzo [c]chromene core substituted by a hydroxyl group at position 1, two methyl groups at position 6, one methyl group at position 9, and a pentyl group at position 3 (<xref ref-type="bibr" rid="B192">Tyrakis et al., 2024</xref>). Pharmacologically, THC acts primarily as a partial agonist at CB<sub>1</sub> and CB<sub>2</sub> receptors, producing neuroactive, analgesic, and psychotropic effects (<xref ref-type="bibr" rid="B99">Lee et al., 2024</xref>; <xref ref-type="bibr" rid="B220">Zou and Kumar, 2018</xref>; <xref ref-type="bibr" rid="B142">Paronis et al., 2012</xref>). Its actions extend beyond canonical ECS to include modulation of neurotransmission, oxidative stress, and amyloid processing&#x2014;mechanisms highly relevant to AD pathophysiology.</p>
<p>Preclinical evidence indicates that THC targets multiple AD-related pathways. <italic>In vitro</italic>, THC attenuates pathological processes in neuro-2a APPSwe cells (<xref ref-type="bibr" rid="B111">Marsh et al., 2024</xref>). A notable finding is its competitive inhibition of AChE, preventing the breakdown of ACh, a neurotransmitter significantly depleted in AD (<xref ref-type="bibr" rid="B168">Sam and Bordoni, 2023</xref>; <xref ref-type="bibr" rid="B150">Puopolo et al., 2022</xref>). By enhancing cholinergic signalling, THC may provide symptomatic benefits similar to conventional AChE inhibitors but without the hepatotoxicity associated with agents such as Tacrine (Cognex). THC has also been shown to inhibit A&#x3b2; aggregation, thereby potentially reducing amyloid plaque formation and associated neurotoxicity (<xref ref-type="bibr" rid="B49">Eubanks et al., 2006</xref>; <xref ref-type="bibr" rid="B25">Calabrese and Rubio-Casillas, 2018</xref>).</p>
<p>Recent preclinical findings further reinforce THC&#x2019;s mechanistic relevance in AD models. A 2024 study using APP/PS1 mice demonstrated that low-dose THC combined with CBD modulates hippocampal glutamate dynamics, reducing extracellular glutamate and hippocampal hyperexcitability - a key contributor to excitotoxic injury in AD (<xref ref-type="bibr" rid="B111">Marsh et al., 2024</xref>). Complementing these <italic>in vivo</italic> findings, the <italic>in vitro</italic> experiments using cannabis extracts standardized for THC demonstrated neuroprotection against A&#x3b2;-induced cytotoxicity, improving neuronal viability and reducing amyloid-mediated oxidative damage.</p>
<p>In clinical contexts, THC-based formulations have primarily been used for appetite stimulation, antiemetic purposes, and the management of behavioral and psychological symptoms of dementia, including agitation and weight loss (223&#x2013;226). Such interactions are dose-dependent and often biphasic, meaning that therapeutic outcomes depend critically on dose ratios, treatment duration, and biological context (232&#x2013;234).</p>
<p>Although clinical evidence remains limited, research interest in THC-based interventions for AD is increasing. Two ongoing clinical trials (NCT04516057, NCT02792257) are specifically assessing THC-containing treatments for agitation in AD patients. These studies aim to determine the optimal dosing strategies, safety profiles, and whether THC - alone or in combination with CBD - may offer symptomatic relief or even disease-modifying potential. These investigations are supported by preclinical and narrative review evidence, which highlights THC&#x2019;s multilayered neuroprotective effects, including anti-inflammatory, antioxidant, and anti-amyloidogenic actions (<xref ref-type="bibr" rid="B192">Tyrakis et al., 2024</xref>), positioning it as a promising candidate for modulating AD-related neurodegeneration.</p>
</sec>
<sec id="s6-3">
<label>6.3</label>
<title>Multi-cannabinoid approaches in AD pathophysiology</title>
<p>Although clinical evidence remains limited, research interest in cannabinoid-based interventions for AD has increased substantially in recent years. Two ongoing trials (NCT04516057, NCT02792257) are evaluating THC-containing interventions for agitation in AD patients, reflecting a broader shift toward assessing cannabinoids for both behavioral and potential neuroprotective effects. Emerging evidence increasingly supports multi-cannabinoid formulations, particularly THC and CBD combinations, which produce effects not observed with either compound alone.</p>
<p>The first robust clinical evidence for such combinations was provided by <xref ref-type="bibr" rid="B39">Cury et al. (2025)</xref>, who conducted a 26-week, randomized, double-blind, placebo-controlled Phase-2 trial of a low-dose balanced THC: CBD extract (0.350&#xa0;mg THC &#x2b;0.245&#xa0;mg CBD daily) in older adults with AD-associated dementia. The THC: CBD group showed significant improvement in Mini-Mental State Examination (MMSE) scores versus placebo, without increased adverse events (<xref ref-type="bibr" rid="B39">Cury et al., 2025</xref>). Although secondary outcomes were unchanged, the study demonstrates that chronic low-dose THC: CBD can be safely administered and provides preliminary evidence of symptomatic cognitive benefit, warranting larger, biomarker-rich trials.</p>
<p>Mechanistic is provided by <xref ref-type="bibr" rid="B169">S&#xe1;nchez-Fern&#xe1;ndez et al. (2024)</xref>, who examined hippocampal glutamate dynamics in APP/PS1 mice chronically treated with non-psychoactive doses of THC &#x2b; CBD. The combination, but not either cannabinoid alone, reduced extracellular glutamate levels and lowered hippocampal excitability, two alterations closely linked to excitotoxic injury and cognitive decline in AD. Notably, these effects occurred without overt changes in synaptic structure or canonical synaptic plasticity markers, suggesting that THC &#x2b; CBD may act through modulation of glutamate uptake, clearance, or network-level excitability rather than direct synaptic remodelling (<xref ref-type="bibr" rid="B169">S&#xe1;nchez-Fern&#xe1;ndez et al., 2024</xref>). These results support a mechanistic rationale for combination therapy, with THC and CBD appearing to produce emergent effects that cannot be inferred from single-approach studies. This highlights the importance of including neurochemical and electrophysiological biomarkers, such as magnetic resonance spectroscopy (glutamate), EEG markers of excitability, and fluid synaptic injury markers, when evaluating cannabinoid interventions in translational studies.</p>
<p>Further preclinical evidence from <xref ref-type="bibr" rid="B10">Arnanz et al. (2024)</xref> in the 5xFAD mouse model, an aggressive amyloidogenic AD model, showed that chronic low-dose treatment with a THC: CBD combination improved spatial memory, whereas the single agents did not. Interestingly, all cannabinoid-treated groups, including the combination, exhibited increased A&#x3b2;<sub>42</sub> cortical levels, highlighting complex effects on amyloid processing. Cognitive improvements occurred without significant changes in classical inflammatory markers, underscoring that multi-cannabinoid therapy may exert functional benefits via mechanisms distinct from classical anti-inflammatory pathways. These findings indicate that while combination therapy offers synergistic behavioural benefits, careful longitudinal assessment of amyloid and other disease-modifying endpoints is essential.</p>
<p>Collectively, these studies highlight that multi-cannabinoid regimens exert synergistic effects across cognitive, excitotoxic, and network-level outcomes. THC and CBD engage complementary mechanisms, including CB1/CB2 modulation, glutamate regulation, and antioxidant activity, while divergent effects on amyloid pathology underscore the need for mechanistically informed, biomarker-guided clinical trials. Overall, the evidence provides a strong rationale for advancing multi-cannabinoid therapeutics in AD, with clear priorities for dose optimization, biomarker integration, and longitudinal evaluation to determine both symptomatic and disease-modifying potential in future translational and clinical studies.</p>
</sec>
<sec id="s6-4">
<label>6.4</label>
<title>Potential cannabinoid interactions with FDA-approved AD therapies</title>
<p>Multi-cannabinoid interventions in AD raise important considerations regarding interactions with FDA-approved therapies, including AChEIs and MEM. Recent <italic>in vitro</italic> studies demonstrate that CBD, THC, and other cannabinoids moderately inhibit AChE and butyrylcholinesterase (BChE), a related cholinergic enzyme that hydrolyzes acetylcholine and other choline esters. In AD, BChE activity increases in later stages, and its inhibition can help sustain cholinergic signaling, complementing AChE-targeted therapies (<xref ref-type="bibr" rid="B150">Puopolo et al., 2022</xref>; <xref ref-type="bibr" rid="B144">Patil et al., 2023</xref>). While these interactions suggest potential synergy, high doses could theoretically amplify cholinergic effects and increase adverse events.</p>
<p>Interactions with MEM are more complex: both cannabinoids and MEM modulate glutamatergic signaling, with preclinical data indicating potential for synergistic neuroprotection as well as receptor-level antagonism depending on dose and context (<xref ref-type="bibr" rid="B112">Marszalek-Grabska et al., 2021</xref>). Pharmacokinetic interactions are also notable, as CBD and THC influence cytochrome P450 enzymes (CYP3A4, CYP2C19, CYP2D6), which metabolize many AChEIs and memantine, highlighting the need for dose optimization and careful monitoring in older adults with polypharmacy (<xref ref-type="bibr" rid="B12">Balachandran et al., 2021</xref>; <xref ref-type="bibr" rid="B15">Beers et al., 2021</xref>).</p>
<p>Future studies should prioritize preclinical combination models alongside early-phase clinical trials to comprehensively evaluate safety, pharmacokinetics, pharmacodynamics, and efficacy. This includes preclinical experiments assessing cognitive, synaptic, and biomarker outcomes, as well as phase 1-2 trials examining cannabinoids in combination with AChEIs or MEM. Such research is essential to determine whether multi-cannabinoid therapy can safely and effectively complement existing AD treatments, optimizing symptomatic relief while minimizing potential adverse interactions.</p>
</sec>
</sec>
<sec sec-type="conclusion" id="s7">
<label>7</label>
<title>Conclusion</title>
<p>The therapeutic potential of cannabinoid-based interventions for AD is well-supported; however, the inherent chemical complexity of <italic>Cannabis sativa</italic> continues to pose significant translational challenges. Precisely defined formulations, as well as careful control of dose, ratio, and route of administration routes, remain essential to achieving consistent therapeutic outcomes. Emerging evidence, including a recent case report (<xref ref-type="bibr" rid="B166">Ruver-Martins et al., 2022</xref>), suggests that cannabinoid microdosing may offer a potential strategy for reducing AD-related symptoms while minimizing adverse effects. Yet, these preliminary findings require rigorous validation through larger, well-controlled clinical studies. Pharmacokinetic data further indicate that multi-cannabinoid formulations, particularly those combining THC and CBD, add additional minor cannabinoids, may provide enhanced therapeutic efficacy and improved safety profiles compared to monotherapy (<xref ref-type="bibr" rid="B223">Zuardi et al., 2012</xref>). However, it is important to note that evidence on cannabinoid-induced autophagy in AD remains limited and heterogeneous. Most studies are preclinical, with variations in cannabinoid type, dose, and measurement of autophagy markers, and quantitative data in disease-relevant models are sparse, highlighting a critical knowledge gap. Although both <italic>in vitro</italic> and <italic>in vivo</italic> studies increasingly support the potential of such combination therapies, the mechanistic interplay between multi-cannabinoid therapeutics, autophagy modulation, and neuronal survival remains insufficiently understood. Therefore, there is an urgent need for comprehensive, mechanistically grounded research to define the optimal THC: CBD ratio and broader cannabinoid profiles capable of effectively modulating autophagy, mitigating amyloidogenic and inflammatory pathways, and ultimately providing robust neuroprotection in AD-relevant experimental systems. Such work will be critical for translating cannabinoid-based treatments from promising preclinical leads into safe, targeted, and effective clinical interventions for AD.</p>
</sec>
</body>
<back>
<sec sec-type="author-contributions" id="s8">
<title>Author contributions</title>
<p>CN: Conceptualization, Visualization, Funding acquisition, Project administration, Validation, Resources, Data curation, Formal Analysis, Software, Writing &#x2013; review and editing, Writing &#x2013; original draft, Investigation. MW: Software, Writing &#x2013; original draft, Visualization, Writing &#x2013; review and editing. RC: Writing &#x2013; review and editing, Writing &#x2013; original draft. TJ: Writing &#x2013; review and editing, Writing &#x2013; original draft. MM: Writing &#x2013; original draft, Writing &#x2013; review and editing.</p>
</sec>
<ack>
<title>Acknowledgements</title>
<p>We express our gratitude to the UFS Faculty of Health Sciences, School of Biomedical Sciences, Department of Basic Medical Sciences, for their invaluable support.</p>
</ack>
<sec sec-type="COI-statement" id="s10">
<title>Conflict of interest</title>
<p>The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="ai-statement" id="s11">
<title>Generative AI statement</title>
<p>The author(s) declared that generative AI was used in the creation of this manuscript. Generative AI tools, including Grammarly and QuillBot, were used solely for minor editorial purposes such as grammar, phrasing, and readability improvements. All intellectual content, analysis, and interpretations in this manuscript were conceived, developed, and verified by the authors, who take full responsibility for the accuracy and integrity of the work.</p>
<p>Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.</p>
</sec>
<sec sec-type="disclaimer" id="s12">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<fn-group>
<fn fn-type="custom" custom-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/28921/overview">Karl Tsim</ext-link>, Hong Kong University of Science and Technology, Hong Kong SAR, China</p>
</fn>
<fn fn-type="custom" custom-type="reviewed-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1919773/overview">Ramoji Kosuru</ext-link>, Versiti Blood Research Institute, United States</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/2798057/overview">Gabriela Dumitrita Stanciu</ext-link>, Grigore T. Popa University of Medicine and Pharmacy, Romania</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="B1">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Agnello</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Ciaccio</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Neurodegenerative diseases: from molecular basis to therapy</article-title>. <source>Int. J. Mol. Sci.</source> <volume>23</volume> (<issue>21</issue>), <fpage>12854</fpage>. <pub-id pub-id-type="doi">10.3390/ijms232112854</pub-id>
<pub-id pub-id-type="pmid">36361643</pub-id>
</mixed-citation>
</ref>
<ref id="B2">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aguado</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Romero</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Monory</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Palazuelos</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Sendtner</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Marsicano</surname>
<given-names>G.</given-names>
</name>
<etal/>
</person-group> (<year>2007</year>). <article-title>The CB1 cannabinoid receptor mediates excitotoxicity-induced neural progenitor proliferation and neurogenesis</article-title>. <source>J. Biol. Chem.</source> <volume>282</volume> (<issue>33</issue>), <fpage>23892</fpage>&#x2013;<lpage>23898</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M700678200</pub-id>
<pub-id pub-id-type="pmid">17556369</pub-id>
</mixed-citation>
</ref>
<ref id="B3">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aizpurua-Olaizola</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Elezgarai</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Rico-Barrio</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Zarandona</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Etxebarria</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Usobiaga</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Targeting the endocannabinoid system: future therapeutic strategies</article-title>. <source>Drug Discov. Today</source> <volume>22</volume> (<issue>1</issue>), <fpage>105</fpage>&#x2013;<lpage>110</lpage>. <pub-id pub-id-type="doi">10.1016/j.drudis.2016.08.005</pub-id>
<pub-id pub-id-type="pmid">27554802</pub-id>
</mixed-citation>
</ref>
<ref id="B4">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alawode</surname>
<given-names>D. O. T.</given-names>
</name>
<name>
<surname>Fox</surname>
<given-names>N. C.</given-names>
</name>
<name>
<surname>Zetterberg</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Heslegrave</surname>
<given-names>A. J.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Alzheimer&#x2019;s disease biomarkers revisited from the amyloid Cascade hypothesis standpoint</article-title>. <source>Front. Neurosci.</source> <volume>16</volume>, <fpage>837390</fpage>. <pub-id pub-id-type="doi">10.3389/fnins.2022.837390</pub-id>
<pub-id pub-id-type="pmid">35573283</pub-id>
</mixed-citation>
</ref>
<ref id="B5">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alexander</surname>
<given-names>S. P. H.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Therapeutic potential of cannabis-related drugs</article-title>. <source>Prog. Neuropsychopharmacol. Biol. Psychiatry</source> <volume>64</volume>, <fpage>157</fpage>&#x2013;<lpage>166</lpage>. <pub-id pub-id-type="doi">10.1016/j.pnpbp.2015.07.001</pub-id>
<pub-id pub-id-type="pmid">26216862</pub-id>
</mixed-citation>
</ref>
<ref id="B6">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alhazmi</surname>
<given-names>H. A.</given-names>
</name>
<name>
<surname>Albratty</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>An update on the novel and approved drugs for Alzheimer disease</article-title>. <source>Saudi Pharm. J. SPJ</source> <volume>30</volume> (<issue>12</issue>), <fpage>1755</fpage>&#x2013;<lpage>1764</lpage>. <pub-id pub-id-type="doi">10.1016/j.jsps.2022.10.004</pub-id>
<pub-id pub-id-type="pmid">36601504</pub-id>
</mixed-citation>
</ref>
<ref id="B7">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aman</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Schmauck-Medina</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Hansen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Morimoto</surname>
<given-names>R. I.</given-names>
</name>
<name>
<surname>Simon</surname>
<given-names>A. K.</given-names>
</name>
<name>
<surname>Bjedov</surname>
<given-names>I.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Autophagy in healthy aging and disease</article-title>. <source>Nat. Aging</source> <volume>1</volume> (<issue>8</issue>), <fpage>634</fpage>&#x2013;<lpage>650</lpage>. <pub-id pub-id-type="doi">10.1038/s43587-021-00098-4</pub-id>
<pub-id pub-id-type="pmid">34901876</pub-id>
</mixed-citation>
</ref>
<ref id="B9">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anderson</surname>
<given-names>R. M.</given-names>
</name>
<name>
<surname>Hadjichrysanthou</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Evans</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>M. M.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Why do so many clinical trials of therapies for Alzheimer&#x2019;s disease fail?</article-title> <source>Lancet</source> <volume>390</volume> (<issue>10110</issue>), <fpage>2327</fpage>&#x2013;<lpage>2329</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(17)32399-1</pub-id>
<pub-id pub-id-type="pmid">29185425</pub-id>
</mixed-citation>
</ref>
<ref id="B10">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arnanz</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Ruiz de Mart&#xed;n Esteban</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Mart&#xed;nez Relimpio</surname>
<given-names>A. M.</given-names>
</name>
<name>
<surname>Rimmerman</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Tweezer Zaks</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Grande</surname>
<given-names>M. T.</given-names>
</name>
<etal/>
</person-group> (<year>2024</year>). <article-title>Effects of chronic, low-dose cannabinoids, cannabidiol, Delta-9-Tetrahydrocannabinol and a combination of both, on amyloid pathology in the 5xFAD mouse model of alzheimer&#x2019;s disease</article-title>. <source>Cannabis Cannabinoid Res.</source> <volume>9</volume> (<issue>5</issue>), <fpage>1312</fpage>&#x2013;<lpage>1325</lpage>. <pub-id pub-id-type="doi">10.1089/can.2023.0101</pub-id>
<pub-id pub-id-type="pmid">37862567</pub-id>
</mixed-citation>
</ref>
<ref id="B11">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>B</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>A du</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Jh</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Defining and measuring autophagosome Flux&#x2014;concept and reality</article-title>. <source>Autophagy</source> <volume>10</volume> (<issue>11</issue>), <fpage>2087</fpage>&#x2013;<lpage>2096</lpage>. <pub-id pub-id-type="doi">10.4161/15548627.2014.973338</pub-id>
<pub-id pub-id-type="pmid">25484088</pub-id>
</mixed-citation>
</ref>
<ref id="B12">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Balachandran</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Elsohly</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hill</surname>
<given-names>K. P.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Cannabidiol interactions with medications, illicit substances, and alcohol: a comprehensive review</article-title>. <source>J. Gen. Intern Med.</source> <volume>36</volume> (<issue>7</issue>), <fpage>2074</fpage>&#x2013;<lpage>2084</lpage>. <pub-id pub-id-type="doi">10.1007/s11606-020-06504-8</pub-id>
<pub-id pub-id-type="pmid">33515191</pub-id>
</mixed-citation>
</ref>
<ref id="B13">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barber</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Mendonca</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Soliman</surname>
<given-names>K. F. A.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>The neuroprotective effects and therapeutic potential of the chalcone cardamonin for alzheimer&#x2019;s disease</article-title>. <source>Brain Sci.</source> <volume>13</volume> (<issue>1</issue>), <fpage>145</fpage>. <pub-id pub-id-type="doi">10.3390/brainsci13010145</pub-id>
<pub-id pub-id-type="pmid">36672126</pub-id>
</mixed-citation>
</ref>
<ref id="B14">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Basavarajappa</surname>
<given-names>B. S.</given-names>
</name>
<name>
<surname>Shivakumar</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Joshi</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Subbanna</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Endocannabinoid system in neurodegenerative disorders</article-title>. <source>J. Neurochem.</source> <volume>142</volume> (<issue>5</issue>), <fpage>624</fpage>&#x2013;<lpage>648</lpage>. <pub-id pub-id-type="doi">10.1111/jnc.14098</pub-id>
<pub-id pub-id-type="pmid">28608560</pub-id>
</mixed-citation>
</ref>
<ref id="B15">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beers</surname>
<given-names>J. L.</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Jackson</surname>
<given-names>K. D.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Cytochrome P450&#x2013;Catalyzed metabolism of cannabidiol to the active metabolite 7-Hydroxy-Cannabidiol</article-title>. <source>Drug Metab. Dispos.</source> <volume>49</volume> (<issue>10</issue>), <fpage>882</fpage>&#x2013;<lpage>891</lpage>. <pub-id pub-id-type="doi">10.1124/dmd.120.000350</pub-id>
<pub-id pub-id-type="pmid">34330718</pub-id>
</mixed-citation>
</ref>
<ref id="B16">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Benito</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>N&#xfa;&#xf1;ez</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Tol&#xf3;n</surname>
<given-names>R. M.</given-names>
</name>
<name>
<surname>Carrier</surname>
<given-names>E. J.</given-names>
</name>
<name>
<surname>R&#xe1;bano</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hillard</surname>
<given-names>C. J.</given-names>
</name>
<etal/>
</person-group> (<year>2003</year>). <article-title>Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer&#x2019;s disease brains</article-title>. <source>J. Neurosci. Off. J. Soc. Neurosci.</source> <volume>23</volume> (<issue>35</issue>), <fpage>11136</fpage>&#x2013;<lpage>11141</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.23-35-11136.2003</pub-id>
<pub-id pub-id-type="pmid">14657172</pub-id>
</mixed-citation>
</ref>
<ref id="B17">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Benito</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Tol&#xf3;n</surname>
<given-names>R. M.</given-names>
</name>
<name>
<surname>Pazos</surname>
<given-names>M. R.</given-names>
</name>
<name>
<surname>N&#xfa;&#xf1;ez</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Castillo</surname>
<given-names>A. I.</given-names>
</name>
<name>
<surname>Romero</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Cannabinoid CB2 receptors in human brain inflammation</article-title>. <source>Br. J. Pharmacol.</source> <volume>153</volume> (<issue>2</issue>), <fpage>277</fpage>&#x2013;<lpage>285</lpage>. <pub-id pub-id-type="doi">10.1038/sj.bjp.0707505</pub-id>
<pub-id pub-id-type="pmid">17934510</pub-id>
</mixed-citation>
</ref>
<ref id="B18">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bergstr&#xf6;m</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Agholme</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Nazir</surname>
<given-names>F. H.</given-names>
</name>
<name>
<surname>Satir</surname>
<given-names>T. M.</given-names>
</name>
<name>
<surname>Toombs</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wellington</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Amyloid precursor protein expression and processing are differentially regulated during cortical neuron differentiation</article-title>. <source>Sci. Rep.</source> <volume>6</volume>, <fpage>29200</fpage>. <pub-id pub-id-type="doi">10.1038/srep29200</pub-id>
<pub-id pub-id-type="pmid">27383650</pub-id>
</mixed-citation>
</ref>
<ref id="B19">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bloemberg</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Quadrilatero</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Autophagy, apoptosis, and mitochondria: molecular integration and physiological relevance in skeletal muscle</article-title>. <source>Am. J. Physiol. - Cell Physiol.</source> <volume>317</volume> (<issue>1</issue>), <fpage>C111</fpage>&#x2013;<lpage>C130</lpage>. <pub-id pub-id-type="doi">10.1152/ajpcell.00261.2018</pub-id>
<pub-id pub-id-type="pmid">31017800</pub-id>
</mixed-citation>
</ref>
<ref id="B20">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boland</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Platt</surname>
<given-names>F. M.</given-names>
</name>
<name>
<surname>Wegiel</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>W. H.</given-names>
</name>
<etal/>
</person-group> (<year>2008</year>). <article-title>Autophagy induction and autophagosome clearance in neurons: relationship to autophagic pathology in Alzheimer&#x2019;s disease</article-title>. <source>J. Neurosci. Off. J. Soc. Neurosci.</source> <volume>28</volume> (<issue>27</issue>), <fpage>6926</fpage>&#x2013;<lpage>6937</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.0800-08.2008</pub-id>
<pub-id pub-id-type="pmid">18596167</pub-id>
</mixed-citation>
</ref>
<ref id="B21">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bordi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Berg</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Mohan</surname>
<given-names>P. S.</given-names>
</name>
<name>
<surname>Peterhoff</surname>
<given-names>C. M.</given-names>
</name>
<name>
<surname>Alldred</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Che</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Autophagy flux in CA1 neurons of Alzheimer hippocampus: increased induction overburdens failing lysosomes to propel neuritic dystrophy</article-title>. <source>Autophagy</source> <volume>12</volume> (<issue>12</issue>), <fpage>2467</fpage>&#x2013;<lpage>2483</lpage>. <pub-id pub-id-type="doi">10.1080/15548627.2016.1239003</pub-id>
<pub-id pub-id-type="pmid">27813694</pub-id>
</mixed-citation>
</ref>
<ref id="B22">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boutouja</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Stiehm</surname>
<given-names>C. M.</given-names>
</name>
<name>
<surname>Platta</surname>
<given-names>H. W.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>mTOR: a cellular regulator interface in health and disease</article-title>. <source>Cells</source> <volume>8</volume> (<issue>1</issue>), <fpage>18</fpage>. <pub-id pub-id-type="doi">10.3390/cells8010018</pub-id>
<pub-id pub-id-type="pmid">30609721</pub-id>
</mixed-citation>
</ref>
<ref id="B23">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Burstein</surname>
<given-names>S. H.</given-names>
</name>
<name>
<surname>Zurier</surname>
<given-names>R. B.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Cannabinoids, endocannabinoids, and related analogs in inflammation</article-title>. <source>AAPS J.</source> <volume>11</volume> (<issue>1</issue>), <fpage>109</fpage>&#x2013;<lpage>119</lpage>. <pub-id pub-id-type="doi">10.1208/s12248-009-9084-5</pub-id>
<pub-id pub-id-type="pmid">19199042</pub-id>
</mixed-citation>
</ref>
<ref id="B24">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cai</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Ke</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Autophagy dysfunction upregulates beta-amyloid peptides <italic>via</italic> enhancing the activity of &#x3b3;-secretase complex</article-title>. <source>Neuropsychiatr. Dis. Treat.</source> <volume>11</volume>, <fpage>2091</fpage>&#x2013;<lpage>2099</lpage>. <pub-id pub-id-type="doi">10.2147/NDT.S84755</pub-id>
<pub-id pub-id-type="pmid">26316755</pub-id>
</mixed-citation>
</ref>
<ref id="B25">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Calabrese</surname>
<given-names>E. J.</given-names>
</name>
<name>
<surname>Rubio-Casillas</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Biphasic effects of THC in memory and cognition</article-title>. <source>Eur. J. Clin. Invest</source> <volume>48</volume> (<issue>5</issue>), <fpage>e12920</fpage>. <pub-id pub-id-type="doi">10.1111/eci.12920</pub-id>
<pub-id pub-id-type="pmid">29574698</pub-id>
</mixed-citation>
</ref>
<ref id="B26">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cao</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Bai</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Mayl</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>The potential therapeutic effects of THC on Alzheimer&#x2019;s disease</article-title>. <source>J. Alzheimers Dis. Jad.</source> <volume>42</volume> (<issue>3</issue>), <fpage>973</fpage>&#x2013;<lpage>984</lpage>. <pub-id pub-id-type="doi">10.3233/JAD-140093</pub-id>
<pub-id pub-id-type="pmid">25024327</pub-id>
</mixed-citation>
</ref>
<ref id="B27">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Caprioglio</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Amin</surname>
<given-names>H. I. M.</given-names>
</name>
<name>
<surname>Taglialatela-Scafati</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Mu&#xf1;oz</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>AppendinoPhytocannabinoids</surname>
<given-names>G. M.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>A misleading name but a promising opportunity for biomedical research</article-title>. <source>Biomolecules</source> <volume>12</volume> (<issue>8</issue>), <fpage>1084</fpage>. <pub-id pub-id-type="doi">10.3390/biom12081084</pub-id>
<pub-id pub-id-type="pmid">36008978</pub-id>
</mixed-citation>
</ref>
<ref id="B28">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carro</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Trejo</surname>
<given-names>J. L.</given-names>
</name>
<name>
<surname>Spuch</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Bohl</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Heard</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Torres-Aleman</surname>
<given-names>I.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Blockade of the insulin-like growth factor I receptor in the choroid plexus originates alzheimer&#x2019;s-like neuropathology in rodents: new cues into the human disease?</article-title> <source>Neurobiol. Aging</source> <volume>27</volume> (<issue>11</issue>), <fpage>1618</fpage>&#x2013;<lpage>1631</lpage>. <pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2005.09.039</pub-id>
<pub-id pub-id-type="pmid">16274856</pub-id>
</mixed-citation>
</ref>
<ref id="B29">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Catania</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Giaccone</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Salmona</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Tagliavini</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Di Fede</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Dreaming of a new world where alzheimer&#x2019;s is a treatable disorder</article-title>. <source>Front. Aging Neurosci.</source> <volume>11</volume>, <fpage>317</fpage>. <pub-id pub-id-type="doi">10.3389/fnagi.2019.00317</pub-id>
<pub-id pub-id-type="pmid">31803047</pub-id>
</mixed-citation>
</ref>
<ref id="B30">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>Y. P.</given-names>
</name>
<etal/>
</person-group> (<year>2012</year>). <article-title>Monoacylglycerol lipase is a new therapeutic target for Alzheimer&#x2019;s disease</article-title>. <source>Cell Rep.</source> <volume>2</volume> (<issue>5</issue>), <fpage>1329</fpage>&#x2013;<lpage>1339</lpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2012.09.030</pub-id>
<pub-id pub-id-type="pmid">23122958</pub-id>
</mixed-citation>
</ref>
<ref id="B31">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>Z. R.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>J. B.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>S. L.</given-names>
</name>
<name>
<surname>Hong</surname>
<given-names>F. F.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Role of cholinergic signaling in Alzheimer&#x2019;s disease</article-title>. <source>Molecules</source> <volume>27</volume> (<issue>6</issue>), <fpage>1816</fpage>. <pub-id pub-id-type="doi">10.3390/molecules27061816</pub-id>
<pub-id pub-id-type="pmid">35335180</pub-id>
</mixed-citation>
</ref>
<ref id="B32">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cheng</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Low</surname>
<given-names>J. K.</given-names>
</name>
<name>
<surname>Logge</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Garner</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Karl</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2014a</year>). <article-title>Chronic cannabidiol treatment improves social and object recognition in double transgenic APPswe/PS1&#x394;E9 mice</article-title>. <source>Psychopharmacol. Berl.</source> <volume>231</volume> (<issue>15</issue>), <fpage>3009</fpage>&#x2013;<lpage>3017</lpage>. <pub-id pub-id-type="doi">10.1007/s00213-014-3478-5</pub-id>
<pub-id pub-id-type="pmid">24577515</pub-id>
</mixed-citation>
</ref>
<ref id="B33">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cheng</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Spiro</surname>
<given-names>A. S.</given-names>
</name>
<name>
<surname>Jenner</surname>
<given-names>A. M.</given-names>
</name>
<name>
<surname>Garner</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Karl</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2014b</year>). <article-title>Long-term cannabidiol treatment prevents the development of social recognition memory deficits in Alzheimer&#x2019;s disease transgenic mice</article-title>. <source>J. Alzheimers Dis. Jad.</source> <volume>42</volume> (<issue>4</issue>), <fpage>1383</fpage>&#x2013;<lpage>1396</lpage>. <pub-id pub-id-type="doi">10.3233/JAD-140921</pub-id>
<pub-id pub-id-type="pmid">25024347</pub-id>
</mixed-citation>
</ref>
<ref id="B34">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chung</surname>
<given-names>K. W.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>K. M.</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>Y. J.</given-names>
</name>
<name>
<surname>An</surname>
<given-names>H. J.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>D. H.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>The critical role played by endotoxin-induced liver autophagy in the maintenance of lipid metabolism during sepsis</article-title>. <source>Autophagy</source> <volume>13</volume> (<issue>7</issue>), <fpage>1113</fpage>&#x2013;<lpage>1129</lpage>. <pub-id pub-id-type="doi">10.1080/15548627.2017.1319040</pub-id>
<pub-id pub-id-type="pmid">28575583</pub-id>
</mixed-citation>
</ref>
<ref id="B35">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Coles</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Steiner-Lim</surname>
<given-names>G. Z.</given-names>
</name>
<name>
<surname>Karl</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Therapeutic properties of multi-cannabinoid treatment strategies for Alzheimer&#x2019;s disease</article-title>. <source>Front. Neurosci.</source> <volume>16</volume>, <fpage>962922</fpage>. <pub-id pub-id-type="doi">10.3389/fnins.2022.962922</pub-id>
<pub-id pub-id-type="pmid">36117622</pub-id>
</mixed-citation>
</ref>
<ref id="B36">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cui</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2025</year>). <article-title>Autophagy and apoptosis in Alzheimer&#x2019;s disease-associated neurons</article-title>. <source>Discov. Neurosci.</source> <volume>20</volume> (<issue>1</issue>), <fpage>11</fpage>. <pub-id pub-id-type="doi">10.1186/s13064-025-00210-z</pub-id>
</mixed-citation>
</ref>
<ref id="B37">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cummings</surname>
<given-names>J. L.</given-names>
</name>
<name>
<surname>Goldman</surname>
<given-names>D. P.</given-names>
</name>
<name>
<surname>Simmons-Stern</surname>
<given-names>N. R.</given-names>
</name>
<name>
<surname>Ponton</surname>
<given-names>E.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>The costs of developing treatments for Alzheimer&#x2019;s disease: a retrospective exploration</article-title>. <source>Alzheimers Dement.</source> <volume>18</volume> (<issue>3</issue>), <fpage>469</fpage>&#x2013;<lpage>477</lpage>. <pub-id pub-id-type="doi">10.1002/alz.12450</pub-id>
<pub-id pub-id-type="pmid">34581499</pub-id>
</mixed-citation>
</ref>
<ref id="B38">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cummings</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Nahed</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Kambar</surname>
<given-names>MEZN</given-names>
</name>
<name>
<surname>Zhong</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Fonseca</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Alzheimer&#x2019;s disease drug development pipeline: 2022</article-title>. <source>Alzheimers Dement. Transl. Res. Clin. Interv.</source> <volume>8</volume> (<issue>1</issue>), <fpage>e12295</fpage>. <pub-id pub-id-type="doi">10.1002/trc2.12295</pub-id>
<pub-id pub-id-type="pmid">35516416</pub-id>
</mixed-citation>
</ref>
<ref id="B39">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cury</surname>
<given-names>R. de M.</given-names>
</name>
<name>
<surname>da Silva</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Cezar-dos-Santos</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Fakih</surname>
<given-names>Y. R. C.</given-names>
</name>
<name>
<surname>Narvaez</surname>
<given-names>K. A. R.</given-names>
</name>
<name>
<surname>Gouvea</surname>
<given-names>M. C.</given-names>
</name>
<etal/>
</person-group> (<year>2025</year>). <article-title>A randomized clinical trial of low-dose cannabis extract in Alzheimer&#x2019;s disease</article-title>. <source>J. Alzheimer&#x2019;s Dis.</source>, <fpage>13872877251389608</fpage>. <pub-id pub-id-type="doi">10.1177/13872877251389608</pub-id>
<pub-id pub-id-type="pmid">41160460</pub-id>
</mixed-citation>
</ref>
<ref id="B40">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Rojas</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Moreno-Grau</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Tesi</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Grenier-Boley</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Andrade</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Jansen</surname>
<given-names>I. E.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Common variants in Alzheimer&#x2019;s disease and risk stratification by polygenic risk scores</article-title>. <source>Nat. Commun.</source> <volume>12</volume> (<issue>1</issue>), <fpage>3417</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-021-22491-8</pub-id>
<pub-id pub-id-type="pmid">34099642</pub-id>
</mixed-citation>
</ref>
<ref id="B41">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>DeTure</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Dickson</surname>
<given-names>D. W.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>The neuropathological diagnosis of Alzheimer&#x2019;s disease</article-title>. <source>Mol. Neurodegener.</source> <volume>14</volume> (<issue>1</issue>), <fpage>32</fpage>. <pub-id pub-id-type="doi">10.1186/s13024-019-0333-5</pub-id>
<pub-id pub-id-type="pmid">31375134</pub-id>
</mixed-citation>
</ref>
<ref id="B42">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dinamarca</surname>
<given-names>M. C.</given-names>
</name>
<name>
<surname>Sagal</surname>
<given-names>J. P.</given-names>
</name>
<name>
<surname>Quintanilla</surname>
<given-names>R. A.</given-names>
</name>
<name>
<surname>Godoy</surname>
<given-names>J. A.</given-names>
</name>
<name>
<surname>Arr&#xe1;zola</surname>
<given-names>M. S.</given-names>
</name>
<name>
<surname>Inestrosa</surname>
<given-names>N. C.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Amyloid-&#x3b2;-Acetylcholinesterase complexes potentiate neurodegenerative changes induced by the A&#x3b2; peptide. Implications for the pathogenesis of Alzheimer&#x2019;s disease</article-title>. <source>Mol. Neurodegener.</source> <volume>5</volume> (<issue>1</issue>), <fpage>4</fpage>. <pub-id pub-id-type="doi">10.1186/1750-1326-5-4</pub-id>
<pub-id pub-id-type="pmid">20205793</pub-id>
</mixed-citation>
</ref>
<ref id="B43">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dowling</surname>
<given-names>C. A.</given-names>
</name>
<name>
<surname>Melzer</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Schilling</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Timing is everything: the genetics of flowering time in Cannabis sativa</article-title>. <source>Biochem.</source> <volume>43</volume> (<issue>3</issue>), <fpage>34</fpage>&#x2013;<lpage>38</lpage>. <pub-id pub-id-type="doi">10.1042/bio_2021_138</pub-id>
</mixed-citation>
</ref>
<ref id="B44">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>d&#x2018;Errico</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Meyer-Luehmann</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Mechanisms of pathogenic tau and A&#x3b2; protein spreading in alzheimer&#x2019;s disease</article-title>. <source>Front. Aging Neurosci.</source> <volume>12</volume>, <fpage>265</fpage>. <pub-id pub-id-type="doi">10.3389/fnagi.2020.00265</pub-id>
<pub-id pub-id-type="pmid">33061903</pub-id>
</mixed-citation>
</ref>
<ref id="B45">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Elsohly</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Slade</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Chemical constituents of marijuana: the complex mixture of natural cannabinoids</article-title>. <source>Life Sci.</source> <volume>78</volume> (<issue>5</issue>), <fpage>539</fpage>&#x2013;<lpage>548</lpage>. <pub-id pub-id-type="doi">10.1016/j.lfs.2005.09.011</pub-id>
<pub-id pub-id-type="pmid">16199061</pub-id>
</mixed-citation>
</ref>
<ref id="B46">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Esposito</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>De Filippis</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Carnuccio</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Izzo</surname>
<given-names>A. A.</given-names>
</name>
<name>
<surname>Iuvone</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>The marijuana component cannabidiol inhibits beta-amyloid-induced tau protein hyperphosphorylation through wnt/beta-catenin pathway rescue in PC12 cells</article-title>. <source>J. Mol. Med. Berl. Ger.</source> <volume>84</volume> (<issue>3</issue>), <fpage>253</fpage>&#x2013;<lpage>258</lpage>. <pub-id pub-id-type="doi">10.1007/s00109-005-0025-1</pub-id>
<pub-id pub-id-type="pmid">16389547</pub-id>
</mixed-citation>
</ref>
<ref id="B47">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Esposito</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Iuvone</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Savani</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Scuderi</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>De Filippis</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Papa</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2007a</year>). <article-title>Opposing control of cannabinoid receptor stimulation on amyloid-beta-induced reactive gliosis: <italic>in vitro</italic> and <italic>in vivo</italic> evidence</article-title>. <source>J. Pharmacol. Exp. Ther.</source> <volume>322</volume> (<issue>3</issue>), <fpage>1144</fpage>&#x2013;<lpage>1152</lpage>. <pub-id pub-id-type="doi">10.1124/jpet.107.121566</pub-id>
<pub-id pub-id-type="pmid">17545311</pub-id>
</mixed-citation>
</ref>
<ref id="B48">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Esposito</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Scuderi</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Savani</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Steardo</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>De Filippis</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Cottone</surname>
<given-names>P.</given-names>
</name>
<etal/>
</person-group> (<year>2007b</year>). <article-title>Cannabidiol <italic>in vivo</italic> blunts beta-amyloid induced neuroinflammation by suppressing IL-1beta and iNOS expression</article-title>. <source>Br. J. Pharmacol.</source> <volume>151</volume> (<issue>8</issue>), <fpage>1272</fpage>&#x2013;<lpage>1279</lpage>. <pub-id pub-id-type="doi">10.1038/sj.bjp.0707337</pub-id>
<pub-id pub-id-type="pmid">17592514</pub-id>
</mixed-citation>
</ref>
<ref id="B49">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eubanks</surname>
<given-names>L. M.</given-names>
</name>
<name>
<surname>Rogers</surname>
<given-names>C. J.</given-names>
</name>
<name>
<surname>Beuscher</surname>
<given-names>A. E.</given-names>
</name>
<name>
<surname>Koob</surname>
<given-names>G. F.</given-names>
</name>
<name>
<surname>Olson</surname>
<given-names>A. J.</given-names>
</name>
<name>
<surname>Dickerson</surname>
<given-names>T. J.</given-names>
</name>
<etal/>
</person-group> (<year>2006</year>). <article-title>A molecular link between the active component of marijuana and alzheimer&#x2019;s disease pathology</article-title>. <source>Mol. Pharm.</source> <volume>3</volume> (<issue>6</issue>), <fpage>773</fpage>&#x2013;<lpage>777</lpage>. <pub-id pub-id-type="doi">10.1021/mp060066m</pub-id>
<pub-id pub-id-type="pmid">17140265</pub-id>
</mixed-citation>
</ref>
<ref id="B50">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Evans</surname>
<given-names>C. S.</given-names>
</name>
<name>
<surname>Holzbaur</surname>
<given-names>E. L. F.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Quality control in neurons: mitophagy and other selective autophagy mechanisms</article-title>. <source>J. Mol. Biol.</source> <volume>432</volume> (<issue>1</issue>), <fpage>240</fpage>&#x2013;<lpage>260</lpage>. <pub-id pub-id-type="doi">10.1016/j.jmb.2019.06.031</pub-id>
<pub-id pub-id-type="pmid">31295455</pub-id>
</mixed-citation>
</ref>
<ref id="B51">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fawcett</surname>
<given-names>J. W.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>The struggle to make CNS axons regenerate: why has it been so difficult?</article-title> <source>Neurochem. Res.</source> <volume>45</volume> (<issue>1</issue>), <fpage>144</fpage>&#x2013;<lpage>158</lpage>. <pub-id pub-id-type="doi">10.1007/s11064-019-02844-y</pub-id>
<pub-id pub-id-type="pmid">31388931</pub-id>
</mixed-citation>
</ref>
<ref id="B52">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Folch</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Busquets</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Ettcheto</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>S&#xe1;nchez-L&#xf3;pez</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Castro-Torres</surname>
<given-names>R. D.</given-names>
</name>
<name>
<surname>Verdaguer</surname>
<given-names>E.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Memantine for the treatment of dementia: a review on its current and future applications</article-title>. <source>J. Alzheimers Dis.</source> <volume>62</volume> (<issue>3</issue>), <fpage>1223</fpage>&#x2013;<lpage>1240</lpage>. <pub-id pub-id-type="doi">10.3233/JAD-170672</pub-id>
<pub-id pub-id-type="pmid">29254093</pub-id>
</mixed-citation>
</ref>
<ref id="B53">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fong</surname>
<given-names>L. K.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>M. M.</given-names>
</name>
<name>
<surname>dos Santos Chaves</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Reyna</surname>
<given-names>S. M.</given-names>
</name>
<name>
<surname>Langness</surname>
<given-names>V. F.</given-names>
</name>
<name>
<surname>Woodruff</surname>
<given-names>G.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Full-length amyloid precursor protein regulates lipoprotein metabolism and amyloid-&#x3b2; clearance in human astrocytes</article-title>. <source>J. Biol. Chem.</source> <volume>293</volume> (<issue>29</issue>), <fpage>11341</fpage>&#x2013;<lpage>11357</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.RA117.000441</pub-id>
<pub-id pub-id-type="pmid">29858247</pub-id>
</mixed-citation>
</ref>
<ref id="B54">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Galluzzi</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Baehrecke</surname>
<given-names>E. H.</given-names>
</name>
<name>
<surname>Ballabio</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Boya</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Bravo-San Pedro</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Cecconi</surname>
<given-names>F.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Molecular definitions of autophagy and related processes</article-title>. <source>EMBO J.</source> <volume>36</volume> (<issue>13</issue>), <fpage>1811</fpage>&#x2013;<lpage>1836</lpage>. <pub-id pub-id-type="doi">10.15252/embj.201796697</pub-id>
<pub-id pub-id-type="pmid">28596378</pub-id>
</mixed-citation>
</ref>
<ref id="B55">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Moten</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>H. K.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Akt: a new activation mechanism</article-title>. <source>Cell Res.</source> <volume>24</volume> (<issue>7</issue>), <fpage>785</fpage>&#x2013;<lpage>786</lpage>. <pub-id pub-id-type="doi">10.1038/cr.2014.57</pub-id>
<pub-id pub-id-type="pmid">24797432</pub-id>
</mixed-citation>
</ref>
<ref id="B56">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Garcia</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Shaw</surname>
<given-names>R. J.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>AMPK: mechanisms of cellular energy sensing and restoration of metabolic balance</article-title>. <source>Mol. Cell</source> <volume>66</volume> (<issue>6</issue>), <fpage>789</fpage>&#x2013;<lpage>800</lpage>. <pub-id pub-id-type="doi">10.1016/j.molcel.2017.05.032</pub-id>
<pub-id pub-id-type="pmid">28622524</pub-id>
</mixed-citation>
</ref>
<ref id="B57">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Garc&#xed;a</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Palomo-Garo</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Garc&#xed;a-Arencibia</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ramos</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Pertwee</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Fern&#xe1;ndez-Ruiz</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Symptom-relieving and neuroprotective effects of the phytocannabinoid &#x394;9-THCV in animal models of Parkinson&#x2019;s disease</article-title>. <source>Br. J. Pharmacol.</source> <volume>163</volume> (<issue>7</issue>), <fpage>1495</fpage>&#x2013;<lpage>1506</lpage>. <pub-id pub-id-type="doi">10.1111/j.1476-5381.2011.01278.x</pub-id>
<pub-id pub-id-type="pmid">21323909</pub-id>
</mixed-citation>
</ref>
<ref id="B58">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Garc&#xed;a-Ayll&#xf3;n</surname>
<given-names>M. S.</given-names>
</name>
<name>
<surname>Small</surname>
<given-names>D. H.</given-names>
</name>
<name>
<surname>Avila</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>S&#xe1;ez-Valero</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Revisiting the role of acetylcholinesterase in alzheimer&#x2019;s disease: cross-talk with P-tau and &#x3b2;-Amyloid</article-title>. <source>Front. Mol. Neurosci.</source> <volume>13</volume> (<issue>4</issue>), <fpage>22</fpage>. <pub-id pub-id-type="doi">10.1016/j.molcel.2017.05.032</pub-id>
<pub-id pub-id-type="pmid">21949503</pub-id>
</mixed-citation>
</ref>
<ref id="B59">
<mixed-citation publication-type="journal">
<collab>GBD 2019</collab> (<year>2022</year>). <article-title>Dementia forecasting collaborators. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the global burden of disease study 2019</article-title>. <source>Lancet Public Health</source> <volume>7</volume> (<issue>2</issue>), <fpage>e105</fpage>&#x2013;<lpage>e125</lpage>. <pub-id pub-id-type="doi">10.1016/S2468-2667(21)00249-8</pub-id>
<pub-id pub-id-type="pmid">34998485</pub-id>
</mixed-citation>
</ref>
<ref id="B60">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ghosh</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Stansak</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Walters</surname>
<given-names>B. J.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Cannabinoid signaling in auditory function and development</article-title>. <source>Front. Mol. Neurosci.</source> <volume>14</volume>, <fpage>678510</fpage>. <pub-id pub-id-type="doi">10.3389/fnmol.2021.678510</pub-id>
<pub-id pub-id-type="pmid">34079440</pub-id>
</mixed-citation>
</ref>
<ref id="B61">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gomes</surname>
<given-names>L. R.</given-names>
</name>
<name>
<surname>Menck</surname>
<given-names>C. F. M.</given-names>
</name>
<name>
<surname>Cuervo</surname>
<given-names>A. M.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Chaperone-mediated autophagy prevents cellular transformation by regulating MYC proteasomal degradation</article-title>. <source>Autophagy</source> <volume>13</volume> (<issue>5</issue>), <fpage>928</fpage>&#x2013;<lpage>940</lpage>. <pub-id pub-id-type="doi">10.1080/15548627.2017.1293767</pub-id>
<pub-id pub-id-type="pmid">28410006</pub-id>
</mixed-citation>
</ref>
<ref id="B62">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gong</surname>
<given-names>C. X.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Iqbal</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Multifactorial hypothesis and multi-targets for alzheimer&#x2019;s disease</article-title>. <source>J. Alzheimers Dis.</source> <volume>64</volume> (<issue>s1</issue>), <fpage>S107</fpage>&#x2013;<lpage>S117</lpage>. <pub-id pub-id-type="doi">10.3233/JAD-179921</pub-id>
<pub-id pub-id-type="pmid">29562523</pub-id>
</mixed-citation>
</ref>
<ref id="B63">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gowran</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Noonan</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Campbell</surname>
<given-names>V. A.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>The multiplicity of action of cannabinoids: implications for treating neurodegeneration</article-title>. <source>CNS Neurosci. Ther.</source> <volume>17</volume> (<issue>6</issue>), <fpage>637</fpage>&#x2013;<lpage>644</lpage>. <pub-id pub-id-type="doi">10.1111/j.1755-5949.2010.00195.x</pub-id>
<pub-id pub-id-type="pmid">20875047</pub-id>
</mixed-citation>
</ref>
<ref id="B64">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>G&#xfc;lck</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>M&#xf8;ller</surname>
<given-names>B. L.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Phytocannabinoids: origins and biosynthesis</article-title>. <source>Trends Plant Sci.</source> <volume>25</volume> (<issue>10</issue>), <fpage>985</fpage>&#x2013;<lpage>1004</lpage>. <pub-id pub-id-type="doi">10.1016/j.tplants.2020.05.005</pub-id>
<pub-id pub-id-type="pmid">32646718</pub-id>
</mixed-citation>
</ref>
<ref id="B65">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guzm&#xe1;n</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2003</year>). <article-title>Neurons on cannabinoids: dead or alive?</article-title> <source>Br. J. Pharmacol.</source> <volume>140</volume> (<issue>3</issue>), <fpage>439</fpage>&#x2013;<lpage>440</lpage>. <pub-id pub-id-type="doi">10.1038/sj.bjp.0705465</pub-id>
<pub-id pub-id-type="pmid">14522839</pub-id>
</mixed-citation>
</ref>
<ref id="B66">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guzm&#xe1;n</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>S&#xe1;nchez</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Galve-Roperh</surname>
<given-names>I.</given-names>
</name>
</person-group> (<year>2002</year>). <article-title>Cannabinoids and cell fate</article-title>. <source>Pharmacol. Ther.</source> <volume>95</volume> (<issue>2</issue>), <fpage>175</fpage>&#x2013;<lpage>184</lpage>. <pub-id pub-id-type="doi">10.1016/s0163-7258(02)00256-5</pub-id>
<pub-id pub-id-type="pmid">12182964</pub-id>
</mixed-citation>
</ref>
<ref id="B67">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>H Ferreira-Vieira</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>M Guimaraes</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>R Silva</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>M Ribeiro</surname>
<given-names>F.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Alzheimer&#x2019;s disease: targeting the cholinergic system</article-title>. <source>Curr. Neuropharmacol.</source> <volume>14</volume> (<issue>1</issue>), <fpage>101</fpage>&#x2013;<lpage>115</lpage>. <pub-id pub-id-type="doi">10.2174/1570159x13666150716165726</pub-id>
<pub-id pub-id-type="pmid">26813123</pub-id>
</mixed-citation>
</ref>
<ref id="B68">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haass</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Selkoe</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>If amyloid drives Alzheimer disease, why have anti-amyloid therapies not yet slowed cognitive decline?</article-title> <source>PLOS Biol.</source> <volume>20</volume> (<issue>7</issue>), <fpage>e3001694</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pbio.3001694</pub-id>
<pub-id pub-id-type="pmid">35862308</pub-id>
</mixed-citation>
</ref>
<ref id="B69">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Halawani</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Tessier</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Anzellotti</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Bennett</surname>
<given-names>D. A.</given-names>
</name>
<name>
<surname>Latterich</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>LeBlanc</surname>
<given-names>A. C.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Identification of Caspase-6-mediated processing of the valosin containing protein (p97) in Alzheimer&#x2019;s disease: a novel link to dysfunction in ubiquitin proteasome system-mediated protein degradation</article-title>. <source>J. Neurosci. Off. J. Soc. Neurosci.</source> <volume>30</volume> (<issue>17</issue>), <fpage>6132</fpage>&#x2013;<lpage>6142</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.5874-09.2010</pub-id>
<pub-id pub-id-type="pmid">20427671</pub-id>
</mixed-citation>
</ref>
<ref id="B70">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hampel</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Vassar</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>De Strooper</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Hardy</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Willem</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>N.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>The &#x3b2;-Secretase BACE1 in alzheimer&#x2019;s disease</article-title>. <source>Biol. Psychiatry</source> <volume>89</volume> (<issue>8</issue>), <fpage>745</fpage>&#x2013;<lpage>756</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2020.02.001</pub-id>
<pub-id pub-id-type="pmid">32223911</pub-id>
</mixed-citation>
</ref>
<ref id="B71">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hardy</surname>
<given-names>J. A.</given-names>
</name>
<name>
<surname>Higgins</surname>
<given-names>G. A.</given-names>
</name>
</person-group> (<year>1992</year>). <article-title>Alzheimer&#x2019;s disease: the amyloid Cascade hypothesis</article-title>. <source>Science</source> <volume>256</volume> (<issue>5054</issue>), <fpage>184</fpage>&#x2013;<lpage>185</lpage>. <pub-id pub-id-type="doi">10.1126/science.1566067</pub-id>
<pub-id pub-id-type="pmid">1566067</pub-id>
</mixed-citation>
</ref>
<ref id="B72">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harrison</surname>
<given-names>D. E.</given-names>
</name>
<name>
<surname>Strong</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Sharp</surname>
<given-names>Z. D.</given-names>
</name>
<name>
<surname>Nelson</surname>
<given-names>J. F.</given-names>
</name>
<name>
<surname>Astle</surname>
<given-names>C. M.</given-names>
</name>
<name>
<surname>Flurkey</surname>
<given-names>K.</given-names>
</name>
<etal/>
</person-group> (<year>2009</year>). <article-title>Rapamycin fed late in life extends lifespan in genetically heterogeneous mice</article-title>. <source>Nature</source> <volume>460</volume> (<issue>7253</issue>), <fpage>392</fpage>&#x2013;<lpage>395</lpage>. <pub-id pub-id-type="doi">10.1038/nature08221</pub-id>
<pub-id pub-id-type="pmid">19587680</pub-id>
</mixed-citation>
</ref>
<ref id="B73">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hashimoto</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Rockenstein</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Crews</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Masliah</surname>
<given-names>E.</given-names>
</name>
</person-group> (<year>2003</year>). <article-title>Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer&#x2019;s and Parkinson&#x2019;s diseases</article-title>. <source>Neuromolecular Med.</source> <volume>4</volume> (<issue>1&#x2013;2</issue>), <fpage>21</fpage>&#x2013;<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1385/NMM:4:1-2:21</pub-id>
<pub-id pub-id-type="pmid">14528050</pub-id>
</mixed-citation>
</ref>
<ref id="B74">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hector</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Brouillette</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Hyperactivity induced by soluble Amyloid-&#x3b2; oligomers in the early stages of alzheimer&#x2019;s disease</article-title>. <source>Front. Mol. Neurosci.</source> <volume>13</volume>, <fpage>600084</fpage>. <pub-id pub-id-type="doi">10.3389/fnmol.2020.600084</pub-id>
<pub-id pub-id-type="pmid">33488358</pub-id>
</mixed-citation>
</ref>
<ref id="B75">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Heifets</surname>
<given-names>B. D.</given-names>
</name>
<name>
<surname>Castillo</surname>
<given-names>P. E.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Endocannabinoid signaling and long-term synaptic plasticity</article-title>. <source>Annu. Rev. Physiol.</source> <volume>71</volume>, <fpage>283</fpage>&#x2013;<lpage>306</lpage>. <pub-id pub-id-type="doi">10.1146/annurev.physiol.010908.163149</pub-id>
<pub-id pub-id-type="pmid">19575681</pub-id>
</mixed-citation>
</ref>
<ref id="B76">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ibanez</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Cruchaga</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Fern&#xe1;ndez</surname>
<given-names>M. V.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Advances in genetic and molecular understanding of alzheimer&#x2019;s disease</article-title>. <source>Genes</source> <volume>12</volume> (<issue>8</issue>), <fpage>1247</fpage>. <pub-id pub-id-type="doi">10.3390/genes12081247</pub-id>
<pub-id pub-id-type="pmid">34440421</pub-id>
</mixed-citation>
</ref>
<ref id="B77">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iliyasu</surname>
<given-names>M. O.</given-names>
</name>
<name>
<surname>Musa</surname>
<given-names>S. A.</given-names>
</name>
<name>
<surname>Oladele</surname>
<given-names>S. B.</given-names>
</name>
<name>
<surname>Iliya</surname>
<given-names>A. I.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Amyloid-beta aggregation implicates multiple pathways in Alzheimer&#x2019;s disease: understanding the mechanisms</article-title>. <source>Front. Neurosci.</source> <volume>17</volume>, <fpage>1081938</fpage>. <pub-id pub-id-type="doi">10.3389/fnins.2023.1081938</pub-id>
<pub-id pub-id-type="pmid">37113145</pub-id>
</mixed-citation>
</ref>
<ref id="B78">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jaeger</surname>
<given-names>P. A.</given-names>
</name>
<name>
<surname>Wyss-Coray</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>All-you-can-eat: autophagy in neurodegeneration and neuroprotection</article-title>. <source>Mol. Neurodegener.</source> <volume>4</volume> (<issue>1</issue>), <fpage>16</fpage>. <pub-id pub-id-type="doi">10.1186/1750-1326-4-16</pub-id>
<pub-id pub-id-type="pmid">19348680</pub-id>
</mixed-citation>
</ref>
<ref id="B79">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ji</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Wan</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Mei</surname>
<given-names>X.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Aldehyde dehydrogenase 2 protects against lipopolysaccharide-induced myocardial injury by suppressing mitophagy</article-title>. <source>Front. Pharmacol.</source> <volume>12</volume>, <fpage>641058</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2021.641058</pub-id>
<pub-id pub-id-type="pmid">34025411</pub-id>
</mixed-citation>
</ref>
<ref id="B80">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jogalekar</surname>
<given-names>M. P.</given-names>
</name>
<name>
<surname>Veerabathini</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Gangadaran</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Recent developments in autophagy-targeted therapies in cancer</article-title>. <source>Exp. Biol. Med.</source> <volume>246</volume> (<issue>2</issue>), <fpage>207</fpage>&#x2013;<lpage>212</lpage>. <pub-id pub-id-type="doi">10.1177/1535370220966545</pub-id>
<pub-id pub-id-type="pmid">33167689</pub-id>
</mixed-citation>
</ref>
<ref id="B81">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jung</surname>
<given-names>K. M.</given-names>
</name>
<name>
<surname>Astarita</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Yasar</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Vasilevko</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Cribbs</surname>
<given-names>D. H.</given-names>
</name>
<name>
<surname>Head</surname>
<given-names>E.</given-names>
</name>
<etal/>
</person-group> (<year>2012</year>). <article-title>An amyloid &#x3b2;42-dependent deficit in anandamide mobilization is associated with cognitive dysfunction in Alzheimer&#x2019;s disease</article-title>. <source>Neurobiol. Aging</source> <volume>33</volume> (<issue>8</issue>), <fpage>1522</fpage>&#x2013;<lpage>1532</lpage>. <pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2011.03.012</pub-id>
<pub-id pub-id-type="pmid">21546126</pub-id>
</mixed-citation>
</ref>
<ref id="B82">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Cannabidiol induces autophagy to protects neural cells from mitochondrial dysfunction by upregulating SIRT1 to inhibits NF-&#x3ba;B and NOTCH pathways</article-title>. <source>Front. Cell Neurosci.</source> <volume>15</volume>, <fpage>654340</fpage>. <pub-id pub-id-type="doi">10.3389/fncel.2021.654340/full</pub-id>
<pub-id pub-id-type="pmid">33859553</pub-id>
</mixed-citation>
</ref>
<ref id="B83">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kapadia</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Yi</surname>
<given-names>J. H.</given-names>
</name>
<name>
<surname>Vemuganti</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists</article-title>. <source>Front. Biosci. J. Virtual Libr.</source> <volume>13</volume>, <fpage>1813</fpage>&#x2013;<lpage>1826</lpage>. <pub-id pub-id-type="doi">10.2741/2802</pub-id>
<pub-id pub-id-type="pmid">17981670</pub-id>
</mixed-citation>
</ref>
<ref id="B84">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Karki</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Aschner</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>E.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Role of transcription factor yin yang 1 in manganese-induced reduction of astrocytic glutamate transporters: putative mechanism for manganese-induced neurotoxicity</article-title>. <source>Neurochem. Int.</source> <volume>1</volume> (<issue>88</issue>), <fpage>53</fpage>&#x2013;<lpage>59</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuint.2014.08.002</pub-id>
<pub-id pub-id-type="pmid">25128239</pub-id>
</mixed-citation>
</ref>
<ref id="B85">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Karsli-Uzunbas</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>J. Y.</given-names>
</name>
<name>
<surname>Price</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Teng</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Laddha</surname>
<given-names>S. V.</given-names>
</name>
<name>
<surname>Khor</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>Autophagy is required for glucose homeostasis and lung tumor maintenance</article-title>. <source>Cancer Discov.</source> <volume>4</volume> (<issue>8</issue>), <fpage>914</fpage>&#x2013;<lpage>927</lpage>. <pub-id pub-id-type="doi">10.1158/2159-8290.CD-14-0363</pub-id>
<pub-id pub-id-type="pmid">24875857</pub-id>
</mixed-citation>
</ref>
<ref id="B86">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kasatkina</surname>
<given-names>L. A.</given-names>
</name>
<name>
<surname>Rittchen</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sturm</surname>
<given-names>E. M.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Neuroprotective and immunomodulatory action of the endocannabinoid system under neuroinflammation</article-title>. <source>Int. J. Mol. Sci.</source> <volume>22</volume> (<issue>11</issue>), <fpage>5431</fpage>. <pub-id pub-id-type="doi">10.3390/ijms22115431</pub-id>
<pub-id pub-id-type="pmid">34063947</pub-id>
</mixed-citation>
</ref>
<ref id="B87">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kaushal</surname>
<given-names>G. P.</given-names>
</name>
<name>
<surname>Chandrashekar</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Juncos</surname>
<given-names>L. A.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Molecular interactions between reactive oxygen species and autophagy in kidney disease</article-title>. <source>Int. J. Mol. Sci.</source> <volume>20</volume> (<issue>15</issue>), <fpage>3791</fpage>. <pub-id pub-id-type="doi">10.3390/ijms20153791</pub-id>
<pub-id pub-id-type="pmid">31382550</pub-id>
</mixed-citation>
</ref>
<ref id="B88">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khan</surname>
<given-names>K. H.</given-names>
</name>
<name>
<surname>Yap</surname>
<given-names>T. A.</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Cunningham</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Targeting the PI3K-AKT-mTOR signaling network in cancer</article-title>. <source>Chin. J. Cancer</source> <volume>32</volume> (<issue>5</issue>), <fpage>253</fpage>&#x2013;<lpage>265</lpage>. <pub-id pub-id-type="doi">10.5732/cjc.013.10057</pub-id>
<pub-id pub-id-type="pmid">23642907</pub-id>
</mixed-citation>
</ref>
<ref id="B89">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>S. W.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>J. H.</given-names>
</name>
<name>
<surname>Moon</surname>
<given-names>J. H.</given-names>
</name>
<name>
<surname>Nazim</surname>
<given-names>U. M. D.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>Y. J.</given-names>
</name>
<name>
<surname>Seol</surname>
<given-names>J. W.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>Niacin alleviates TRAIL-mediated colon cancer cell death <italic>via</italic> autophagy flux activation</article-title>. <source>Oncotarget</source> <volume>7</volume> (<issue>4</issue>), <fpage>4356</fpage>&#x2013;<lpage>4368</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.5374</pub-id>
<pub-id pub-id-type="pmid">26517672</pub-id>
</mixed-citation>
</ref>
<ref id="B90">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Klaassens</surname>
<given-names>B. L.</given-names>
</name>
<name>
<surname>van Gerven</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Klaassen</surname>
<given-names>E. S.</given-names>
</name>
<name>
<surname>van der Grond</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Rombouts</surname>
<given-names>S. A.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Cholinergic and serotonergic modulation of resting state functional brain connectivity in Alzheimer&#x2019;s disease</article-title>. <source>Neuroimage.</source> <volume>199</volume>, <fpage>143</fpage>&#x2013;<lpage>152</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroimage.2019.05.044</pub-id>
<pub-id pub-id-type="pmid">31112788</pub-id>
</mixed-citation>
</ref>
<ref id="B91">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Klionsky</surname>
<given-names>D. J.</given-names>
</name>
<name>
<surname>Petroni</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Amaravadi</surname>
<given-names>R. K.</given-names>
</name>
<name>
<surname>Baehrecke</surname>
<given-names>E. H.</given-names>
</name>
<name>
<surname>Ballabio</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Boya</surname>
<given-names>P.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Autophagy in major human diseases</article-title>. <source>EMBO J.</source> <volume>40</volume> (<issue>19</issue>), <fpage>e108863</fpage>. <pub-id pub-id-type="doi">10.15252/embj.2021108863</pub-id>
<pub-id pub-id-type="pmid">34459017</pub-id>
</mixed-citation>
</ref>
<ref id="B92">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kma</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Baruah</surname>
<given-names>T. J.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>The interplay of ROS and the PI3K/Akt pathway in autophagy regulation</article-title>. <source>Biotechnol. Appl. Biochem.</source> <volume>69</volume> (<issue>1</issue>), <fpage>248</fpage>&#x2013;<lpage>264</lpage>. <pub-id pub-id-type="doi">10.1002/bab.2104</pub-id>
<pub-id pub-id-type="pmid">33442914</pub-id>
</mixed-citation>
</ref>
<ref id="B93">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kuang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>C. Y.</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>H. Z.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>L. H.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>M. W.</given-names>
</name>
<name>
<surname>Hong</surname>
<given-names>F. F.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Exploring the bi-directional relationship between autophagy and Alzheimer&#x2019;s disease</article-title>. <source>CNS Neurosci. Ther.</source> <volume>26</volume> (<issue>2</issue>), <fpage>155</fpage>&#x2013;<lpage>166</lpage>. <pub-id pub-id-type="doi">10.1111/cns.13216</pub-id>
<pub-id pub-id-type="pmid">31503421</pub-id>
</mixed-citation>
</ref>
<ref id="B94">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kuo</surname>
<given-names>M. F.</given-names>
</name>
<name>
<surname>Grosch</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Fregni</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Paulus</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Nitsche</surname>
<given-names>M. A.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Focusing effect of acetylcholine on neuroplasticity in the human motor cortex</article-title>. <source>J. Neurosci.</source> <volume>27</volume> (<issue>52</issue>), <fpage>14442</fpage>&#x2013;<lpage>14447</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.4104-07.2007</pub-id>
<pub-id pub-id-type="pmid">18160652</pub-id>
</mixed-citation>
</ref>
<ref id="B95">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lanoisel&#xe9;e</surname>
<given-names>H. M.</given-names>
</name>
<name>
<surname>Nicolas</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Wallon</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Rovelet-Lecrux</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lacour</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Rousseau</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: a genetic screening study of familial and sporadic cases</article-title>. <source>PLoS Med.</source> <volume>14</volume> (<issue>3</issue>), <fpage>e1002270</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pmed.1002270</pub-id>
<pub-id pub-id-type="pmid">28350801</pub-id>
</mixed-citation>
</ref>
<ref id="B96">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lastres-Becker</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Molina-Holgado</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Ramos</surname>
<given-names>J. A.</given-names>
</name>
<name>
<surname>Mechoulam</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Fern&#xe1;ndez-Ruiz</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity <italic>in vivo</italic> and <italic>in vitro:</italic> relevance to Parkinson&#x2019;s disease</article-title>. <source>Neurobiol. Dis.</source> <volume>19</volume> (<issue>1&#x2013;2</issue>), <fpage>96</fpage>&#x2013;<lpage>107</lpage>. <pub-id pub-id-type="doi">10.1016/j.nbd.2004.11.009</pub-id>
<pub-id pub-id-type="pmid">15837565</pub-id>
</mixed-citation>
</ref>
<ref id="B97">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>H. K.</given-names>
</name>
<name>
<surname>Kwon</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Lemere</surname>
<given-names>C. A.</given-names>
</name>
<name>
<surname>de la Monte</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Itamura</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Ha</surname>
<given-names>A. Y.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>mTORC2 (Rictor) in alzheimer&#x2019;s disease and reversal of Amyloid-&#x3b2; expression-induced insulin resistance and toxicity in rat primary cortical neurons</article-title>. <source>J. Alzheimers Dis. Jad.</source> <volume>56</volume> (<issue>3</issue>), <fpage>1015</fpage>&#x2013;<lpage>1036</lpage>. <pub-id pub-id-type="doi">10.3233/JAD-161029</pub-id>
<pub-id pub-id-type="pmid">28035937</pub-id>
</mixed-citation>
</ref>
<ref id="B98">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>J. H.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>D. S.</given-names>
</name>
<name>
<surname>Goulbourne</surname>
<given-names>C. N.</given-names>
</name>
<name>
<surname>Im</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Stavrides</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Pensalfini</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Faulty autolysosome acidification in Alzheimer&#x2019;s disease mouse models induces autophagic build-up of A&#x3b2; in neurons, yielding senile plaques</article-title>. <source>Nat. Neurosci.</source> <volume>25</volume> (<issue>6</issue>), <fpage>688</fpage>&#x2013;<lpage>701</lpage>. <pub-id pub-id-type="doi">10.1038/s41593-022-01084-8</pub-id>
<pub-id pub-id-type="pmid">35654956</pub-id>
</mixed-citation>
</ref>
<ref id="B99">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Rhyu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yoon</surname>
<given-names>K.</given-names>
</name>
<etal/>
</person-group> (<year>2024</year>). <article-title>Beneficial effects of cannabidiol from cannabis</article-title>. <source>Appl. Biol. Chem.</source> <volume>67</volume> (<issue>1</issue>), <fpage>32</fpage>. <pub-id pub-id-type="doi">10.1186/s13765-024-00867-w</pub-id>
</mixed-citation>
</ref>
<ref id="B100">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lemmon</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Schlessinger</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Cell signaling by receptor tyrosine kinases</article-title>. <source>Cell</source> <volume>141</volume> (<issue>7</issue>), <fpage>1117</fpage>&#x2013;<lpage>1134</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2010.06.011</pub-id>
<pub-id pub-id-type="pmid">20602996</pub-id>
</mixed-citation>
</ref>
<ref id="B101">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Levine</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Kroemer</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Biological functions of autophagy genes: a disease perspective</article-title>. <source>Cell</source> <volume>176</volume> (<issue>1</issue>), <fpage>11</fpage>&#x2013;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2018.09.048</pub-id>
<pub-id pub-id-type="pmid">30633901</pub-id>
</mixed-citation>
</ref>
<ref id="B102">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>AMPK and autophagy</article-title>. <source>Adv. Exp. Med. Biol.</source> <volume>1206</volume>, <fpage>85</fpage>&#x2013;<lpage>108</lpage>. <pub-id pub-id-type="doi">10.1007/978-981-15-0602-4_4</pub-id>
<pub-id pub-id-type="pmid">31776981</pub-id>
</mixed-citation>
</ref>
<ref id="B103">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>X. zhi</given-names>
</name>
<name>
<surname>hua</surname>
<given-names>Y. X.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Sensors for the mTORC1 pathway regulated by amino acids</article-title>. <source>J. Zhejiang Univ. Sci. B</source> <volume>20</volume> (<issue>9</issue>), <fpage>699</fpage>&#x2013;<lpage>712</lpage>. <pub-id pub-id-type="doi">10.1631/jzus.B1900181</pub-id>
<pub-id pub-id-type="pmid">31379141</pub-id>
</mixed-citation>
</ref>
<ref id="B104">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>X.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Targeting impaired autophagy as a therapeutic strategy for Koolen-de vries syndrome</article-title>. <source>Autophagy</source> <volume>18</volume> (<issue>12</issue>), <fpage>3040</fpage>&#x2013;<lpage>3042</lpage>. <pub-id pub-id-type="doi">10.1080/15548627.2022.2069904</pub-id>
<pub-id pub-id-type="pmid">35468045</pub-id>
</mixed-citation>
</ref>
<ref id="B105">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Libro</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Diomede</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Scionti</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Piattelli</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Grassi</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Pollastro</surname>
<given-names>F.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Cannabidiol modulates the expression of alzheimer&#x2019;s disease-related genes in mesenchymal stem cells</article-title>. <source>Int. J. Mol. Sci.</source> <volume>18</volume> (<issue>1</issue>), <fpage>26</fpage>. <pub-id pub-id-type="doi">10.3390/ijms18010026</pub-id>
<pub-id pub-id-type="pmid">28025562</pub-id>
</mixed-citation>
</ref>
<ref id="B106">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lipton</surname>
<given-names>S. A.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>H. V.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Paradigm shift in NMDA receptor drug development</article-title>. <source>Expert Opin. Ther. Targets</source> <volume>9</volume> (<issue>3</issue>), <fpage>427</fpage>&#x2013;<lpage>429</lpage>. <pub-id pub-id-type="doi">10.1517/14728222.9.3.427</pub-id>
<pub-id pub-id-type="pmid">15948664</pub-id>
</mixed-citation>
</ref>
<ref id="B107">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Fibroblast growth factor 21 facilitates peripheral nerve regeneration through suppressing oxidative damage and autophagic cell death</article-title>. <source>J. Cell Mol. Med.</source> <volume>23</volume> (<issue>1</issue>), <fpage>497</fpage>&#x2013;<lpage>511</lpage>. <pub-id pub-id-type="doi">10.1111/jcmm.13952</pub-id>
<pub-id pub-id-type="pmid">30450828</pub-id>
</mixed-citation>
</ref>
<ref id="B108">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Luc&#xe0;</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Assenza</surname>
<given-names>M. R.</given-names>
</name>
<name>
<surname>Maiullari</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Pieroni</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Maiullari</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Federici</surname>
<given-names>G.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Inhibition of the mTOR pathway and reprogramming of protein synthesis by MDM4 reduce ovarian cancer metastatic properties</article-title>. <source>Cell Death Dis.</source> <volume>12</volume> (<issue>6</issue>), <fpage>1</fpage>&#x2013;<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1038/s41419-021-03828-z</pub-id>
<pub-id pub-id-type="pmid">34052831</pub-id>
</mixed-citation>
</ref>
<ref id="B109">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Machado</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ferreira</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Grothe</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Eyjolfsdottir</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Almqvist</surname>
<given-names>P. M.</given-names>
</name>
<name>
<surname>Cavallin</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>The cholinergic system in subtypes of Alzheimer&#x2019;s disease: an <italic>in vivo</italic> longitudinal MRI study</article-title>. <source>Alzheimers Res. Ther.</source> <volume>12</volume> (<issue>1</issue>), <fpage>51</fpage>. <pub-id pub-id-type="doi">10.1186/s13195-020-00620-7</pub-id>
<pub-id pub-id-type="pmid">32375872</pub-id>
</mixed-citation>
</ref>
<ref id="B110">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marchalant</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Brothers</surname>
<given-names>H. M.</given-names>
</name>
<name>
<surname>Norman</surname>
<given-names>G. J.</given-names>
</name>
<name>
<surname>Karelina</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>DeVries</surname>
<given-names>A. C.</given-names>
</name>
<name>
<surname>Wenk</surname>
<given-names>G. L.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Cannabinoids attenuate the effects of aging upon neuroinflammation and neurogenesis</article-title>. <source>Neurobiol. Dis.</source> <volume>34</volume> (<issue>2</issue>), <fpage>300</fpage>&#x2013;<lpage>307</lpage>. <pub-id pub-id-type="doi">10.1016/j.nbd.2009.01.014</pub-id>
<pub-id pub-id-type="pmid">19385063</pub-id>
</mixed-citation>
</ref>
<ref id="B111">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marsh</surname>
<given-names>D. T.</given-names>
</name>
<name>
<surname>Shibuta</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kato</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Smid</surname>
<given-names>S. D.</given-names>
</name>
</person-group> (<year>2024</year>). <article-title>Medicinal cannabis extracts are neuroprotective against A&#x3b2;1-42-mediated toxicity <italic>in vitro</italic>
</article-title>. <source>Basic Clin. Pharmacol. Toxicol.</source> <volume>135</volume> (<issue>5</issue>), <fpage>575</fpage>&#x2013;<lpage>592</lpage>. <pub-id pub-id-type="doi">10.1111/bcpt.14078</pub-id>
<pub-id pub-id-type="pmid">39243211</pub-id>
</mixed-citation>
</ref>
<ref id="B112">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marszalek-Grabska</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Smaga</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Surowka</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Grochecki</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Slowik</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Filip</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Memantine prevents the WIN 55,212-2 evoked cross-priming of ethanol-induced conditioned place preference (CPP)</article-title>. <source>Int. J. Mol. Sci.</source> <volume>22</volume> (<issue>15</issue>), <fpage>7940</fpage>. <pub-id pub-id-type="doi">10.3390/ijms22157940</pub-id>
<pub-id pub-id-type="pmid">34360704</pub-id>
</mixed-citation>
</ref>
<ref id="B113">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mart&#xed;n-Moreno</surname>
<given-names>A. M.</given-names>
</name>
<name>
<surname>Reigada</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Ram&#xed;rez</surname>
<given-names>B. G.</given-names>
</name>
<name>
<surname>Mechoulam</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Innamorato</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Cuadrado</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2011</year>). <article-title>Cannabidiol and other cannabinoids reduce microglial activation <italic>in vitro</italic> and <italic>in vivo:</italic> relevance to Alzheimer&#x2019;s disease</article-title>. <source>Mol. Pharmacol.</source> <volume>79</volume> (<issue>6</issue>), <fpage>964</fpage>&#x2013;<lpage>973</lpage>. <pub-id pub-id-type="doi">10.1124/mol.111.071290</pub-id>
<pub-id pub-id-type="pmid">21350020</pub-id>
</mixed-citation>
</ref>
<ref id="B114">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McGleenon</surname>
<given-names>B. M.</given-names>
</name>
<name>
<surname>Dynan</surname>
<given-names>K. B.</given-names>
</name>
<name>
<surname>Passmore</surname>
<given-names>A. P.</given-names>
</name>
</person-group> (<year>1999</year>). <article-title>Acetylcholinesterase inhibitors in Alzheimer&#x2019;s disease</article-title>. <source>Br. J. Clin. Pharmacol.</source> <volume>48</volume> (<issue>4</issue>), <fpage>471</fpage>&#x2013;<lpage>480</lpage>. <pub-id pub-id-type="doi">10.1046/j.1365-2125.1999.00026.x</pub-id>
<pub-id pub-id-type="pmid">10583015</pub-id>
</mixed-citation>
</ref>
<ref id="B115">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McKnight</surname>
<given-names>N. C.</given-names>
</name>
<name>
<surname>Zhenyu</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Beclin 1, an essential component and master regulator of PI3K-III in health and disease</article-title>. <source>Curr. Pathobiol. Rep.</source> <volume>1</volume> (<issue>4</issue>), <fpage>231</fpage>&#x2013;<lpage>238</lpage>. <pub-id pub-id-type="doi">10.1007/s40139-013-0028-5</pub-id>
<pub-id pub-id-type="pmid">24729948</pub-id>
</mixed-citation>
</ref>
<ref id="B116">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Menon</surname>
<given-names>M. B.</given-names>
</name>
<name>
<surname>Dhamija</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Beclin 1 phosphorylation &#x2013; at the center of autophagy regulation</article-title>. <source>Front. Cell Dev. Biol.</source> <volume>6</volume>, <fpage>137</fpage>. <pub-id pub-id-type="doi">10.3389/fcell.2018.00137</pub-id>
<pub-id pub-id-type="pmid">30370269</pub-id>
</mixed-citation>
</ref>
<ref id="B117">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mistretta</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Farini</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Torrente</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Villa</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Multifaceted nanoparticles: emerging mechanisms and therapies in neurodegenerative diseases</article-title>. <source>Brain</source> <volume>2</volume>, <fpage>awad014</fpage>. <pub-id pub-id-type="doi">10.1093/brain/awad014</pub-id>
<pub-id pub-id-type="pmid">36729638</pub-id>
</mixed-citation>
</ref>
<ref id="B118">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Molina</surname>
<given-names>P. E.</given-names>
</name>
<name>
<surname>Amedee</surname>
<given-names>A. M.</given-names>
</name>
<name>
<surname>LeCapitaine</surname>
<given-names>N. J.</given-names>
</name>
<name>
<surname>Zabaleta</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Mohan</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Winsauer</surname>
<given-names>P. J.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>Modulation of Gut-specific mechanisms by chronic &#x394;9-Tetrahydrocannabinol administration in male rhesus macaques infected with simian immunodeficiency virus: a systems biology analysis</article-title>. <source>AIDS Res. Hum. Retroviruses</source> <volume>30</volume> (<issue>6</issue>), <fpage>567</fpage>&#x2013;<lpage>578</lpage>. <pub-id pub-id-type="doi">10.1089/aid.2013.0182</pub-id>
<pub-id pub-id-type="pmid">24400995</pub-id>
</mixed-citation>
</ref>
<ref id="B119">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Monteiro</surname>
<given-names>K. L. C.</given-names>
</name>
<name>
<surname>dos Santos Alc&#xe2;ntara</surname>
<given-names>M. G.</given-names>
</name>
<name>
<surname>de Aquino</surname>
<given-names>T. M.</given-names>
</name>
<name>
<surname>da Silva-J&#xfa;nior</surname>
<given-names>E. F.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Cannabinoid pharmacology and its therapeutic uses in Alzheimer&#x2019;s disease</article-title>. <source>Neural Regen. Res.</source> <volume>16</volume> (<issue>5</issue>), <fpage>990</fpage>&#x2013;<lpage>991</lpage>. <pub-id pub-id-type="doi">10.4103/1673-5374.294336</pub-id>
<pub-id pub-id-type="pmid">33229747</pub-id>
</mixed-citation>
</ref>
<ref id="B120">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morley</surname>
<given-names>J. E.</given-names>
</name>
<name>
<surname>Farr</surname>
<given-names>S. A.</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>A. D.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>F.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>What is the physiological function of amyloid-beta protein?</article-title> <source>J. Nutr. Health Aging</source> <volume>23</volume> (<issue>3</issue>), <fpage>225</fpage>&#x2013;<lpage>226</lpage>. <pub-id pub-id-type="doi">10.1007/s12603-019-1162-5</pub-id>
<pub-id pub-id-type="pmid">30820508</pub-id>
</mixed-citation>
</ref>
<ref id="B121">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moss</surname>
<given-names>D. E.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Improving anti-neurodegenerative benefits of acetylcholinesterase inhibitors in alzheimer&#x2019;s disease: are irreversible inhibitors the future?</article-title> <source>Int. J. Mol. Sci.</source> <volume>21</volume> (<issue>10</issue>), <fpage>3438</fpage>. <pub-id pub-id-type="doi">10.3390/ijms21103438</pub-id>
<pub-id pub-id-type="pmid">32414155</pub-id>
</mixed-citation>
</ref>
<ref id="B122">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nadler</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Mechoulam</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Sokolovsky</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>1993</year>). <article-title>Blockade of 45Ca2&#x2b; influx through the N-methyl-D-aspartate receptor ion channel by the non-psychoactive cannabinoid HU-211</article-title>. <source>Brain Res.</source> <volume>622</volume> (<issue>1&#x2013;2</issue>), <fpage>79</fpage>&#x2013;<lpage>85</lpage>. <pub-id pub-id-type="doi">10.1016/0006-8993(93)90804-v</pub-id>
<pub-id pub-id-type="pmid">8242387</pub-id>
</mixed-citation>
</ref>
<ref id="B123">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ni</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>You</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Hydroxychloroquine induces apoptosis of myeloid-derived suppressor cells <italic>via</italic> up-regulation of CD81 contributing to alleviate lupus symptoms</article-title>. <source>Mol. Med. Camb Mass</source> <volume>28</volume> (<issue>1</issue>), <fpage>65</fpage>. <pub-id pub-id-type="doi">10.1186/s10020-022-00493-6</pub-id>
<pub-id pub-id-type="pmid">35705919</pub-id>
</mixed-citation>
</ref>
<ref id="B124">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nilsson</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Saido</surname>
<given-names>T. C.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Dual roles for autophagy: degradation and secretion of Alzheimer&#x2019;s disease A&#x3b2; peptide</article-title>. <source>BioEssays News Rev. Mol. Cell Dev. Biol.</source> <volume>36</volume> (<issue>6</issue>), <fpage>570</fpage>&#x2013;<lpage>578</lpage>. <pub-id pub-id-type="doi">10.1002/bies.201400002</pub-id>
<pub-id pub-id-type="pmid">24711225</pub-id>
</mixed-citation>
</ref>
<ref id="B125">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nilsson</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Loganathan</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Sekiguchi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Matsuba</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Hui</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Tsubuki</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2013</year>). <article-title>A&#x3b2; secretion and plaque Formation depend on autophagy</article-title>. <source>Cell Rep.</source> <volume>5</volume> (<issue>1</issue>), <fpage>61</fpage>&#x2013;<lpage>69</lpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2013.08.042</pub-id>
<pub-id pub-id-type="pmid">24095740</pub-id>
</mixed-citation>
</ref>
<ref id="B126">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nilsson</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Sekiguchi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Akagi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Izumi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Komori</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Hui</surname>
<given-names>K.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>Autophagy-related protein 7 deficiency in amyloid &#x3b2; (A&#x3b2;) precursor protein transgenic mice decreases A&#x3b2; in the multivesicular bodies and induces A&#x3b2; accumulation in the golgi</article-title>. <source>Am. J. Pathol.</source> <volume>26</volume>, <fpage>185</fpage>. <pub-id pub-id-type="doi">10.1016/j.ajpath.2014.10.011</pub-id>
<pub-id pub-id-type="pmid">25433221</pub-id>
</mixed-citation>
</ref>
<ref id="B127">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nixon</surname>
<given-names>R. A.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Autophagy, amyloidogenesis and Alzheimer disease</article-title>. <source>J. Cell Sci.</source> <volume>120</volume> (<issue>23</issue>), <fpage>4081</fpage>&#x2013;<lpage>4091</lpage>. <pub-id pub-id-type="doi">10.1242/jcs.019265</pub-id>
<pub-id pub-id-type="pmid">18032783</pub-id>
</mixed-citation>
</ref>
<ref id="B128">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nixon</surname>
<given-names>R. A.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Amyloid precursor protein and endosomal-lysosomal dysfunction in Alzheimer&#x2019;s disease: inseparable partners in a multifactorial disease</article-title>. <source>FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol.</source> <volume>31</volume> (<issue>7</issue>), <fpage>2729</fpage>&#x2013;<lpage>2743</lpage>. <pub-id pub-id-type="doi">10.1096/fj.201700359</pub-id>
<pub-id pub-id-type="pmid">28663518</pub-id>
</mixed-citation>
</ref>
<ref id="B129">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nixon</surname>
<given-names>R. A.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>D. S.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Autophagy failure in Alzheimer&#x2019;s disease--locating the primary defect</article-title>. <source>Neurobiol. Dis.</source> <volume>43</volume> (<issue>1</issue>), <fpage>38</fpage>&#x2013;<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1016/j.nbd.2011.01.021</pub-id>
<pub-id pub-id-type="pmid">21296668</pub-id>
</mixed-citation>
</ref>
<ref id="B130">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nixon</surname>
<given-names>R. A.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>D. S.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Autophagy and neuronal cell death in neurological disorders</article-title>. <source>Cold Spring Harb. Perspect. Biol.</source> <volume>4</volume> (<issue>10</issue>), <fpage>a008839</fpage>. <pub-id pub-id-type="doi">10.1101/cshperspect.a008839</pub-id>
<pub-id pub-id-type="pmid">22983160</pub-id>
</mixed-citation>
</ref>
<ref id="B131">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nixon</surname>
<given-names>R. A.</given-names>
</name>
<name>
<surname>Wegiel</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>W. H.</given-names>
</name>
<name>
<surname>Peterhoff</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Cataldo</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2005</year>). <article-title>Extensive involvement of autophagy in Alzheimer disease: an immuno-electron microscopy study</article-title>. <source>J. Neuropathol. Exp. Neurol.</source> <volume>64</volume> (<issue>2</issue>), <fpage>113</fpage>&#x2013;<lpage>122</lpage>. <pub-id pub-id-type="doi">10.1093/jnen/64.2.113</pub-id>
<pub-id pub-id-type="pmid">15751225</pub-id>
</mixed-citation>
</ref>
<ref id="B132">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ntsapi</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Loos</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Caloric restriction and the precision-control of autophagy: a strategy for delaying neurodegenerative disease progression</article-title>. <source>Exp. Gerontol.</source> <volume>83</volume>, <fpage>97</fpage>&#x2013;<lpage>111</lpage>. <pub-id pub-id-type="doi">10.1016/j.exger.2016.07.014</pub-id>
<pub-id pub-id-type="pmid">27473756</pub-id>
</mixed-citation>
</ref>
<ref id="B133">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ntsapi</surname>
<given-names>C. M.</given-names>
</name>
<name>
<surname>Loos</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Neurons die with heightened but functional macro- and chaperone mediated autophagy upon increased amyloid-&#xdf; induced toxicity with region-specific protection in prolonged intermittent fasting</article-title>. <source>Exp. Cell Res.</source> <volume>408</volume> (<issue>2</issue>), <fpage>112840</fpage>. <pub-id pub-id-type="doi">10.1016/j.yexcr.2021.112840</pub-id>
<pub-id pub-id-type="pmid">34624324</pub-id>
</mixed-citation>
</ref>
<ref id="B134">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ntsapi</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Lumkwana</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Swart</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>du Toit</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Loos</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>New insights into autophagy dysfunction related to amyloid beta toxicity and neuropathology in alzheimer&#x2019;s disease</article-title>. <source>Int. Rev. Cell Mol. Biol.</source> <volume>336</volume>, <fpage>321</fpage>&#x2013;<lpage>361</lpage>. <pub-id pub-id-type="doi">10.1016/bs.ircmb.2017.07.002</pub-id>
<pub-id pub-id-type="pmid">29413893</pub-id>
</mixed-citation>
</ref>
<ref id="B135">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>N&#xfa;&#xf1;ez</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Benito</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Pazos</surname>
<given-names>M. R.</given-names>
</name>
<name>
<surname>Barbachano</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Fajardo</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Gonz&#xe1;lez</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2004</year>). <article-title>Cannabinoid CB2 receptors are expressed by perivascular microglial cells in the human brain: an immunohistochemical study</article-title>. <source>Synap. N. Y. N.</source> <volume>53</volume> (<issue>4</issue>), <fpage>208</fpage>&#x2013;<lpage>213</lpage>. <pub-id pub-id-type="doi">10.1002/syn.20050</pub-id>
<pub-id pub-id-type="pmid">15266552</pub-id>
</mixed-citation>
</ref>
<ref id="B136">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oakes</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Law</surname>
<given-names>W. J.</given-names>
</name>
<name>
<surname>Komuniecki</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Cannabinoids stimulate the TRP channel-dependent release of both serotonin and dopamine to modulate behavior in C. elegans</article-title>. <source>J. Neurosci.</source> <volume>39</volume> (<issue>21</issue>), <fpage>4142</fpage>&#x2013;<lpage>4152</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.2371-18.2019</pub-id>
<pub-id pub-id-type="pmid">30886012</pub-id>
</mixed-citation>
</ref>
<ref id="B137">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>O&#x2019;Brien</surname>
<given-names>R. J.</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>P. C.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Amyloid precursor protein processing and alzheimer&#x2019;s disease</article-title>. <source>Annu. Rev. Neurosci.</source> <volume>34</volume>, <fpage>185</fpage>&#x2013;<lpage>204</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-neuro-061010-113613</pub-id>
<pub-id pub-id-type="pmid">21456963</pub-id>
</mixed-citation>
</ref>
<ref id="B138">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>O&#x2019;Sullivan</surname>
<given-names>S. E.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>An update on PPAR activation by cannabinoids</article-title>. <source>Br. J. Pharmacol.</source> <volume>173</volume> (<issue>12</issue>), <fpage>1899</fpage>&#x2013;<lpage>1910</lpage>. <pub-id pub-id-type="doi">10.1111/bph.13497</pub-id>
<pub-id pub-id-type="pmid">27077495</pub-id>
</mixed-citation>
</ref>
<ref id="B139">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Padman</surname>
<given-names>B. S.</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>T. N.</given-names>
</name>
<name>
<surname>Uoselis</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Skulsuppaisarn</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>L. K.</given-names>
</name>
<name>
<surname>Lazarou</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>LC3/GABARAPs drive ubiquitin-independent recruitment of optineurin and NDP52 to amplify mitophagy</article-title>. <source>Nat. Commun.</source> <volume>10</volume> (<issue>1</issue>), <fpage>408</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-019-08335-6</pub-id>
<pub-id pub-id-type="pmid">30679426</pub-id>
</mixed-citation>
</ref>
<ref id="B140">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pantoja-Ruiz</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Restrepo-Jimenez</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Casta&#xf1;eda-Cardona</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ferreir&#xf3;s</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Rosselli</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Cannabis and pain: a scoping review</article-title>. <source>Braz J. Anesthesiol. Engl.</source> <volume>72</volume> (<issue>1</issue>), <fpage>142</fpage>&#x2013;<lpage>151</lpage>. <pub-id pub-id-type="doi">10.1016/j.bjane.2021.06.018</pub-id>
<pub-id pub-id-type="pmid">34280454</pub-id>
</mixed-citation>
</ref>
<ref id="B141">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Park</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>J. H.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Autophagy in neurodegenerative diseases: a hunter for aggregates</article-title>. <source>Int. J. Mol. Sci.</source> <volume>21</volume> (<issue>9</issue>), <fpage>3369</fpage>. <pub-id pub-id-type="doi">10.3390/ijms21093369</pub-id>
<pub-id pub-id-type="pmid">32397599</pub-id>
</mixed-citation>
</ref>
<ref id="B142">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Paronis</surname>
<given-names>C. A.</given-names>
</name>
<name>
<surname>Nikas</surname>
<given-names>S. P.</given-names>
</name>
<name>
<surname>Shukla</surname>
<given-names>V. G.</given-names>
</name>
<name>
<surname>Makriyannis</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>&#x394;9-Tetrahydrocannabinol acts as a partial agonist/antagonist in mice</article-title>. <source>Behav. Pharmacol.</source> <volume>23</volume> (<issue>8</issue>), <fpage>802</fpage>&#x2013;<lpage>805</lpage>. <pub-id pub-id-type="doi">10.1097/FBP.0b013e32835a7c4d</pub-id>
<pub-id pub-id-type="pmid">23075707</pub-id>
</mixed-citation>
</ref>
<ref id="B143">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Parsons</surname>
<given-names>C. G.</given-names>
</name>
<name>
<surname>Danysz</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Dekundy</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Pulte</surname>
<given-names>I.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer&#x2019;s disease</article-title>. <source>Neurotox. Res.</source> <volume>24</volume> (<issue>3</issue>), <fpage>358</fpage>&#x2013;<lpage>369</lpage>. <pub-id pub-id-type="doi">10.1007/s12640-013-9398-z</pub-id>
<pub-id pub-id-type="pmid">23657927</pub-id>
</mixed-citation>
</ref>
<ref id="B144">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Patil</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Chandel</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Rana</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Jain</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kaushik</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Investigation of Cannabis sativa phytochemicals as anti-alzheimer&#x2019;s agents: an <italic>in silico</italic> study</article-title>. <source>Plants</source> <volume>12</volume> (<issue>3</issue>), <fpage>510</fpage>. <pub-id pub-id-type="doi">10.3390/plants12030510</pub-id>
<pub-id pub-id-type="pmid">36771595</pub-id>
</mixed-citation>
</ref>
<ref id="B145">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pertwee</surname>
<given-names>R. G.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: &#x394;9-tetrahydrocannabinol, cannabidiol and &#x394;9-tetrahydrocannabivarin</article-title>. <source>Br. J. Pharmacol.</source> <volume>153</volume> (<issue>2</issue>), <fpage>199</fpage>&#x2013;<lpage>215</lpage>. <pub-id pub-id-type="doi">10.1038/sj.bjp.0707442</pub-id>
<pub-id pub-id-type="pmid">17828291</pub-id>
</mixed-citation>
</ref>
<ref id="B146">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Picciotto</surname>
<given-names>M. R.</given-names>
</name>
<name>
<surname>Higley</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Mineur</surname>
<given-names>Y. S.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Acetylcholine as a neuromodulator: cholinergic signaling shapes nervous system function and behavior</article-title>. <source>Neuron</source> <volume>76</volume> (<issue>1</issue>), <fpage>116</fpage>&#x2013;<lpage>129</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2012.08.036</pub-id>
<pub-id pub-id-type="pmid">23040810</pub-id>
</mixed-citation>
</ref>
<ref id="B147">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Piette</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Cui</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Gervasi</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Venance</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Lights on endocannabinoid-mediated synaptic potentiation</article-title>. <source>Front. Mol. Neurosci.</source> <volume>13</volume>, <fpage>132</fpage>. <pub-id pub-id-type="doi">10.3389/fnmol.2020.00132</pub-id>
<pub-id pub-id-type="pmid">32848597</pub-id>
</mixed-citation>
</ref>
<ref id="B148">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pongking</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Intuyod</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Thongpon</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Thanan</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Sitthirach</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Chaidee</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2024</year>). <article-title>Cannabidiol suppresses proliferation and induces cell death, autophagy and senescence in human cholangiocarcinoma cells <italic>via</italic> the PI3K/AKT/mTOR pathway</article-title>. <source>J. Tradit. Complement. Med.</source> <volume>14</volume> (<issue>6</issue>), <fpage>622</fpage>&#x2013;<lpage>634</lpage>. <pub-id pub-id-type="doi">10.1016/j.jtcme.2024.04.007</pub-id>
<pub-id pub-id-type="pmid">39850601</pub-id>
</mixed-citation>
</ref>
<ref id="B149">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Porsteinsson</surname>
<given-names>A. P.</given-names>
</name>
<name>
<surname>Isaacson</surname>
<given-names>R. S.</given-names>
</name>
<name>
<surname>Knox</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sabbagh</surname>
<given-names>M. N.</given-names>
</name>
<name>
<surname>Rubino</surname>
<given-names>I.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Diagnosis of early alzheimer&#x2019;s disease: clinical practice in 2021</article-title>. <source>J. Prev. Alzheimers Dis.</source> <volume>8</volume> (<issue>3</issue>), <fpage>371</fpage>&#x2013;<lpage>386</lpage>. <pub-id pub-id-type="doi">10.14283/jpad.2021.23</pub-id>
<pub-id pub-id-type="pmid">34101796</pub-id>
</mixed-citation>
</ref>
<ref id="B150">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Puopolo</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Seeram</surname>
<given-names>N. P.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Inhibitory effects of cannabinoids on acetylcholinesterase and butyrylcholinesterase enzyme activities</article-title>. <source>Med. Cannabis Cannabinoids.</source> <volume>5</volume> (<issue>1</issue>), <fpage>85</fpage>&#x2013;<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1159/000524086</pub-id>
<pub-id pub-id-type="pmid">35702400</pub-id>
</mixed-citation>
</ref>
<ref id="B151">
<mixed-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Rabanal-Ruiz</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Otten</surname>
<given-names>E. G.</given-names>
</name>
<name>
<surname>Korolchuk</surname>
<given-names>V. I.</given-names>
</name>
</person-group> (<year>2017</year>). &#x201c;<article-title>mTORC1 as the main gateway to autophagy</article-title>,&#x201d;. Editors <person-group person-group-type="editor">
<name>
<surname>Lane</surname>
<given-names>J. D.</given-names>
</name>
<name>
<surname>Korolchuk</surname>
<given-names>V. I.</given-names>
</name>
<name>
<surname>Murray</surname>
<given-names>J. T.</given-names>
</name>
</person-group>, <volume>61</volume>, <fpage>565</fpage>&#x2013;<lpage>584</lpage>. <pub-id pub-id-type="doi">10.1042/EBC20170027</pub-id>
<pub-id pub-id-type="pmid">29233869</pub-id>
</mixed-citation>
</ref>
<ref id="B152">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Radu</surname>
<given-names>B. M.</given-names>
</name>
<name>
<surname>Osculati</surname>
<given-names>A. M. M.</given-names>
</name>
<name>
<surname>Suku</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Banciu</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tsenov</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Merigo</surname>
<given-names>F.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>All muscarinic acetylcholine receptors (M1-M5) are expressed in murine brain microvascular endothelium</article-title>. <source>Sci. Rep.</source> <volume>7</volume> (<issue>1</issue>), <fpage>5083</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-017-05384-z</pub-id>
<pub-id pub-id-type="pmid">28698560</pub-id>
</mixed-citation>
</ref>
<ref id="B153">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rahman</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Rahman</surname>
<given-names>M. S.</given-names>
</name>
<name>
<surname>Rahman</surname>
<given-names>M. D. H.</given-names>
</name>
<name>
<surname>Rasheduzzaman</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mamun-Or-Rashid</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Uddin</surname>
<given-names>M. J.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Modulatory effects of autophagy on APP processing as a potential treatment target for alzheimer&#x2019;s disease</article-title>. <source>Biomedicines</source> <volume>9</volume> (<issue>1</issue>), <fpage>5</fpage>. <pub-id pub-id-type="doi">10.3390/biomedicines9010005</pub-id>
<pub-id pub-id-type="pmid">33374126</pub-id>
</mixed-citation>
</ref>
<ref id="B154">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ra&#xef;ch</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Lillo</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Rebassa</surname>
<given-names>J. B.</given-names>
</name>
<name>
<surname>Gri&#xf1;&#xe1;n-Ferr&#xe9;</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Bellver-Sanchis</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Reyes-Resina</surname>
<given-names>I.</given-names>
</name>
<etal/>
</person-group> (<year>2025</year>). <article-title>Cannabidiol as a multifaceted therapeutic agent: mitigating Alzheimer&#x2019;s disease pathology and enhancing cognitive function</article-title>. <source>Alzheimers Res. Ther.</source> <volume>17</volume> (<issue>1</issue>), <fpage>109</fpage>. <pub-id pub-id-type="doi">10.1186/s13195-025-01756-0</pub-id>
<pub-id pub-id-type="pmid">40394655</pub-id>
</mixed-citation>
</ref>
<ref id="B155">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Raja</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ahmadi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>de Costa</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Kerman</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Attenuation of oxidative stress by cannabinoids and cannabis extracts in differentiated neuronal cells</article-title>. <source>Pharmaceuticals</source> <volume>13</volume> (<issue>11</issue>), <fpage>328</fpage>. <pub-id pub-id-type="doi">10.3390/ph13110328</pub-id>
<pub-id pub-id-type="pmid">33105840</pub-id>
</mixed-citation>
</ref>
<ref id="B156">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ram&#xed;rez</surname>
<given-names>B. G.</given-names>
</name>
<name>
<surname>Bl&#xe1;zquez</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>G&#xf3;mez del Pulgar</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Guzm&#xe1;n</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>de Ceballos</surname>
<given-names>M. L.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Prevention of Alzheimer&#x2019;s disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation</article-title>. <source>J. Neurosci. Off. J. Soc. Neurosci.</source> <volume>25</volume> (<issue>8</issue>), <fpage>1904</fpage>&#x2013;<lpage>1913</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.4540-04.2005</pub-id>
<pub-id pub-id-type="pmid">15728830</pub-id>
</mixed-citation>
</ref>
<ref id="B157">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reekie</surname>
<given-names>T. A.</given-names>
</name>
<name>
<surname>Scott</surname>
<given-names>M. P.</given-names>
</name>
<name>
<surname>Kassiou</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>The evolving science of phytocannabinoids</article-title>. <source>Nat. Rev. Chem.</source> <volume>2</volume> (<issue>1</issue>), <fpage>1</fpage>&#x2013;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1038/s41570-017-0101</pub-id>
</mixed-citation>
</ref>
<ref id="B158">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reisberg</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Doody</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>St&#xf6;ffler</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Schmitt</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Ferris</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>M&#xf6;bius</surname>
<given-names>H. J.</given-names>
</name>
<etal/>
</person-group> (<year>2003</year>). <article-title>Memantine in moderate-to-severe Alzheimer&#x2019;s disease</article-title>. <source>N. Engl. J. Med.</source> <volume>348</volume> (<issue>14</issue>), <fpage>1333</fpage>&#x2013;<lpage>1341</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa013128</pub-id>
<pub-id pub-id-type="pmid">12672860</pub-id>
</mixed-citation>
</ref>
<ref id="B159">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ribeiro</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ferraz-de-Paula</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Pinheiro</surname>
<given-names>M. L.</given-names>
</name>
<name>
<surname>Vitoretti</surname>
<given-names>L. B.</given-names>
</name>
<name>
<surname>Mariano-Souza</surname>
<given-names>D. P.</given-names>
</name>
<name>
<surname>Quinteiro-Filho</surname>
<given-names>W. M.</given-names>
</name>
<etal/>
</person-group> (<year>2012</year>). <article-title>Cannabidiol, a non-psychotropic plant-derived cannabinoid, decreases inflammation in a murine model of acute lung injury: role for the adenosine A(2A) receptor</article-title>. <source>Eur. J. Pharmacol.</source> <volume>678</volume> (<issue>1&#x2013;3</issue>), <fpage>78</fpage>&#x2013;<lpage>85</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2011.12.043</pub-id>
<pub-id pub-id-type="pmid">22265864</pub-id>
</mixed-citation>
</ref>
<ref id="B160">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ricciarelli</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Fedele</surname>
<given-names>E.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>The amyloid Cascade hypothesis in alzheimer&#x2019;s disease: it&#x2019;s time to change our mind</article-title>. <source>Curr. Neuropharmacol.</source> <volume>15</volume> (<issue>6</issue>), <fpage>926</fpage>&#x2013;<lpage>935</lpage>. <pub-id pub-id-type="doi">10.2174/1570159X15666170116143743</pub-id>
<pub-id pub-id-type="pmid">28093977</pub-id>
</mixed-citation>
</ref>
<ref id="B161">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Riedel</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Davies</surname>
<given-names>S. N.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Cannabinoid function in learning, memory and plasticity</article-title>. <source>Handb. Exp. Pharmacol.</source> (<issue>168</issue>), <fpage>445</fpage>&#x2013;<lpage>477</lpage>. <pub-id pub-id-type="doi">10.1007/3-540-26573-2_15</pub-id>
<pub-id pub-id-type="pmid">16596784</pub-id>
</mixed-citation>
</ref>
<ref id="B162">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roberds</surname>
<given-names>S. L.</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Basi</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Bienkowski</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Branstetter</surname>
<given-names>D. G.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>K. S.</given-names>
</name>
<etal/>
</person-group> (<year>2001</year>). <article-title>BACE knockout mice are healthy despite lacking the primary &#x3b2;-secretase activity in brain: implications for Alzheimer&#x2019;s disease therapeutics</article-title>. <source>Hum. Mol. Genet.</source> <volume>10</volume> (<issue>12</issue>), <fpage>1317</fpage>&#x2013;<lpage>1324</lpage>. <pub-id pub-id-type="doi">10.1093/hmg/10.12.1317</pub-id>
<pub-id pub-id-type="pmid">11406613</pub-id>
</mixed-citation>
</ref>
<ref id="B163">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rohn</surname>
<given-names>T. T.</given-names>
</name>
<name>
<surname>Head</surname>
<given-names>E.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Caspases as therapeutic targets in Alzheimer&#x2019;s disease: is it time to &#x2018;cut&#x2019; to the chase?</article-title> <source>Int. J. Clin. Exp. Pathol.</source> <volume>2</volume> (<issue>2</issue>), <fpage>108</fpage>&#x2013;<lpage>118</lpage>.<pub-id pub-id-type="pmid">19079646</pub-id>
</mixed-citation>
</ref>
<ref id="B164">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ruangritchankul</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Chantharit</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Srisuma</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gray</surname>
<given-names>L. C.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Adverse drug reactions of acetylcholinesterase inhibitors in older people living with dementia: a comprehensive literature review</article-title>. <source>Ther. Clin. Risk Manag.</source> <volume>4</volume>, <fpage>927</fpage>&#x2013;<lpage>949</lpage>. <pub-id pub-id-type="doi">10.2147/TCRM.S323387</pub-id>
<pub-id pub-id-type="pmid">34511919</pub-id>
</mixed-citation>
</ref>
<ref id="B165">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Russo</surname>
<given-names>E. B.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Cannabis therapeutics and the future of neurology</article-title>. <source>Front. Integr. Neurosci.</source> <volume>12</volume>, <fpage>51</fpage>. <pub-id pub-id-type="doi">10.3389/fnint.2018.00051</pub-id>
<pub-id pub-id-type="pmid">30405366</pub-id>
</mixed-citation>
</ref>
<ref id="B166">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ruver-Martins</surname>
<given-names>A. C.</given-names>
</name>
<name>
<surname>Bicca</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>de Araujo</surname>
<given-names>F. S.</given-names>
</name>
<name>
<surname>de Noronha Sales Maia</surname>
<given-names>B. H. L.</given-names>
</name>
<name>
<surname>Pamplona</surname>
<given-names>F. A.</given-names>
</name>
<name>
<surname>da Silva</surname>
<given-names>E. G.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Cannabinoid extract in microdoses ameliorates mnemonic and nonmnemonic Alzheimer&#x2019;s disease symptoms: a case report</article-title>. <source>J. Med. Case Rep.</source> <volume>16</volume> (<issue>1</issue>), <fpage>277</fpage>. <pub-id pub-id-type="doi">10.1186/s13256-022-03457-w</pub-id>
<pub-id pub-id-type="pmid">35820856</pub-id>
</mixed-citation>
</ref>
<ref id="B167">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Salazar</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Carracedo</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Salanueva</surname>
<given-names>I. J.</given-names>
</name>
<name>
<surname>Hern&#xe1;ndez-Tiedra</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lorente</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Egia</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2009</year>). <article-title>Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells</article-title>. <source>J. Clin. Invest</source> <volume>119</volume> (<issue>5</issue>), <fpage>1359</fpage>&#x2013;<lpage>1372</lpage>. <pub-id pub-id-type="doi">10.1172/jci37948</pub-id>
<pub-id pub-id-type="pmid">19425170</pub-id>
</mixed-citation>
</ref>
<ref id="B168">
<mixed-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Sam</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Bordoni</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2023</year>). &#x201c;<article-title>Physiology, acetylcholine</article-title>,&#x201d; in <source>StatPearls</source> (<publisher-loc>Treasure Island (FL)</publisher-loc>: <publisher-name>StatPearls Publishing</publisher-name>). <comment>Available online at: <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/books/NBK557825/">http://www.ncbi.nlm.nih.gov/books/NBK557825/</ext-link>.</comment>
</mixed-citation>
</ref>
<ref id="B169">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>S&#xe1;nchez-Fern&#xe1;ndez</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>G&#xf3;mez-Acero</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Casta&#xf1;&#xe9;</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Adell</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Campa</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Bonaventura</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2024</year>). <article-title>A combination of &#x394;9-tetrahydrocannabinol and cannabidiol modulates glutamate dynamics in the hippocampus of an animal model of Alzheimer&#x2019;s disease</article-title>. <source>Neurotherapeutics</source> <volume>21</volume> (<issue>5</issue>), <fpage>e00439</fpage>. <pub-id pub-id-type="doi">10.1016/j.neurot.2024.e00439</pub-id>
<pub-id pub-id-type="pmid">39232876</pub-id>
</mixed-citation>
</ref>
<ref id="B170">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saxton</surname>
<given-names>R. A.</given-names>
</name>
<name>
<surname>Sabatini</surname>
<given-names>D. M.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>mTOR signaling in growth, metabolism, and disease</article-title>. <source>Cell</source> <volume>168</volume> (<issue>6</issue>), <fpage>960</fpage>&#x2013;<lpage>976</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2017.02.004</pub-id>
<pub-id pub-id-type="pmid">28283069</pub-id>
</mixed-citation>
</ref>
<ref id="B171">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schott</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Aisen</surname>
<given-names>P. S.</given-names>
</name>
<name>
<surname>Cummings</surname>
<given-names>J. L.</given-names>
</name>
<name>
<surname>Howard</surname>
<given-names>R. J.</given-names>
</name>
<name>
<surname>Fox</surname>
<given-names>N. C.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Unsuccessful trials of therapies for Alzheimer&#x2019;s disease</article-title>. <source>Lancet</source> <volume>393</volume> (<issue>10166</issue>), <fpage>29</fpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(18)31896-8</pub-id>
<pub-id pub-id-type="pmid">30614456</pub-id>
</mixed-citation>
</ref>
<ref id="B172">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schubert</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Kepchia</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Dargusch</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Goldberg</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Maher</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Efficacy of cannabinoids in a pre-clinical drug-screening platform for alzheimer&#x2019;s disease</article-title>. <source>Mol. Neurobiol.</source> <volume>56</volume> (<issue>11</issue>), <fpage>7719</fpage>&#x2013;<lpage>7730</lpage>. <pub-id pub-id-type="doi">10.1007/s12035-019-1637-8</pub-id>
<pub-id pub-id-type="pmid">31104297</pub-id>
</mixed-citation>
</ref>
<ref id="B173">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schuster</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Gerold</surname>
<given-names>K. D.</given-names>
</name>
<name>
<surname>Schober</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Probst</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Boerner</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>M. J.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>The autoimmunity-associated gene CLEC16A modulates thymic epithelial cell autophagy and alters T cell selection</article-title>. <source>Immunity</source> <volume>42</volume> (<issue>5</issue>), <fpage>942</fpage>&#x2013;<lpage>952</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2015.04.011</pub-id>
<pub-id pub-id-type="pmid">25979422</pub-id>
</mixed-citation>
</ref>
<ref id="B174">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sharma</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Cholinesterase inhibitors as Alzheimer&#x2019;s therapeutics</article-title>. <source>Mol. Med. Rep.</source> <volume>20</volume> (<issue>2</issue>), <fpage>1479</fpage>&#x2013;<lpage>1487</lpage>. <pub-id pub-id-type="doi">10.3892/mmr.2019.10374</pub-id>
<pub-id pub-id-type="pmid">31257471</pub-id>
</mixed-citation>
</ref>
<ref id="B175">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sinha</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>J. P.</given-names>
</name>
<name>
<surname>Barbour</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Basi</surname>
<given-names>G. S.</given-names>
</name>
<name>
<surname>Caccavello</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>D.</given-names>
</name>
<etal/>
</person-group> (<year>1999</year>). <article-title>Purification and cloning of amyloid precursor protein beta-secretase from human brain</article-title>. <source>Nature</source> <volume>402</volume> (<issue>6761</issue>), <fpage>537</fpage>&#x2013;<lpage>540</lpage>. <pub-id pub-id-type="doi">10.1038/990114</pub-id>
<pub-id pub-id-type="pmid">10591214</pub-id>
</mixed-citation>
</ref>
<ref id="B176">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Son</surname>
<given-names>J. H.</given-names>
</name>
<name>
<surname>Shim</surname>
<given-names>J. H.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>K. H.</given-names>
</name>
<name>
<surname>Ha</surname>
<given-names>J. Y.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>J. Y.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Neuronal autophagy and neurodegenerative diseases</article-title>. <source>Exp. Mol. Med.</source> <volume>44</volume> (<issue>2</issue>), <fpage>89</fpage>&#x2013;<lpage>98</lpage>. <pub-id pub-id-type="doi">10.3858/emm.2012.44.2.031</pub-id>
<pub-id pub-id-type="pmid">22257884</pub-id>
</mixed-citation>
</ref>
<ref id="B177">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stavoe</surname>
<given-names>A. K. H.</given-names>
</name>
<name>
<surname>Holzbaur</surname>
<given-names>E. L. F.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Autophagy in neurons</article-title>. <source>Annu. Rev. Cell Dev. Biol.</source> <volume>35</volume>, <fpage>477</fpage>&#x2013;<lpage>500</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-cellbio-100818-125242</pub-id>
<pub-id pub-id-type="pmid">31340124</pub-id>
</mixed-citation>
</ref>
<ref id="B178">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Suresh</surname>
<given-names>S. N.</given-names>
</name>
<name>
<surname>Chakravorty</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Giridharan</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Garimella</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Manjithaya</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Pharmacological tools to modulate autophagy in neurodegenerative diseases</article-title>. <source>J. Mol. Biol.</source> <volume>432</volume> (<issue>8</issue>), <fpage>2822</fpage>&#x2013;<lpage>2842</lpage>. <pub-id pub-id-type="doi">10.1016/j.jmb.2020.02.023</pub-id>
<pub-id pub-id-type="pmid">32105729</pub-id>
</mixed-citation>
</ref>
<ref id="B179">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Suzuki</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Osawa</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Fujioka</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Noda</surname>
<given-names>N. N.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Structural biology of the core autophagy machinery</article-title>. <source>Curr. Opin. Struct. Biol.</source> <volume>43</volume>, <fpage>10</fpage>&#x2013;<lpage>17</lpage>. <pub-id pub-id-type="doi">10.1016/j.sbi.2016.09.010</pub-id>
<pub-id pub-id-type="pmid">27723509</pub-id>
</mixed-citation>
</ref>
<ref id="B180">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>&#x15a;wietlik</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Kusiak</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ossowska</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Computational modeling of therapy with the NMDA antagonist in neurodegenerative disease: information theory in the mechanism of action of memantine</article-title>. <source>Int. J. Environ. Res. Public Health</source> <volume>19</volume> (<issue>8</issue>), <fpage>4727</fpage>. <pub-id pub-id-type="doi">10.3390/ijerph19084727</pub-id>
<pub-id pub-id-type="pmid">35457595</pub-id>
</mixed-citation>
</ref>
<ref id="B181">
<mixed-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Tailor</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Pilozzi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>X.</given-names>
</name>
</person-group> (<year>2019</year>). &#x201c;<article-title>Contributing factors of neurodegeneration in alzheimer&#x2019;s disease</article-title>,&#x201d; in <source>Alzheimer&#x2019;s disease</source>. Editor <person-group person-group-type="editor">
<name>
<surname>Wisniewski</surname>
<given-names>T.</given-names>
</name>
</person-group> (<publisher-loc>Brisbane (AU)</publisher-loc>: <publisher-name>Codon Publications</publisher-name>). <comment>Available online at: <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/books/NBK552140/">http://www.ncbi.nlm.nih.gov/books/NBK552140/</ext-link>.</comment>
</mixed-citation>
</ref>
<ref id="B182">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Takahashi</surname>
<given-names>R. H.</given-names>
</name>
<name>
<surname>Nagao</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Gouras</surname>
<given-names>G. K.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Plaque formation and the intraneuronal accumulation of &#x3b2;-amyloid in Alzheimer&#x2019;s disease</article-title>. <source>Pathol. Int.</source> <volume>67</volume> (<issue>4</issue>), <fpage>185</fpage>&#x2013;<lpage>193</lpage>. <pub-id pub-id-type="doi">10.1111/pin.12520</pub-id>
<pub-id pub-id-type="pmid">28261941</pub-id>
</mixed-citation>
</ref>
<ref id="B183">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tamargo-G&#xf3;mez</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Mari&#xf1;o</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>AMPK: regulation of metabolic dynamics in the context of autophagy</article-title>. <source>Int. J. Mol. Sci.</source> <volume>19</volume> (<issue>12</issue>), <fpage>3812</fpage>. <pub-id pub-id-type="doi">10.3390/ijms19123812</pub-id>
<pub-id pub-id-type="pmid">30501132</pub-id>
</mixed-citation>
</ref>
<ref id="B184">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tekirdag</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Cuervo</surname>
<given-names>A. M.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Chaperone-mediated autophagy and endosomal microautophagy: joint by a chaperone</article-title>. <source>J. Biol. Chem.</source> <volume>293</volume> (<issue>15</issue>), <fpage>5414</fpage>&#x2013;<lpage>5424</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.R117.818237</pub-id>
<pub-id pub-id-type="pmid">29247007</pub-id>
</mixed-citation>
</ref>
<ref id="B185">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tian</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Bustos</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Flajolet</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Greengard</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>A small-molecule enhancer of autophagy decreases levels of A&#x3b2; and APP-CTF <italic>via</italic> Atg5-dependent autophagy pathway</article-title>. <source>FASEB J.</source> <volume>25</volume> (<issue>6</issue>), <fpage>1934</fpage>&#x2013;<lpage>1942</lpage>. <pub-id pub-id-type="doi">10.1096/fj.10-175158</pub-id>
<pub-id pub-id-type="pmid">21368103</pub-id>
</mixed-citation>
</ref>
<ref id="B186">
<mixed-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Tizabi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Getachew</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Tsytsarev</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Csoka</surname>
<given-names>A. B.</given-names>
</name>
<name>
<surname>Copeland</surname>
<given-names>R. L.</given-names>
</name>
<name>
<surname>Heinbockel</surname>
<given-names>T.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). &#x201c;<article-title>Central nicotinic and muscarinic receptors in health and disease</article-title>,&#x201d; in <source>Acetylcholine - Recent advances and new perspectives</source> (<publisher-name>London, United Kingdom: IntechOpen</publisher-name>). <comment>Available online at: <ext-link ext-link-type="uri" xlink:href="https://www.intechopen.com/chapters/87811">https://www.intechopen.com/chapters/87811</ext-link>.</comment>
</mixed-citation>
</ref>
<ref id="B187">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Toledano</surname>
<given-names>R. S.</given-names>
</name>
<name>
<surname>Akirav</surname>
<given-names>I.</given-names>
</name>
</person-group> (<year>2025</year>). <article-title>Cannabidiol prevents cognitive and social deficits in a male rat model of Alzheimer&#x2019;s disease through CB1 activation and inflammation modulation</article-title>. <source>Neuropsychopharmacology</source> <volume>50</volume> (<issue>13</issue>), <fpage>1916</fpage>&#x2013;<lpage>1927</lpage>. <pub-id pub-id-type="doi">10.1038/s41386-025-02213-0</pub-id>
<pub-id pub-id-type="pmid">40859005</pub-id>
</mixed-citation>
</ref>
<ref id="B188">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tol&#xf3;n</surname>
<given-names>R. M.</given-names>
</name>
<name>
<surname>N&#xfa;&#xf1;ez</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Pazos</surname>
<given-names>M. R.</given-names>
</name>
<name>
<surname>Benito</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Castillo</surname>
<given-names>A. I.</given-names>
</name>
<name>
<surname>Mart&#xed;nez-Orgado</surname>
<given-names>J. A.</given-names>
</name>
<etal/>
</person-group> (<year>2009</year>). <article-title>The activation of cannabinoid CB2 receptors stimulates <italic>in situ</italic> and <italic>in vitro</italic> beta-amyloid removal by human macrophages</article-title>. <source>Brain Res.</source> <volume>1283</volume>, <fpage>148</fpage>&#x2013;<lpage>154</lpage>. <pub-id pub-id-type="doi">10.1016/j.brainres.2009.05.098</pub-id>
<pub-id pub-id-type="pmid">19505450</pub-id>
</mixed-citation>
</ref>
<ref id="B189">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Towers</surname>
<given-names>C. G.</given-names>
</name>
<name>
<surname>Thorburn</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Therapeutic targeting of autophagy</article-title>. <source>EBioMedicine</source> <volume>14</volume>, <fpage>15</fpage>&#x2013;<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1016/j.ebiom.2016.10.034</pub-id>
<pub-id pub-id-type="pmid">28029600</pub-id>
</mixed-citation>
</ref>
<ref id="B190">
<mixed-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Trang</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Khandhar</surname>
<given-names>P. B.</given-names>
</name>
</person-group> (<year>2023</year>). <source>Physiology, acetylcholinesterase. In: Statpearls</source>. <publisher-loc>Treasure Island (FL)</publisher-loc>: <publisher-name>StatPearls Publishing</publisher-name>. <comment>Available online at: <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/books/NBK539735/">http://www.ncbi.nlm.nih.gov/books/NBK539735/</ext-link>.</comment>
</mixed-citation>
</ref>
<ref id="B191">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Trezza</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Campolongo</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>The endocannabinoid system as a possible target to treat both the cognitive and emotional features of post-traumatic stress disorder (PTSD)</article-title>. <source>Front. Behav. Neurosci.</source> <volume>7</volume>, <fpage>100</fpage>. <pub-id pub-id-type="doi">10.3389/fnbeh.2013.00100</pub-id>
<pub-id pub-id-type="pmid">23950739</pub-id>
</mixed-citation>
</ref>
<ref id="B192">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tyrakis</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Agridi</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Kourti</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2024</year>). <article-title>A comprehensive exploration of the multifaceted neuroprotective role of cannabinoids in alzheimer&#x2019;s disease across a decade of research</article-title>. <source>Int. J. Mol. Sci.</source> <volume>25</volume> (<issue>16</issue>), <fpage>8630</fpage>. <pub-id pub-id-type="doi">10.3390/ijms25168630</pub-id>
<pub-id pub-id-type="pmid">39201317</pub-id>
</mixed-citation>
</ref>
<ref id="B193">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Valencia</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>S. R.</given-names>
</name>
<name>
<surname>Jang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>S. H.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Neuronal autophagy: characteristic features and roles in neuronal pathophysiology</article-title>. <source>Biomol. Ther.</source> <volume>29</volume> (<issue>6</issue>), <fpage>605</fpage>&#x2013;<lpage>614</lpage>. <pub-id pub-id-type="doi">10.4062/biomolther.2021.012</pub-id>
<pub-id pub-id-type="pmid">33875624</pub-id>
</mixed-citation>
</ref>
<ref id="B194">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>van der Stelt</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mazzola</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Esposito</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Matias</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Petrosino</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>De Filippis</surname>
<given-names>D.</given-names>
</name>
<etal/>
</person-group> (<year>2006</year>). <article-title>Endocannabinoids and beta-amyloid-induced neurotoxicity <italic>in vivo:</italic> effect of pharmacological elevation of endocannabinoid levels</article-title>. <source>Cell Mol. Life Sci. CMLS</source> <volume>63</volume> (<issue>12</issue>), <fpage>1410</fpage>&#x2013;<lpage>1424</lpage>. <pub-id pub-id-type="doi">10.1007/s00018-006-6037-3</pub-id>
<pub-id pub-id-type="pmid">16732431</pub-id>
</mixed-citation>
</ref>
<ref id="B195">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vassar</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Bennett</surname>
<given-names>B. D.</given-names>
</name>
<name>
<surname>Babu-Khan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kahn</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Mendiaz</surname>
<given-names>E. A.</given-names>
</name>
<name>
<surname>Denis</surname>
<given-names>P.</given-names>
</name>
<etal/>
</person-group> (<year>1999</year>). <article-title>Beta-secretase cleavage of Alzheimer&#x2019;s amyloid precursor protein by the transmembrane aspartic protease BACE</article-title>. <source>Science.</source> <volume>286</volume> (<issue>5440</issue>), <fpage>735</fpage>&#x2013;<lpage>741</lpage>. <pub-id pub-id-type="doi">10.1126/science.286.5440.735</pub-id>
<pub-id pub-id-type="pmid">10531052</pub-id>
</mixed-citation>
</ref>
<ref id="B196">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vrechi</surname>
<given-names>T. A. M.</given-names>
</name>
<name>
<surname>Le&#xe3;o</surname>
<given-names>AHFF</given-names>
</name>
<name>
<surname>Morais</surname>
<given-names>I. B. M.</given-names>
</name>
<name>
<surname>Ab&#xed;lio</surname>
<given-names>V. C.</given-names>
</name>
<name>
<surname>Zuardi</surname>
<given-names>A. W.</given-names>
</name>
<name>
<surname>Hallak</surname>
<given-names>J. E. C.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Cannabidiol induces autophagy <italic>via</italic> ERK1/2 activation in neural cells</article-title>. <source>Sci. Rep.</source> <volume>11</volume>, <fpage>5434</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-021-84879-2</pub-id>
<pub-id pub-id-type="pmid">33686185</pub-id>
</mixed-citation>
</ref>
<ref id="B197">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Reddy</surname>
<given-names>P. H.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Role of glutamate and NMDA receptors in alzheimer&#x2019;s disease</article-title>. <source>J. Alzheimers Dis. Jad.</source> <volume>57</volume> (<issue>4</issue>), <fpage>1041</fpage>&#x2013;<lpage>1048</lpage>. <pub-id pub-id-type="doi">10.3233/JAD-160763</pub-id>
<pub-id pub-id-type="pmid">27662322</pub-id>
</mixed-citation>
</ref>
<ref id="B198">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Z.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>LC3 fluorescent puncta in autophagosomes or in protein aggregates can be distinguished by FRAP analysis in living cells</article-title>. <source>Autophagy</source> <volume>9</volume> (<issue>5</issue>), <fpage>756</fpage>&#x2013;<lpage>769</lpage>. <pub-id pub-id-type="doi">10.4161/auto.23814</pub-id>
<pub-id pub-id-type="pmid">23482084</pub-id>
</mixed-citation>
</ref>
<ref id="B199">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Cai</surname>
<given-names>Z.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Role of AMPK in autophagy</article-title>. <source>Front. Physiol.</source> <volume>13</volume>, <fpage>1015500</fpage>. <pub-id pub-id-type="doi">10.3389/fphys.2022.1015500</pub-id>
<pub-id pub-id-type="pmid">36505072</pub-id>
</mixed-citation>
</ref>
<ref id="B200">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Weston-Green</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Solowij</surname>
<given-names>N.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Cannabidiol induces autophagy and improves neuronal health associated with SIRT1 mediated longevity</article-title>. <source>GeroScience</source> <volume>44</volume> (<issue>3</issue>), <fpage>1505</fpage>&#x2013;<lpage>1524</lpage>. <pub-id pub-id-type="doi">10.1007/s11357-022-00559-7</pub-id>
<pub-id pub-id-type="pmid">35445360</pub-id>
</mixed-citation>
</ref>
<ref id="B201">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Westlake</surname>
<given-names>T. M.</given-names>
</name>
<name>
<surname>Howlett</surname>
<given-names>A. C.</given-names>
</name>
<name>
<surname>Bonner</surname>
<given-names>T. I.</given-names>
</name>
<name>
<surname>Matsuda</surname>
<given-names>L. A.</given-names>
</name>
<name>
<surname>Herkenham</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>1994</year>). <article-title>Cannabinoid receptor binding and messenger RNA expression in human brain: an <italic>in vitro</italic> receptor autoradiography and <italic>in situ</italic> hybridization histochemistry study of normal aged and Alzheimer&#x2019;s brains</article-title>. <source>Neuroscience</source> <volume>63</volume> (<issue>3</issue>), <fpage>637</fpage>&#x2013;<lpage>652</lpage>. <pub-id pub-id-type="doi">10.1016/0306-4522(94)90511-8</pub-id>
<pub-id pub-id-type="pmid">7898667</pub-id>
</mixed-citation>
</ref>
<ref id="B202">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wright</surname>
<given-names>M. C.</given-names>
</name>
<name>
<surname>Potluri</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Dentcheva</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Gautam</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Tessler</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2009</year>). <article-title>Distinct muscarinic acetylcholine receptor subtypes contribute to stability and growth, but not compensatory plasticity, of neuromuscular synapses</article-title>. <source>J. Neurosci.</source> <volume>29</volume> (<issue>47</issue>), <fpage>14942</fpage>&#x2013;<lpage>14955</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.2276-09.2009</pub-id>
<pub-id pub-id-type="pmid">19940190</pub-id>
</mixed-citation>
</ref>
<ref id="B203">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>M. M.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Asher</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Thayer</surname>
<given-names>S. A.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Druggable targets of the endocannabinoid system: implications for the treatment of HIV-associated neurocognitive disorder</article-title>. <source>Brain Res.</source> <volume>1724</volume>, <fpage>146467</fpage>. <pub-id pub-id-type="doi">10.1016/j.brainres.2019.146467</pub-id>
<pub-id pub-id-type="pmid">31539547</pub-id>
</mixed-citation>
</ref>
<ref id="B204">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xiao</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Jiao</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>APP, PSEN1, and PSEN2 variants in alzheimer&#x2019;s disease: systematic Re-evaluation according to ACMG guidelines</article-title>. <source>Front. Aging Neurosci.</source> <volume>13</volume>, <fpage>695808</fpage>. <pub-id pub-id-type="doi">10.3389/fnagi.2021.695808</pub-id>
<pub-id pub-id-type="pmid">34220489</pub-id>
</mixed-citation>
</ref>
<ref id="B205">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xiong</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Lim</surname>
<given-names>C. S.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Understanding the modulatory effects of cannabidiol on alzheimer&#x2019;s disease</article-title>. <source>Brain Sci.</source> <volume>11</volume> (<issue>9</issue>), <fpage>1211</fpage>. <pub-id pub-id-type="doi">10.3390/brainsci11091211</pub-id>
<pub-id pub-id-type="pmid">34573232</pub-id>
</mixed-citation>
</ref>
<ref id="B206">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Hermes</surname>
<given-names>D. J.</given-names>
</name>
<name>
<surname>Nwanguma</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Jacobs</surname>
<given-names>I. R.</given-names>
</name>
<name>
<surname>Mackie</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Mukhopadhyay</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Endocannabinoids exert CB1 receptor-mediated neuroprotective effects in models of neuronal damage induced by HIV-1 Tat protein</article-title>. <source>Mol. Cell Neurosci.</source> <volume>83</volume>, <fpage>92</fpage>&#x2013;<lpage>102</lpage>. <pub-id pub-id-type="doi">10.1016/j.mcn.2017.07.003</pub-id>
<pub-id pub-id-type="pmid">28733129</pub-id>
</mixed-citation>
</ref>
<ref id="B207">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Klionsky</surname>
<given-names>D. J.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Mammalian autophagy: core molecular machinery and signaling regulation</article-title>. <source>Curr. Opin. Cell Biol.</source> <volume>22</volume> (<issue>2</issue>), <fpage>124</fpage>&#x2013;<lpage>131</lpage>. <pub-id pub-id-type="doi">10.1016/j.ceb.2009.11.014</pub-id>
<pub-id pub-id-type="pmid">20034776</pub-id>
</mixed-citation>
</ref>
<ref id="B208">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yankner</surname>
<given-names>B. A.</given-names>
</name>
<name>
<surname>Dawes</surname>
<given-names>L. R.</given-names>
</name>
<name>
<surname>Fisher</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Villa-Komaroff</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Oster-Granite</surname>
<given-names>M. L.</given-names>
</name>
<name>
<surname>Neve</surname>
<given-names>R. L.</given-names>
</name>
</person-group> (<year>1989</year>). <article-title>Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer&#x2019;s disease</article-title>. <source>Science.</source> <volume>245</volume> (<issue>4916</issue>), <fpage>417</fpage>&#x2013;<lpage>420</lpage>. <pub-id pub-id-type="doi">10.1126/science.2474201</pub-id>
<pub-id pub-id-type="pmid">2474201</pub-id>
</mixed-citation>
</ref>
<ref id="B209">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yiannopoulou</surname>
<given-names>K. G.</given-names>
</name>
<name>
<surname>Papageorgiou</surname>
<given-names>S. G.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Current and future treatments in alzheimer disease: an update</article-title>. <source>J. Cent. Nerv. Syst. Dis.</source> <volume>12</volume>, <fpage>1179573520907397</fpage>. <pub-id pub-id-type="doi">10.1177/1179573520907397</pub-id>
<pub-id pub-id-type="pmid">32165850</pub-id>
</mixed-citation>
</ref>
<ref id="B210">
<mixed-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Yoder</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2017</year>). &#x201c;<article-title>Chapter 7 - the endocannabinoid system and chronic disease: opportunity for innovative therapies</article-title>,&#x201d; in <source>Physical activity and the aging brain</source>. Editor <person-group person-group-type="editor">
<name>
<surname>Watson</surname>
<given-names>R. R.</given-names>
</name>
</person-group> (<publisher-name>Academic Press</publisher-name>), <fpage>65</fpage>&#x2013;<lpage>73</lpage>. <comment>Available online at: <ext-link ext-link-type="uri" xlink:href="https://www.sciencedirect.com/science/article/pii/B9780128050941000071">https://www.sciencedirect.com/science/article/pii/B9780128050941000071</ext-link>.</comment>
</mixed-citation>
</ref>
<ref id="B211">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Young</surname>
<given-names>A. P.</given-names>
</name>
<name>
<surname>Denovan-Wright</surname>
<given-names>E. M.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>The dynamic role of microglia and the endocannabinoid system in neuroinflammation</article-title>. <source>Front. Pharmacol.</source> <volume>12</volume>, <fpage>806417</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2021.806417</pub-id>
<pub-id pub-id-type="pmid">35185547</pub-id>
</mixed-citation>
</ref>
<ref id="B212">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname>
<given-names>J. J.</given-names>
</name>
<name>
<surname>Goncharova</surname>
<given-names>E. A.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>mTOR signaling network in cell biology and human disease</article-title>. <source>Int. J. Mol. Sci.</source> <volume>23</volume> (<issue>24</issue>), <fpage>16142</fpage>. <pub-id pub-id-type="doi">10.3390/ijms232416142</pub-id>
<pub-id pub-id-type="pmid">36555783</pub-id>
</mixed-citation>
</ref>
<ref id="B213">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname>
<given-names>W. H.</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Peterhoff</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Shapiro Kulnane</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Uchiyama</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Lamb</surname>
<given-names>B. T.</given-names>
</name>
<etal/>
</person-group> (<year>2004</year>). <article-title>Autophagic vacuoles are enriched in amyloid precursor protein-secretase activities: implications for beta-amyloid peptide over-production and localization in Alzheimer&#x2019;s disease</article-title>. <source>Int. J. Biochem. Cell Biol.</source> <volume>36</volume> (<issue>12</issue>), <fpage>2531</fpage>&#x2013;<lpage>2540</lpage>. <pub-id pub-id-type="doi">10.1016/j.biocel.2004.05.010</pub-id>
<pub-id pub-id-type="pmid">15325590</pub-id>
</mixed-citation>
</ref>
<ref id="B214">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zempel</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Thies</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Mandelkow</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Mandelkow</surname>
<given-names>E. M.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Abeta oligomers cause localized Ca(2&#x2b;) elevation, missorting of endogenous tau into dendrites, tau phosphorylation, and destruction of microtubules and spines</article-title>. <source>J. Neurosci. Off. J. Soc. Neurosci.</source> <volume>30</volume> (<issue>36</issue>), <fpage>11938</fpage>&#x2013;<lpage>11950</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.2357-10.2010</pub-id>
<pub-id pub-id-type="pmid">20826658</pub-id>
</mixed-citation>
</ref>
<ref id="B215">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Cuervo</surname>
<given-names>A. M.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Restoration of chaperone-mediated autophagy in aging liver improves cellular maintenance and hepatic function</article-title>. <source>Nat. Med.</source> <volume>14</volume> (<issue>9</issue>), <fpage>959</fpage>&#x2013;<lpage>965</lpage>. <pub-id pub-id-type="doi">10.1038/nm.1851</pub-id>
<pub-id pub-id-type="pmid">18690243</pub-id>
</mixed-citation>
</ref>
<ref id="B216">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>H. M.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Impairment of the autophagy&#x2013;lysosomal pathway in Alzheimer&#x2019;s diseases: pathogenic mechanisms and therapeutic potential</article-title>. <source>Acta Pharm. Sin. B</source> <volume>12</volume> (<issue>3</issue>), <fpage>1019</fpage>&#x2013;<lpage>1040</lpage>. <pub-id pub-id-type="doi">10.1016/j.apsb.2022.01.008</pub-id>
<pub-id pub-id-type="pmid">35530153</pub-id>
</mixed-citation>
</ref>
<ref id="B217">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Xia</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Targeting amyloidogenic processing of APP in alzheimer&#x2019;s disease</article-title>. <source>Front. Mol. Neurosci.</source> <volume>13</volume>, <fpage>137</fpage>. <pub-id pub-id-type="doi">10.3389/fnmol.2020.00137</pub-id>
<pub-id pub-id-type="pmid">32848600</pub-id>
</mixed-citation>
</ref>
<ref id="B218">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Yazdi</surname>
<given-names>A. S.</given-names>
</name>
<name>
<surname>Menu</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Tschopp</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>A role for mitochondria in NLRP3 inflammasome activation</article-title>. <source>Nature</source> <volume>469</volume> (<issue>7329</issue>), <fpage>221</fpage>&#x2013;<lpage>225</lpage>. <pub-id pub-id-type="doi">10.1038/nature09663</pub-id>
<pub-id pub-id-type="pmid">21124315</pub-id>
</mixed-citation>
</ref>
<ref id="B219">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zinecker</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Simon</surname>
<given-names>A. K.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Autophagy takes it all &#x2013; autophagy inducers target immune aging</article-title>. <source>Dis. Model Mech.</source> <volume>15</volume> (<issue>1</issue>), <fpage>dmm049345</fpage>. <pub-id pub-id-type="doi">10.1242/dmm.049345</pub-id>
<pub-id pub-id-type="pmid">35098310</pub-id>
</mixed-citation>
</ref>
<ref id="B220">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zou</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>U.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Cannabinoid receptors and the endocannabinoid system: signaling and function in the central nervous system</article-title>. <source>Int. J. Mol. Sci.</source> <volume>19</volume> (<issue>3</issue>), <fpage>833</fpage>. <pub-id pub-id-type="doi">10.3390/ijms19030833</pub-id>
<pub-id pub-id-type="pmid">29533978</pub-id>
</mixed-citation>
</ref>
<ref id="B221">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zou</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Tao</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>X.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges</article-title>. <source>Cell Biosci.</source> <volume>10</volume> (<issue>1</issue>), <fpage>1</fpage>&#x2013;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1186/s13578-020-00396-1</pub-id>
<pub-id pub-id-type="pmid">32175074</pub-id>
</mixed-citation>
</ref>
<ref id="B222">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zuardi</surname>
<given-names>A. W.</given-names>
</name>
</person-group> (<year>1999</year>). <article-title>History of cannabis as a medicine: a review</article-title>. <source>Rev. Bras. Psiquiatr. Sao Paulo Braz</source> <volume>28</volume> (<issue>2</issue>), <fpage>153</fpage>&#x2013;<lpage>157</lpage>. <pub-id pub-id-type="doi">10.1590/s1516-44462006000200015</pub-id>
<pub-id pub-id-type="pmid">16810401</pub-id>
</mixed-citation>
</ref>
<ref id="B223">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zuardi</surname>
<given-names>A. W.</given-names>
</name>
<name>
<surname>Hallak</surname>
<given-names>J. E. C.</given-names>
</name>
<name>
<surname>Crippa</surname>
<given-names>J. A. S.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Interaction between cannabidiol (CBD) and &#x394;(9)-tetrahydrocannabinol (THC): influence of administration interval and dose ratio between the cannabinoids</article-title>. <source>Psychopharmacol. Berl.</source> <volume>219</volume> (<issue>1</issue>), <fpage>247</fpage>&#x2013;<lpage>249</lpage>. <pub-id pub-id-type="doi">10.1007/s00213-011-2495-x</pub-id>
<pub-id pub-id-type="pmid">21947314</pub-id>
</mixed-citation>
</ref>
</ref-list>
<sec id="s13">
<title>Glossary</title>
<def-list>
<def-item>
<term id="G1-fphar.2025.1748368">
<bold>AD</bold>
</term>
<def>
<p>Alzheimer&#x2019;s disease</p>
</def>
</def-item>
<def-item>
<term id="G2-fphar.2025.1748368">
<bold>APP</bold>
</term>
<def>
<p>Amyloid precursor protein</p>
</def>
</def-item>
<def-item>
<term id="G3-fphar.2025.1748368">
<bold>PS1/2</bold>
</term>
<def>
<p>Presenilin-1 PS1 and 2</p>
</def>
</def-item>
<def-item>
<term id="G4-fphar.2025.1748368">
<bold>A&#x3b2;</bold>
</term>
<def>
<p>amyloid-&#x3b2;</p>
</def>
</def-item>
<def-item>
<term id="G5-fphar.2025.1748368">
<bold>BACE</bold>
</term>
<def>
<p>&#x3b2;-secretase</p>
</def>
</def-item>
<def-item>
<term id="G6-fphar.2025.1748368">
<bold>sAPP&#x3b2;</bold>
</term>
<def>
<p>Soluble amyloid precursor proteins beta</p>
</def>
</def-item>
<def-item>
<term id="G7-fphar.2025.1748368">
<bold>sAPP&#x3b1;</bold>
</term>
<def>
<p>Soluble amyloid precursor proteins alpha</p>
</def>
</def-item>
<def-item>
<term id="G39-fphar.2025.1748368">
<bold>CTF&#x3b2; or C99</bold>
</term>
<def>
<p>Carboxy-terminal fragment &#x3b2;</p>
</def>
</def-item>
<def-item>
<term id="G8-fphar.2025.1748368">
<bold>CTF&#x3b3; or AICD</bold>
</term>
<def>
<p>Carboxy-terminal fragment &#x3b3; or APP intracellular domain</p>
</def>
</def-item>
<def-item>
<term id="G9-fphar.2025.1748368">
<bold>NMDA</bold>
</term>
<def>
<p>N-methyl-D-aspartate</p>
</def>
</def-item>
<def-item>
<term id="G10-fphar.2025.1748368">
<bold>FDA</bold>
</term>
<def>
<p>Food and Drug Administration</p>
</def>
</def-item>
<def-item>
<term id="G11-fphar.2025.1748368">
<bold>Ach</bold>
</term>
<def>
<p>Acetylcholine</p>
</def>
</def-item>
<def-item>
<term id="G12-fphar.2025.1748368">
<bold>AChE</bold>
</term>
<def>
<p>Acetylcholinesterase</p>
</def>
</def-item>
<def-item>
<term id="G13-fphar.2025.1748368">
<bold>M1</bold>
</term>
<def>
<p>Muscarinic receptor 1</p>
</def>
</def-item>
<def-item>
<term id="G14-fphar.2025.1748368">
<bold>A&#x3b2;--AChE</bold>
</term>
<def>
<p>A&#x3b2;&#x2013;acetylcholinesterase macromolecular complex</p>
</def>
</def-item>
<def-item>
<term id="G15-fphar.2025.1748368">
<bold>CMA</bold>
</term>
<def>
<p>Chaperone-mediated autophagy</p>
</def>
</def-item>
<def-item>
<term id="G16-fphar.2025.1748368">
<bold>mTORC1/2</bold>
</term>
<def>
<p>Mammalian target of rapamycin complex 1 or 2</p>
</def>
</def-item>
<def-item>
<term id="G17-fphar.2025.1748368">
<bold>ATGs</bold>
</term>
<def>
<p>Autophagy-related genes</p>
</def>
</def-item>
<def-item>
<term id="G18-fphar.2025.1748368">
<bold>Akt/PKB</bold>
</term>
<def>
<p>Phosphoinositide 3-kinase (PI3K) and protein kinase pathway</p>
</def>
</def-item>
<def-item>
<term id="G19-fphar.2025.1748368">
<bold>LC3I or MAP1LC3B</bold>
</term>
<def>
<p>Microtubule-associated protein light chain 3</p>
</def>
</def-item>
<def-item>
<term id="G20-fphar.2025.1748368">
<bold>p62/SQSTM1</bold>
</term>
<def>
<p>sequestosome 1</p>
</def>
</def-item>
<def-item>
<term id="G21-fphar.2025.1748368">
<bold>AMPK</bold>
</term>
<def>
<p>AMP-activated protein kinase</p>
</def>
</def-item>
<def-item>
<term id="G22-fphar.2025.1748368">
<bold>ULK1</bold>
</term>
<def>
<p>Unc-51 like autophagy activating kinase 1 complex</p>
</def>
</def-item>
<def-item>
<term id="G23-fphar.2025.1748368">
<bold>TSC1/2</bold>
</term>
<def>
<p>Tuberous sclerosis complex subunit 2</p>
</def>
</def-item>
<def-item>
<term id="G24-fphar.2025.1748368">
<bold>AVs</bold>
</term>
<def>
<p>Autophagic vacuoles</p>
</def>
</def-item>
<def-item>
<term id="G25-fphar.2025.1748368">
<bold>3-MA</bold>
</term>
<def>
<p>3-Methyladenine</p>
</def>
</def-item>
<def-item>
<term id="G26-fphar.2025.1748368">
<bold>ECS</bold>
</term>
<def>
<p>Endocannabinoid system</p>
</def>
</def-item>
<def-item>
<term id="G27-fphar.2025.1748368">
<bold>CB1R and CB2R</bold>
</term>
<def>
<p>cannabinoid receptors 1 and 2</p>
</def>
</def-item>
<def-item>
<term id="G28-fphar.2025.1748368">
<bold>AEA</bold>
</term>
<def>
<p>Anandamide</p>
</def>
</def-item>
<def-item>
<term id="G29-fphar.2025.1748368">
<bold>FAAH</bold>
</term>
<def>
<p>fatty acid amide hydrolase</p>
</def>
</def-item>
<def-item>
<term id="G30-fphar.2025.1748368">
<bold>MAGL</bold>
</term>
<def>
<p>Monoglyceride lipase</p>
</def>
</def-item>
<def-item>
<term id="G31-fphar.2025.1748368">
<bold>PPAR)&#x3b3;</bold>
</term>
<def>
<p>Peroxisome proliferator-activated receptor</p>
</def>
</def-item>
<def-item>
<term id="G32-fphar.2025.1748368">
<bold>CBD</bold>
</term>
<def>
<p>Cannabidiol</p>
</def>
</def-item>
<def-item>
<term id="G33-fphar.2025.1748368">
<bold>PPAR</bold>
</term>
<def>
<p>Peroxisome proliferator-activated receptor</p>
</def>
</def-item>
<def-item>
<term id="G34-fphar.2025.1748368">
<bold>UFS</bold>
</term>
<def>
<p>University of the Free State</p>
</def>
</def-item>
<def-item>
<term id="G35-fphar.2025.1748368">
<bold>TRPV1</bold>
</term>
<def>
<p>Transient receptor potential vanilloid 1</p>
</def>
</def-item>
<def-item>
<term id="G36-fphar.2025.1748368">
<bold>ER</bold>
</term>
<def>
<p>Endoplasmic reticulum</p>
</def>
</def-item>
<def-item>
<term id="G37-fphar.2025.1748368">
<bold>ERK</bold>
</term>
<def>
<p>Extracellular signal-regulated kinase</p>
</def>
</def-item>
<def-item>
<term id="G38-fphar.2025.1748368">
<bold>BChE</bold>
</term>
<def>
<p>Butyrylcholinesterase.</p>
</def>
</def-item>
</def-list>
</sec>
</back>
</article>